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ABSTRACT
KEELE ELISE WURST: Assessing the Utility of the General Practice Research Database 
(GPRD) to Identify Major Congenital Heart Defects
(Under the direction of Harry Guess and Sara Ephross)
This study aimed to validate that the computerized medical records within the General Practice 
Research Database (GPRD) can successfully identify congenital heart defects.  Specifically, 
ventricular septal defect (VSD), Tetralogy of Fallot (TOF) and coarctation of the aorta (COA) were 
examined.  Additional information from 1) medical record abstraction “questionnaires” sent to 
general practitioners and 2) maternal and infant free text comments fields within the GPRD was 
obtained.  This information was compared to computerized medical records to understand which 
available components of the GPRD provide maximal information about congenital heart defects. 
This study also created case definitions of congenital heart defects within the GPRD and 
examined whether the prevalence rates of congenital heart defects for 2001-2003 obtained from 
the GPRD are similar to those obtained from two UK population-based systems, the National 
Congenital Anomaly System (NCAS) and the European Concerted Action of Congenital 
Anomalies and Twins (EUROCAT).  
Using practitioner questionnaires as the “gold standard," an overall positive predictive value 
(PPV) of the computerized medical record of 93% for the three defects was achieved. Of the 200
records, 44% contained infant free text information pertaining to the congenital heart defect of 
interest: the availability did not vary by specific defect.  The proportion of infant defect information 
in the mother’s free text was low.  The prevalence of all heart defects from the GPRD was more 
than twice as high as in the NCAS and slightly higher than in the EUROCAT. All prevalence rate 
differences reached statistical significance (P=0.05).  
iv
This study confirmed with a high positive predictive value that computerized GPRD 
medical records are sufficient to assess VSD, TOF and COA.  It also demonstrated that the 
GPRD has the potential to produce a more complete estimate of prevalence of congenital 
heart defects compared to currently available UK national systems.  The advantages of the 
GPRD as a medical records database including case ascertainment methods that do not rely 
on voluntary reporting, a theoretically unlimited duration of follow-up time in which a case can 
be detected and the availability of infant free text information make the GPRD a unique 
source for future studies of congenital heart defects.   
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CHAPTER I SPECIFIC AIMS
Currently much of the information on the occurrence of birth defects associated with 
medication use is provided from pharmaceutical company sponsored pregnancy registries.  Using 
the United Kingdom (UK) General Practice Research Database (GPRD), an automated medical 
record database, may reduce the problems of small sample size, reporting bias due to the 
voluntary nature of pharmaceutical company sponsored pregnancy registries, poor exposure 
ascertainment, losses to follow-up, lack of an internal control group, and lack of confounding 
information associated with pharmaceutical company sponsored pregnancy registries.  To date 
there has been limited research that has examined medication use in pregnancy using the 
GPRD.  Studies to date include exposure to antiepileptics, fluconazole and acid-suppressing 
medications and their association with birth defects overall [1-3], with limited validation of birth
outcomes.  It has been thought that teratogens do not usually cause an increase in major birth 
defects overall but rather an increase in one or a set of specific malformations. [4] Thus additional 
validation work, focusing on specific defects, is needed to improve the study of birth defects with 
the eventual aim of studying medication use in pregnancy within the GPRD. 
This study will provide validation work, focusing on some of the most prevalent and fatal types 
of birth defect, congenital heart defects.  The purpose of this research is to validate that three of 
the most common types of congenital heart defects can be studied as outcomes in the GPRD.  
Specifically, ventricular septal defect (VSD), Tetralogy of Fallot (TOF) and coarctation of the aorta 
(COA) will be examined.  The information obtained from this study will be important to future 
research studying congenital heart defects and any exposure within the GPRD.
We propose to: 
1.1 Create a case definition of a congenital heart defect within the GPRD
21.2 Examine whether the rates of congenital heart defects obtained from the GPRD are similar to 
those obtained from UK population-based sources
1.3 Determine the positive predictive value of the computerized recorded diagnosis of specific 
congenital heart defects using a medical records abstraction form as the gold standard
1.4 Determine whether the GPRD can provide additional information about timing and 
presentation of specific congenital heart defects
1.5 Evaluate whether the free text comments section from the infant’s and mother’s record 
provides supplemental information to the congenital heart defect data obtained from the infant’s 
computerized record.  
The information obtained from this study will be important to future research of any exposure 
and the outcome of congenital heart defects.  It is extremely important to create a case definition 
of congenital heart defects within the GPRD.  A standardized group of Oxford Medical Information 
System (OXMIS) and Read codes corresponding to congenital heart defects within the GPRD 
does not exist.  These case definitions will be essential to future research examining drug 
exposures and congenital heart defects within the GPRD.  
3A goal of this study is for future researchers to be able to use the GPRD to correctly identify 
patients with congenital heart defects.  The case definitions of congenital heart defects, 
categories of congenital heart defects and any specific heart defect definitions will be useful to 
other researchers in future studies within the GPRD.  This study will determine whether a 
grouping of codes for congenital heart defects can provide similar prevalence estimates to 
population based estimates.  The results from this study will determine whether the computerized 
medical record information within the GPRD is sufficient to study congenital heart defects.  If the 
computerized medical record information is found to yield a high positive predictive value, medical 
records abstraction form validation may not be necessary for future research examining VSD, 
TOF, and COA.  If the comments section obtained from the mother’s record do not provide 
additional information beyond that provided by the diagnostic codes in the GPRD in this study 
then future researchers can feel confident that the medical record information on the three 
specific congenital heart defects in the GPRD is sufficient for their research.  
The ultimate aim of this study is to provide validation that VSD, TOF, and COA can be studied 
within the GPRD.  This study will attempt to compare the type of data determined from this study 
to the type of data that can be obtained from pharmaceutical company sponsored pregnancy 
registries and population based prevalence data.
CHAPTER II BACKGROUND AND SIGNIFICANCE
GPRD compared to product specific pharmaceutical company sponsored pregnancy 
registries
Currently much of the information on the occurrence of birth defects associated with 
medication use is provided from pharmaceutical company sponsored pregnancy registries. 
Pharmaceutical company sponsored pregnancy registries were established for the purpose of 
monitoring prenatal drug exposures for evidence of teratogenicity.  They provide an early warning 
system for potential teratogenic effects associated with the use of specific medications during 
pregnancy and provide data to supplement animal toxicology studies [5]. Health care 
professionals are asked to register patients and assist in providing follow-up information 
postpartum.
Pharmaceutical company sponsored pregnancy registries are good for detecting a signal of a 
problem but there are some known limitations of using a pharmaceutical company sponsored 
pregnancy registry to determine the risk of birth defects.
First, pharmaceutical company sponsored pregnancy registries are voluntary systems. 
Typically voluntary pharmaceutical company sponsored pregnancy registries receive a low 
number of reports [6]. The ascertainment of birth defects may be incomplete since it is usually 
limited to defects diagnosed at birth [6]. The under-ascertainment combined with small sample 
sizes obtained from registries provides an insufficient number to rule out small increases in 
frequency of all major birth defects or large increases in the frequency of rare major birth defects.  
A database such as the GPRD may provide larger numbers of women exposed to medications 
during pregnancy.
5Second, information in pharmaceutical company sponsored pregnancy registries may be 
incomplete.  Birth defect information is most often from the obstetrician who may not have full 
information about the infant [6]. Registries receive a mix of prospective and retrospective case 
reports [7]. Information received retrospectively may be subject to recall bias.  The overall quality 
of the information received by drug manufacturers about exposure is usually inadequate [7]. Use 
of the GPRD will allow more accurate and detailed prospectively recorded information about 
medication exposure.  The GPRD includes information regarding full date for each prescription, 
indication, dosage form, timing, dose, concomitant medications, prescriber, and treatment 
frequency.  
Another limitation of the pharmaceutical company sponsored pregnancy registry system is that 
there is often no follow-up with subsequent providers such as the infant’s pediatrician.  Registries 
often rely on accurate reporting of malformations by the health care worker who initially reported 
the exposed pregnancy.  Since the health care worker is often an obstetrician, the physician may 
not be aware of all of the infant's diagnoses [6].  The GPRD has integrated medical records and 
therefore the diagnosis of a birth defect can be verified using the medical record.  The GPRD also 
allows for longer follow-up because a mother- infant record linkage is available. 
Another problem occurs if there is loss to follow up with the provider or the patient.  It has been 
shown in a study comparing pharmaceutical company sponsored pregnancy registries, that 8-
27% of all prospective exposure reports were not able to obtain any outcome information [6]. 
Since there is continuous enrollment in the GPRD there may be less loss to follow up compared 
to a registry system.  Use of the GPRD allows for more complete outcome ascertainment 
because all medical records are automated.  The infant can be followed for a year or more to 
capture birth defects not detected at birth.   
6Pharmaceutical company sponsored pregnancy registries are also costly to maintain on a per 
outcome basis because they are single use databases.  The registries cannot be used for 
anything other than studying pregnancy outcomes following drug exposure in pregnancy. While 
the GPRD is expensive to maintain, it is used for many different purposes. 
Previous Research using GPRD to assess medication use in pregnancy
To date there has been limited research that has examined medication use in pregnancy using 
the GPRD.  Exposure to antiepileptics, fluconazole, and acid-suppressing medications have been 
examined.  A study by Jick and Terris (1997) compared 297 women exposed to an antiepileptic 
medication during the first trimester of pregnancy to a control group of 594 women without 
epilepsy and unexposed to any epileptic medication.  The authors reported a relative risk of major 
congenital malformations of 3.3  (95% CI (1.2-9.2)) [1] . The study was limited to major congenital 
malformations that could be drug-induced and that were identified at or around the time of birth 
[1].   A study by Jick (1999) compared 234 women exposed to fluconazole during the first 
trimester of pregnancy to a control group of 1629 women unexposed to fluconazole or another 
azole during the first trimester of pregnancy.  The authors reported a relative risk of any 
congenital disorder of 1.1 (95% CI (0.4-3.3)) [2]. A congenital disorder was defined as a 
congenital anomaly present at birth that resulted in surgery or other treatment for functional or 
cosmetic reasons [2] .  A study by Ruigomez et al (1999) compared 554 women exposed to an 
acid-suppressing drug during the first trimester of pregnancy to a control group of 635 women 
from the same source population unexposed to an acid-suppressing drug during the first trimester 
of pregnancy.  The authors reported a relative risk of any congenital malformation of 1.0 (95% CI 
(0.6-1.6)) [3].  A congenital malformation was defined as any live birth or still birth with a structural 
defect and detected either prenatally, at birth or within the first year of life [3]. 
Most of the studies mentioned above were limited to major birth defects that could be drug-
induced and that were identified at or around the time of birth.  If these medications were 
associated with birth defects diagnosed sometime after birth, these defects would be missed.  It 
has never been validated whether the GPRD can detect defects diagnosed after birth.   
7Jick and Terris included a practitioner survey in their study design to validate the accuracy of 
the medical record coding.  They reported 100% concordance of the information recorded on the 
computer and the information received from the general practitioner [1]. However the details and 
methodology of this survey are unclear.  There was no mention of how the birth defects were 
validated in the Ruigomez study. 
GPRD background and structure
The General Practice Research Database contains information on 3 million patients in the UK, 
which accounts for more than 35 million person years of data [8].  The UK National Health 
System provides universal coverage therefore it is unlikely that a segment of the population is 
systematically excluded from the GPRD [9]. The geographical, sex, age and smoking status 
distributions have been shown to be representative of the UK population [9] . The GPRD includes 
data on medication use, diagnoses, procedures, and some information on patient characteristics 
such as height, weight, smoking status, alcohol use, and social status. 
The GPRD was established in June 1987, at which time participating general practitioners 
received practice computers and a text-based practice management system in return for 
undertaking data quality training and submitting anonymized patient data for research purposes 
[9, 10]. There are about 1500 contributing general practitioners within the GPRD who are all 
members of the National Health Service (NHS) in England and act as the main means of access 
to all forms of health care provision within the NHS.  Practitioners enrolled in the GPRD must 
follow a recording protocol.  The practitioners are asked to enter into the computer record 1) all 
events resulting in hospitalization or referral to any specialist, and the outcome of the referral 2) 
any significant test results, 3) all events resulting in a prescription or withdrawal of treatment 
including the indication for the medication, 4) all adverse reactions to a medication, 5) other 
events which the patient will consult with the practitioner on more than one occasion (childhood 
diseases, pregnancy) [11]. The practitioners are instructed to record the outcome of pregnancy in 
the mother’s record.  The condition of each newborn must be recorded in the child’s own record, 
as normal birth, prematurity or any birth defect [12].  Practitioners are also instructed to place 
birth defects in the mother’s comment section as well as in the infants’ record.  Infants usually do 
8not receive their own record until after 6 months of age.  Neonatal death should be noted in the 
mother’s record. [12]
It is feasible to study birth outcomes using the GPRD because women of childbearing age 
make up 41% of the total population and a mother –infant link has also been established [11]. 
The mother-infant link is developed from an algorithm which links to the registration of newborns 
with deliveries in women, using common family and practice numbers [13].  An estimate of the 
number of live births can be derived from an algorithm taking into account the number of 
newborns registered in GPRD within 3-6 months from their date of birth [14].  A validation study of 
the mother-infant linkage demonstrated that the agreement between the number of births and 
deliveries linked was within 5% (in 1997 20032 births and 20694 deliveries were recorded in 
England and Wales practices) [13].  In 1997, 1998, 1999 and 2000 the percentage of birth 
records linked to the mothers record was 80.7%, 81.3%, 83.1% and 84.4% [13].   
The computerized records of the GPRD are structured around eighteen files; the general 
events table, seven events tables (Clinical, Consultation, Immunization, Referral, Repeat, Test, 
Therapy), eight attribute tables with background or historical data on the patients, practice or staff 
(Patient, Practice, Region, Staff, Historic patient attributes, Historic organization attributes, 
Historic registration history, and Historic Status attributes), and the medical and product 
dictionaries [11]. Within the GPRD, each medical encounter is listed as an event which has a free 
text comments section associated with it.  A unique reference number identifies the existence of 
free text comments associated each event record.  This free text can be retrieved from the 
Medicines and Healthcare products Regulatory Agency (MHRA) by providing the free text 
reference number.  The coding system of the GPRD is based on a modification of the OXMIS
classification of medical conditions and the Read coding system [11]. 
There are several ways to access the information contained within the GPRD. 
Detailed data can be obtained as 1) a dataset of computerized medical records including all 
clinical and prescription events, 2) computerized medical records plus follow up information 
including anonymized copies of death certificates, post mortems, hospital discharge summaries 
9or questionnaires to GPs, or 3) computerized medical records plus a notes section which contains 
free text comments or 4) a combination of all three types of information.
GPRD Computerized Medical Record Information 
Published literature indicates that there is good agreement between the computerized medical 
record and the practitioner’s medical record for a number of diagnoses within the GPRD.  In a 
validation study of general practitioner diagnosed chronic obstructive pulmonary disease (COPD) 
in the GPRD, Soriano et al (2001) demonstrated a kappa of 0.52 indicating good agreement 
between the diagnoses of COPD found in the computerized database and those determined from 
medical records abstraction forms [15]. The authors used a Fleiss reference of kappa values of 0-
0.3 to indicate poor agreement, 0.31-0.60 to indicate good agreement and 0.61-1.0 to indicate 
very good agreement [15, 16].  Nazareth et al (1993) showed that the classification of psychotic 
illness entered into the GPRD was accurate.  The rate of misclassification was low (3 in 251) and 
few cases (4 cases out of 251) were not entered into the computer by the general practitioner 
[17]. In a validation study examining patients prescribed non-steroidal anti-inflammatory 
medications, the clinical diagnosis reflecting the diagnosis in the consultant letter was present on 
the computer record in 87% of the patients [18]. Van Staa et al (1994) examined the quality of 
information about hospitalizations recorded in the computerized records by comparing information 
derived from photocopied hospital discharge summaries and general practitioner medical record 
abstraction forms to the information recorded in the computerized medical record.  They 
demonstrated a sensitivity and a positive predictive value for the computerized record for the 
diagnosis related to hospitalization of over 90 percent for most conditions[19].  Lawrenson et al 
(2000) validated the diagnosis of venous thromboembolism in the GPRD by comparing the 
computerized medical record information to practitioner medical record abstraction forms, hospital 
investigations, and death certificates.  They showed that in 84% of the cases the computerized 
medical record information was supported by the practitioner medical record abstraction forms, 
hospital investigations and death certificates [20].  In a study assessing the relationship between 
colorectal cancer and nonsteroidal anti-inflammatory use, Garcia-Rodriguez et al (2001) 
performed a validation of a sample of cases.  After reviewing the computerized medical record 
10
information, they requested the medical records from the general practitioner [21]. They found 
that the confirmation rate of colorectal cancer was 95%.  Margolis et al (2002), estimating the 
prevalence of pressure ulcers within the GPRD, estimated the accuracy of their case definition of 
pressure ulcers.  They used a practitioner medical record abstraction form to determine whether a 
patient truly had a pressure ulcer.  They determined a sensitivity of 91%   (95% CI 83-99) and a 
positive predictive value of 100% (95%CI of 92,100) [22]  . 
GPRD Free text comments section 
Historically, the free text comments section was a part of the GPRD computerized medical 
record.  In order to retain patient confidentiality, the free text comments were removed and are 
only available in an anonymized form from the MHRA. 
There are few studies pertaining to the information contained in the free text comments section 
of the GPRD.  The free text field is not easily queried using standard computer programs and is 
not generally used in GPRD studies to identify exposures and outcomes [23]. 
In a study of the prevalence of anaphylaxis, Peng and Jick (2004) reviewed computerized 
medical record information as well as the free text comments section.  Of the 898 patients that 
they identified with anaphylaxis 12% (n=115) were identified using the comments fields [24].  
However, it has never been examined whether the free text sections contain detailed information 
pertaining to the timing, presentation, and details of diagnosis.  Obtaining the free text information 
may be more efficient than obtaining practitioner questionnaires. 
UK Population based estimates
As part of our validation of congenital heart defect diagnoses in the GPRD, we will compare the 
prevalence of congenital heart defects in the GPRD with that reported in the general population of 
the UK.  There are a few sources of data in which the prevalence of congenital heart defects 
within the population can be derived.  The European Concerted Action on Congenital Anomalies 
and Twins (EUROCAT) and the National Congenital Anomaly System (NCAS) are two sources.  
The EUROCAT started in 1979 and is a European network of population-based registries for the
epidemiologic surveillance of congenital anomalies [25, 26].  There are six registries that make up 
the EUROCAT system of the UK.  Glasgow started contributing to EUROCAT in 1979, Mersey in
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1995, Thames in 1996, Oxford in 2002, Wales in 1998, and Wessex in 2002.  EUROCAT collects 
data about the infant (e.g. date of birth, live or stillbirth or induced abortion, birth weight, singleton 
or multiple) and diagnosis (syndrome and up to eight malformations can be coded, as well as 
family history) and the mother (age, occupation, drug exposures and illnesses, previous 
reproductive history).  EUROCAT reports describe prevalence rates of 32 congenital anomaly 
subgroups in each Registry, with the number of cases reported among live births, stillbirths, and 
terminations of pregnancy following prenatal diagnosis.  Data validation is performed at each 
individual registry before the data is transmitted to the EUROCAT central registry.  Duplication 
checks, range error checks and the presence of 1)local identification number, 2)date of birth, 
3)sex, 4)number of infants delivered, 5)type of birth or abortion, 6 )birth weight and/or gestation 
and 7)at least one malformation or syndrome code are verified.  In EUROCAT prevalence rate 
calculations, an infant with several birth defects is counted once within each class of birth defect.  
The number of cases by type of birth along with the population and prevalence rate can be 
obtained per year [25]. 
The National Congenital Anomaly System (NCAS), started in 1949, records congenital 
anomalies for live and stillbirths in England and Wales.  It is run by the Office for National 
Statistics and contributes data to the International Clearinghouse for Birth Defects Monitoring 
System.  The ONS uses the exclusion list developed by EUROCAT in 1990.  It is a voluntary 
system.  Spontaneous and induced abortions are not included in the system.  BINOCAR (British 
Isles Network of Congenital Anomaly Registers) also contributes data to the NCAS.  Most 
notifications received by NCAS come from NHS Hospital Trusts who fill in a form SD56 using 
details from the birth notification.  Notifications to NCAS can be made at any time, for instance, 
when a diagnosis is made in older infants, but anomalies not detected at birth tend to be under-
reported.  The main purpose of the National Congenital Anomaly System is surveillance.  The 
primary purpose is to detect changes in the frequency of reporting any particular birth defect or 
group of birth defects rather than trying to estimate the prevalence at birth, although it has also 
been shown to provide the most extensive data on prevalence levels in England and Wales[26]. A 
disadvantage of the system is that in measuring prevalence there are deficiencies in the areas in 
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which the NCAS covers [26]. In 1999, the system covered all births in Wales and 23% of births in 
England [26]. 
The congenital anomaly notification system, which is voluntary at all stages, is usually linked to 
the statutory system of birth notification to local health authorities.  The local health authorities 
extract details of infants born with anomalies from the birth notifications.  The information is 
supplemented by details from midwives, hospitals, doctors, and health visitors.  The Trent 
congenital anomaly register, the Wales congenital register, the North Thames and the 
Merseyside registers all contribute data to the NCAS as well [26]. 
A comparison between the population based sources and the GPRD is likely to produce 
different rates of congenital heart defects.  The rates of congenital heart defects are likely to differ 
because the population based data sources are voluntary which may miss some cases.  
Voluntary systems are often incomplete [6].  The populations covered may also be different both 
in terms of location and population characteristics.  
An unpublished preliminary analysis of all birth defects (KW) was performed to estimate the 
crude number of patients six years of age and younger in the GPRD who had a birth defect 
recorded in the year 2001.  In order to perform the preliminary analysis, an OXMIS and Read 
code list corresponding to a birth defect had to be created.  The list was created using definitions 
and ICD-9 codes used by the Metropolitan Atlanta Congenital Defects Program [27]. The broad 
definition of a birth defect encompassed 324 OXMIS and Read codes.  The number of codes is 
separated by organ system shown in table 2.1.  
The analysis produced a total of 415 birth defects recorded in 2001 within the GPRD.  Table 
2.2 demonstrates the number of birth defects captured by category of organ system. Using the 
number of live births estimated to be captured by the GPRD in the year 2001, (17000 live births);
the rate of birth defects seen in the year 2001 within the GPRD was 2.14 per 100 live births.  A 
child with more than one birth defect within the same organ system is reported only once.  
However a child with more than one birth defect in a separate organ system may be counted a 
number of times.  This definition may lead to an overrepresentation of total birth defects within the 
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GPRD.  Thus a definition that does not include the same child for numerous defects will be used 
for the current project to determine the prevalence of congenital heart defects within the GPRD.  
The number obtained from the Office of National Statistics (ONS) in the UK (a voluntary 
reporting system) was 1.12 per 100 live births.  The number from the ONS includes all 
notifications of infants born with a birth defect (n=6670) divided by the total number of live births 
within England and Wales (n= 594360) [26]. If the number of birth defects was reported 
(n=11481), comparable to the definition used in the GPRD analysis, it produces a rate of 1.93 per 
100.
Performing the same analysis using only cardiovascular defects produces different rates 
among the populations of the ONS and GPRD.  The number obtained by the ONS was 1.7 per 
1000 live births (n=1014) and the number obtained from the GPRD was 2.6 per 1000 live births 
(n=45).  In both of the data sources the definition of cardiovascular defects allows for a child to be 
counted only once.  Comparing the rates, it seems as though the difference in definition between 
sources may not explain the difference in rates.  The rates may not be comparable because of 
differences in collection of data, the population, and/or the definition of individual birth defects.  
Overview of Normal Heart Function
The heart is divided into four chambers, two upper chambers (the atria) and two lower 
chambers (the ventricles).  The atrial septum divides the right and left atria and the ventricular 
septum divides the right and left ventricles.  Blood flows from the body through the vena cava into 
the right atrium.  When the right atrium is filled with blood, it contracts and the blood flows through 
the tricuspid valve to the right ventricle.  From the right ventricle, the blood flows through the 
pulmonic valve to the pulmonary arteries where it is carried to the lungs.  Once oxygenated in the 
lungs the blood returns to the left atrium of the heart through the pulmonary veins.  When the left 
atrium contracts, the blood flows through the mitral valve into the left ventricle.  From the left 
ventricle, the blood flows through the aortic valve to the aorta where it is carried out to the body 
[28].  (Figure 1)
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Embryology of the Heart
Congenital heart defects occur due to abnormal development of the fetal heart during the first 8 
weeks of pregnancy.  A single cardiac tube develops by Day 22 of gestation, the major septa 
form between Days 27 and 37, valvular development starts at Day 35 and heart development is 
complete by Day 56-60 [29]. 
During the first month of gestation (by approximately day 22), the primitive cardiac tube forms 
[29].  It has four segments consisting of the sinoatrium, primitive ventricle, bulbus cordis, and 
conotruncus.  During the second month of gestation, the primitive cardiac tube changes to a heart 
with two systems, each having an atrium, a ventricle, and a great artery.  The sinoatrium forms 
into right and left atria and the truncus into the aorta and pulmonary artery.  While the two atria 
form, the atrioventricular (AV) canal is divided by the endocardial cushions into tricuspid and 
mitral inlets, both connecting to the primitive ventricle.  The left and right ventricles develop form 
from the primitive ventricle and bulbus cordis, respectively.  The distal end of the bulbus cordis 
divides into two portions: the subaortic conus and the subpulmonic conus.  The subpulmonic 
conus increases in length, but the subaortic conus resorbs as the aorta migrates posteriorly to 
connect with the left ventricle [30]. 
The ventricular septum of the heart can be separated into three components: the muscular, 
outlet, and inlet septa.  The first, the muscular septum, comprises the majority of the ventricular 
septum; it arises from tissue in between the primitive (left) ventricle and the bulbis cordis (right 
ventricle).  Muscular ventricular septal defects result from incomplete extension of the tissue 
across the connection between the two chambers.  The most common ventricular septal defects 
occur in the region where the muscular, inlet, and outlet portions of the septum meet.  These 
defects are called perimembranous ventricular septal defects[30]. 
The conotruncus is the most distal portion of the primitive heart tube.  Its normal development 
is required for separation of the aorta and pulmonary outflow tracts and their alignment with the 
appropriate ventricles.  Normal conotruncal development involves four processes: the 
proliferation of cells within the conotruncal cushions; the migration of cells into the conotruncus 
from the cardiac neural crest; the resorption of the subaortic conus; and the leftward movement of 
15
the conotruncus.  The conotruncus is positioned over the future right ventricle and for appropriate 
separation of the aortic and pulmonary outflows to occur, the aortic portion of the conotruncus 
must move leftward and posteriorly so that the aorta will be connected to the left ventricle.  When 
the outlet septum doesn’t align properly with the remainder of the ventricular septum (the outlet 
septum deviates anteriorly), it can result in an outlet VSD, overriding aorta, and hypoplasia of the 
right ventricular outlet, which is typical of Tetralogy of Fallot.  When the outlet septum is deviated 
posteriorly, it can result in a VSD.  If the outlet septum obstructs the aortic outflow, it can produce 
subaortic stenosis and secondary hypoplasia of the aortic arch or coarctation of the aorta [30, 31]. 
Congenital Heart Defects
The formation of the heart is a complex process and there are many places for errors to occur.  
Thus, it is not surprising that congenital heart defects are the most common type of major 
structural birth defect.  Congenital heart defects are not only the most prevalent but also the most 
fatal type of birth defect.  According to the 2002 National Vital Statistics Report , of the 5608 
infant deaths related to congenital malformations, 28% (n=1570)  were attributed to malformation 
of the heart.  [32]. The prevalence of congenital heart defects among live births, which ranges 
from 1.74 to 8 in 1000, varies by source and type of data collection [25, 33-40] The prevalence 
estimates depend on the way cases are ascertained, the inclusion/exclusion criteria used, the 
degree to which prenatal diagnoses are included and the duration of follow-up during the 
neonatal period [33, 41]. Some of the prevalence rates (EUROCAT and ONS) rely on voluntary 
reporting in which there may be incomplete ascertainment of all cases [25, 26].  There also may 
be differences in the definition of a congenital heart defect and different diagnostic 
categorizations used between studies [36]. Some studies may include only major or severe 
congenital heart defects while others may include minor defects as well.  Table 2.3 shows the 
prevalence of some population estimates of congenital heart defects.
At least 35 types of congenital heart defects are recognized, with many additional anatomic 
variations [42] .Congenital heart defects can be separated into two categories: cyanotic and 
noncyanotic  (Table 2.4).
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In cyanotic heart defects, there is mixing of oxygenated and unoxygenated blood. Blood that is 
poorly oxygenated reaches the tissues of the body which results in the development of a bluish 
tint called cyanosis in the skin, lips, and nail beds. 
Noncyanotic heart defects are defects that do not normally interfere with the amount of oxygen or 
blood that reaches the tissues of the body.  A bluish tint of the skin is not common in babies with 
noncyanotic heart defects, although it may occur during activities when the baby needs more 
oxygen, such as when crying and feeding [43]. Table 2.4 lists the separation of defects by 
cyanotic category and by the percentage of all congenital heart defects. 
Ventricular Septal Defects
A ventricular septal defect is the most common kind of congenital heart defect.  This condition 
is sometimes referred to as a 'hole-in-the-heart'.  In this condition there is an opening in the 
septum (or the wall) that separates the right and left ventricles (or chambers) of the heart. 
    Normally, the blood on the right side of the heart (right atrium and right ventricle) is oxygen 
deficient while blood on the left side (left atrium and left ventricle) is oxygen rich.  An opening 
between the ventricles forces blood from the left side of the heart to go to the right side every time 
the heart beats.  Oxygen rich blood from the left side goes back to the lungs unnecessarily thus 
mixing with blood that is not yet oxygen rich.  This may increase the amount of work that the heart 
has to do to deliver adequate amounts of oxygenated blood to the body.  When the size of the 
opening is large, the heart may become unable to generate enough output to meet the metabolic 
demands of the body which can lead to congestive heart failure.  
The signs and symptoms of a VSD depend on the degree of blood flow across the opening.  
The most common signs and symptoms of a VSD are difficulty eating and gaining weight, 
breathlessness, and easy fatigability.  A baby with a large VSD tires quickly after not eating very 
much, falls asleep, wakes up in a short while still hungry, tries to eat again, falls asleep, and the 
cycle is repeated [44].
A ventricular septal defect is usually diagnosed during a physical examination.  A heart murmur 
is usually heard.  The heart murmur is caused by the sound of blood flowing through the opening 
from the left side of the heart to the right.  Interestingly, small defects may produce more audible 
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murmurs than larger ones, because there is less turbulent flow across large defects.  More 
significant VSDs often are heard at the age of 2 to 3 weeks as pulmonary vascular resistance 
decreases and left-to-right shunting increases.  Significant VSDs may first become noticed at 6 to 
8 weeks when signs and symptoms  of heart failure occur [45]. 
A chest x-ray on a patient with a VSD may show an enlarged heart because the right ventricle 
handles larger amounts of blood flow than normal.  The x-ray may also show pulmonary 
hypertension which causes changes to take place in the lungs due to extra blood flow.  High 
pressure may occur in the blood vessels because there is more blood going to the lungs which 
may cause permanent damage to the walls of the blood vessels over time.  An electrocardiogram 
(ECG or EKG) may show abnormal rhythms (arrhythmias or dysrhythmias) and may show 
electrocardiographic evidence of right ventricular hypertrophy [45] . An echocardiogram and/or 
cardiac catheterization may show the pattern of blood flow through the septal opening, and 
determine how large the opening is, as well as much blood is passing through it [44, 46, 47]. 
The prevalence of VSD is 100-500 of 100,000 live births in the United States and it has an 
equal prevalence between males and females [48]. Small ventricular septal defects may close 
spontaneously as the infant grows.  25-45% of VSD will close spontaneously by age three [47].  A 
larger VSD usually requires surgical repair.  The goal of management of a VSD is to prevent lung 
problems that will develop from long-time exposure to extra blood flow and pressure. 
Tetralogy of Fallot
Tetralogy of Fallot is the most common form of cyanotic congenital heart defects.  Tetralogy of 
Fallot is comprised of four separate congenital heart defects.  The first one is a VSD which as 
mentioned previously is an opening in the septum between the ventricles.  The second one is 
pulmonary stenosis which is narrowing at or just below the pulmonary valve.  The third defect is 
right ventricular hypertrophy, which is an increase in the thickness of the right ventricle.  The final 
defect is an overriding aorta, which means that the aorta lies directly over the ventricular septal 
defect instead of the left ventricle [49] [50] The ventricular septal defect is usually large and blood 
flows from the right ventricle through the VSD into the left ventricle.  The aorta arises dominantly 
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from the left ventricle but overrides the VSD so that there is a tendency for blood to flow into the 
aorta from both the left and the right ventricle.  
The severity of the narrowing of the pulmonary valve varies from one patient to another.  The 
effect of the pulmonary stenosis is to increase the resistance to blood flow from the right ventricle 
to the lungs thus the flow of blood to the lungs is reduced.  Once the blood flows into the left 
ventricle, it is ejected into the aorta and delivers a mixture of unoxygenated or poorly oxygenated 
blood into the body.  Consequently, the infant shows the features of cyanosis.  The greater the 
severity of the pulmonary stenosis, the more severe is the degree of cyanosis.
The most common signs and symptoms of a TOF are cyanosis and the infant may have 
difficulty breathing upon exertion.  Some infants have low birth weight or retarded growth.  Infants 
who have severe reduction in blood flow to the lungs and more profound cyanosis present early 
in the newborn period and require early measures to improve pulmonary blood flow.  In those 
where the pulmonary stenosis is less severe, may not show any symptoms until they are several 
months old, or not even until they become toddlers.  Essentially all children with Tetralogy of 
Fallot are limited in their physical activities and are at risk of complications.  The most common of 
these is the occurrence of `spells' in which the infant suddenly becomes extremely blue and 
floppy and often loses consciousness for a few minutes.  Recovery is usually rapid but on rare 
occasions an attack can be fatal.  These ‘spells’ are believed to be caused by a sudden 
narrowing of the outflow tract of the right ventricle as a result of a form of `spasm' of the right 
ventricular muscle below the pulmonary valve. When the spasm is relieved, the infant recovers 
from the spell. 
Another serious complication is related to bacteria entering the blood stream from an 
apparently mild infection of the skin or throat. Instead of passing normally to the lungs where the 
bacteria are trapped, they pass from the right ventricle, through the VSD to the body and may 
settle in the brain causing an abscess which can prove fatal [46, 49, 50] . 
TOF is usually diagnosed on the basis of the presenting symptoms and physical examination of 
the patient.  A chest x-ray on a patient with TOF may show a small boot-shaped heart with 
diminished pulmonary blood flow, a prominent right ventricle and possibly a right sided aortic arch 
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and knob.  The diagnosis of TOF is usually confirmed by echocardiography.  The echocardiogram 
demonstrates the VSD, overriding aorta, extent and location of the infundibular obstruction, 
assessment of pulmonic valve, and right ventricular hypertrophy [51] Cardiac catheterization is 
usually reserved for cases that are more severe and complex [52]. Most institutions perform 
cardiac catheterization prior to complete repair of complex defects [52]. In the United Kingdom, 
additional investigation by cardiac catheterization has been regarded as mandatory in some 
centers in order to demonstrate every fine detail of the abnormality [46]. 
Due to the risk of complications, it is recommended that an infant with Tetralogy of Fallot have 
a corrective operation as early as it can safely be performed.  A team of cardiac surgeons usually 
performs the surgery, usually before an infant is one year old.  In many cases, the repair is made 
at around 6 months of age, or even a little earlier.  Repairing the heart defects will allow oxygen-
poor blood to travel its normal route through the pulmonary artery to receive oxygen.[46, 53] If an 
infant is severely cyanotic, it may be necessary to undertake an emergency operation known as a 
`Blalock -Taussig shunt' in which a small tube is used to connect a branch of the aorta to the 
pulmonary artery[46].  Tetralogy of Fallot occurs in 40 in 100,000 live births [54].  There is a slight 
predominance in males over females[51, 54].
Coarctation of the Aorta
The aorta is the main artery that sends oxygenated blood from the heart to the body.  
Coarctation of the aorta is a constricted segment of the aorta that obstructs blood flow to the 
body.  Coarctation of the aorta causes low blood pressure and low blood flow in the arteries that 
branch off below the narrow spot; high blood pressure occurs in the arteries that branch off closer 
to the heart. As a result, coarctation of the aorta often leads to high blood pressure in the upper 
body and arms (or one arm) and low blood pressure in the lower body and legs. The left ventricle 
has to pump harder than normal in order to pump blood to the lower part of the body. The high 
pressure causes the heart to enlarge or hypertrophy.  The left ventricle may fail to pump blood 
adequately and the infant may go into heart failure. 
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Coarctations typically occur as isolated defects, but may occur with a ventricular septal defect, 
subaortic stenosis, or complex congenital heart defects.  Aortic coarctation is more common in 
some genetic conditions, such as Turner's syndrome. [55]
Coarctation of the aorta is commonly diagnosed between the ages of one to four weeks [56].
Infants with coarctation of the aorta frequently come to medical attention because of congestive 
heart failure[57].  Although heart failure can develop any time during the first six months of life, it 
typically develops during the first 6 weeks of life.  The major features associated with heart failure 
are a rapid heart and respiratory rate and poor weight gain.[57]
Coarctation of the aorta can also have no symptoms. Coarctation is often discovered during a 
newborn infant's first examination or during a well-baby exam. [55]  The health care provider will 
detect that the femoral pulses are absent or very weak.  A systolic murmur that is loudest in the 
back below the left shoulder blade is usually heard. [57] There may be signs of left-sided heart 
failure  or signs of aortic regurgitation.  An examination reveals high blood pressure in the arms 
and low blood pressure in the legs, with a significant blood pressure difference between the arms 
and legs.  The femoral pulse is weaker than the carotid pulse, or the femoral pulse may be totally 
absent.  A chest x-ray may show abnormal ribs or "notching" of ribs caused by enlargement of the 
rib arteries. An ECG may indicate left ventricular enlargement.  An echocardiogram and/or 
cardiac catheterization may detect an aortic pressure gradient, a difference in pressure within the 
aorta, caused by the coarctation.  [46, 55, 56]
Aortic coarctation occurs in approximately 10 out of 100,000 people.  It is twice as common in 
males as in females [55].  Repair of a coarctation, either surgically or using balloon angioplasty, is 
usually recommended by 18-24 months of age. Surgical repair typically involves removing the 
narrowed segment of aorta and reconnecting the ends directly [57] If a longer segment must be 
removed, a Dacron graft is used to fill the gap. Occasionally, balloon angioplasty  may be an 
alternative to surgical repair. [55]
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Prenatal exposures and congenital heart defects
A number of medications have been implicated in causing congenital heart defects when used 
by pregnant women during the first trimester. A causal relationship cannot be confirmed or ruled 
out for many of the medications. [58]
Congenital heart disease has been seen in children who were exposed to coumarin derivatives 
during the first trimester of pregnancy but no consistent pattern of malformations exists. [58, 59]
Thalidomide has been shown to induce congenital heart defects.  Exposure to thalidomide 36–
45 days after the first day of the last menstrual period has been associated with congenital heart 
defects specifically ductus, conotruncal defects, and septal defects. [59] A number of studies 
have shown that maternal thalidomide use was associated with congenital heart defects such as 
ventricular septal defect, atrial septal defect, Tetralogy of Fallot, cor triloculare, pericardial 
effusion, hypertrophy of atrium and ventricle, coarctation of aorta, and systolic murmurs. [59]
Congenital heart defects can occur with most anticonvulsants including carbamazepine, 
valproic acid, and phenobarbital. The following defects have been observed with first trimester 
exposure to valproate: patent ductus arteriousus, anomalies of great vessels, valvular aortic 
stenosis, ventricular septal defect, Tetralogy of Fallot, and partial right bundle-branch block.  [59]
A 2000 study, using data from the Malformation and Drug Exposure surveillance project, 
demonstrated a statistically significant association between 1) first trimester valproic acid 
monotherapy and coarctation of aorta, and 2) first trimester phenobarbital monotherapy and 
cardiac defects.  [60]   A prospective study published in 1999, observed cases of Tetralogy of 
Fallot associated with phenobarbital monotherapy.  [61]
Infants exposed to Isotretinoin during the first trimester of pregnancy exhibit a characteristic 
pattern of defects which was similar to that seen in animal models.  [59] The congenital heart 
defects consisting of the syndrome of those exposed to Isotretinoin include conotruncal 
malformations, transposition of the great vessels, Tetralogy of Fallot, double-outlet right ventricle, 
truncus ateriosus communis, ventricular septal defect and atrial septal defect.  [7, 29, 59]
Data accumulated by the Lithium Baby Register demonstrated that in those exposed to lithium 
in the first trimester,  77% (17 of 22) of the malformations involved congenital heart defects, 
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including 5 with the rare Ebstein's anomaly (Llewellyn 1998).  Other studies have also noted the 
increased prevalence of Ebstein's anomaly in lithium-exposed babies.  Coarctation of the aorta, 
mitral atresia, tricuspid atresia and ventricular septal defect have also been reported in infants 
exposed to lithium in utero [29, 59]
In a surveillance study of Michigan Medicaid recipients, a higher than expected rate of 
congenital heart defects among infants exposed to enalapril during the first trimester was 
observed.  [59]
Cardiac defects have also been observed in infants with congenital rubella syndrome.  The 
most common defects observed are patent ductus arteriosus and peripheral pulmonary artery 
stenosis.  [62]
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Table 2.1 Number of OXMIS and Read birth defect codes by organ system for preliminary 
validation analysis to estimate the number of patients in GPRD who had a birth defect 
recorded in 2001
Organ System Number of OXMIS and Read codes
Central Nervous System 100
Eye 32
Genitourinary 46
Cardiovascular 45
Cleft Lip/Palate 37
Respiratory 17
Alimentary 22
Musculoskeletal 13
Endocrine 5
Other 7
Total 324
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Table 2.2: Number of Birth defects recorded in 2001 within the GPRD by organ system
Organ System Number of birth defects recorded
Cardiovascular 197
Genitourinary 96
Central Nervous System 44
Alimentary 34
Cleft Lip/Palate 20
Eye 13
Respiratory 9
Musculoskeletal 2
Endocrine 0
Other 0
Total 415
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Table 2.3:   Prevalence of all congenital heart defects, selected published literature 1999-
2004
Author, Year Population  and Year Prevalence of all congenital heart defects 
among live births
Garne, 2004 Denmark, 1986-1993 7.9 in 10001
ONS, 2000 England and Wales, 2000 1.74 in 10002
Honein 1999 Metropolitan Atlanta, US, 
1991-1995
9 in 10003
Calzolari, 2003 Italy, 1980-1994 4.65 in 1000  
Baron 2001 Arizona Medicaid, US, 
1990-1994
6 in 1000
Wren 2000 UK, 1985-1997 5.6 in 1000 
Samanek 1999 Bohemia, 1980-1990 6.16 in 1000 
Bosi 2003 Italy, 1980-2000 3.1 – 7.5 in 1000 
Pradat 2003 California, US, 1985-1992 3.16 in 1000 4
Pradat 2003 Sweden, 1981-1992 2.50 in 1000 4
Pradat 2003 France, 1983-1992 2.89 in 1000 4
1- Includes children diagnosed up to five years of age
2- Includes heart and circulatory defects
3- Includes stillbirths greater than 20 weeks of gestation
4- Includes stillbirths greater than 28 weeks of gestation
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Table 2.4:  Specific Congenital Heart Defects by cyanotic category and percentage of total 
number of heart defects
Classification Defect % of Congenital Heart 
Defects
Tetralogy Of Fallot 10%
Transposition of the Great Arteries 5%
Total Anomalous Pulmonary Venous 
Return with or without obstruction 
2%
Double Outlet Right Ventricle 2%
Tricuspid Valve Abnormalities 2%
Pulmonary Atresia 2%
Hypoplastic Left Heart Syndrome 1.4-3.8%
Cyanotic
Truncus Arteriosus <1%
Ventricular Septal Defect 30%
Atrial Septal Defect 10%
Patent Ductus Arteriosus 10%
Aortic Stenosis 7%
Coarctation of Aorta 6%
Atrioventricular Septal Defect 4%
Dextrocardia rare
Cor Triatriatum rare
Congenital Mitral Regurgitation rare
Congenital Aortic Regurgitation rare
Absence of the Pulmonary Valve rare
Ebstein’s anomaly rare
Non-Cyanotic
Pulmonary Stenosis rare
[32, 43]
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Figure 1:  Diagram of blood flow through the heart
[27]
CHAPTER III RESEARCH DESIGN AND METHODS
Overview
A validation study of infants with congenital heart defects using the GPRD was conducted. 
The study population for this research study included a cohort of patients aged 0 to 6 years of 
age with a code corresponding to a congenital heart defect from the years 1998 through 2003.  
The clinical outcomes of interest were congenital heart defects and specifically ventricular septal 
defect, Tetralogy of Fallot and coarctation of the aorta.  The clinical outcomes were ascertained 
using computerized records as well as any available clinical information from the general 
practitioner on cases of ventricular septal defect, Tetralogy of Fallot, and coarctation of the aorta.
The validation study created operational case definitions of congenital heart defects and 
determined whether the case definitions created produce similar prevalence rates within the 
GPRD to those derived from population based sources in the UK.  This study assessed what 
available components of the GPRD data provide essential information about congenital heart 
defects. The positive predictive value of the computerized recorded diagnosis of specific 
congenital heart defects was determined using a medical records abstraction medical record 
abstraction form as the gold standard. This study also determined whether the GPRD can 
provide additional information about timing and presentation of specific congenital heart defects. 
Finally it evaluated whether the free text comments section from the infant’s and mother’s records
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provide supplemental information to the congenital heart defect data obtained from the infant’s 
computerized record.  
 Clinical outcomes of interest
The clinical outcomes of interest were congenital heart defects and specifically ventricular 
septal defect, Tetralogy of Fallot, and coarctation of the aorta.  VSD was chosen because it is the 
most common non-cyanotic defect and TOF because it is the most common cyanotic defect.
Coarctation of the aorta was chosen because it is one of the more common defects and it is 
associated with a high mortality rate among infants.  [63]
These outcomes were defined by using terms used by the 1) the International Classification of 
Diseases 9th edition (ICD-9) Coding system, 2) the Metropolitan Atlanta Congenital Defects 
Program (MACDP), and 3) the American College of Cardiology and 4) the Association for 
European Pediatric Cardiology to define congenital heart defects.  The clinical outcomes were 
ascertained using computerized records as well as any available clinical information from the 
general practitioner medical record abstraction form and the free text comments sections on 
cases of ventricular septal defect, Tetralogy of Fallot, and coarctation of the aorta.
Study design 
This validation study was completed in five steps. 
Aim 1
The first step was to create operational case definitions of congenital heart defects. Terms 
used by the 1) the ICD-9 Coding system, 2) the MACDP, 3) the American College of Cardiology 
and 4) the Association for European Pediatric Cardiology to define congenital heart defects were 
collected. The terms used by the MACDP include terms modified from the British Pediatric 
Association.  A total of 470 terms were collected. Appendix A contains the text strings that were 
used for the search. These terms were entered into a SAS program to search for OXMIS and 
Read codes within the GPRD system.  The 470 terms produced a total of 205 OXMIS and Read 
codes (Appendix B). Case definitions were created for all congenital heart defects, and 
categories of specific defects including ventricular septal defect, Tetralogy of Fallot, and 
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coarctation of the aorta (Table 3.1-3.3).  The grouping of congenital heart defects into clinical and 
structural categories were finalized by a University of North Carolina pediatric cardiologist.  The 
GPRD medical codes were assigned to the categories of ICD-9 codes corresponding to the 
EUROCAT/NCAS categories (Table 3.4).  GPRD medical codes can include symptoms of a 
condition rather than a definitive diagnosis and therefore did not always correspond exactly to an 
ICD - 9 code.  In such cases, GPRD medical codes were matched to ICD-9 diagnosis that only 
occurs with a specific condition. For example, the GPRD medical term “left ventricle to right atrial 
communication” was included in the atrioventricular septal defect category. Surgery and 
corrective codes were also included to ensure that all patients were captured for the medical 
record abstraction form but were removed for comparisons with EUROCAT and NCAS. Codes 
that may be used as non-congenital codes in adults were included because the patients were up 
to six years of age and thus such a code would indicate a congenital heart defect and not a 
disease of adulthood.
EUROCAT and NCAS define a congenital heart defect as an anomaly of the heart, of great 
vessels and endocardial fibroelastosis corresponding to ICD-9 codes; 745.0-745.9 746.0-746.9, 
747.0-747.4 (Table 3.4 ) [64]   EUROCAT and NCAS both exclude minor heart defects of 
1)functional or unspecified cardiac murmur, 2)absence or hypoplasia of umbilical artery, single 
umbilical artery and 3) patent ductus arteriousus in infants less than 37 weeks or less than 2500 
grams.[26] (Table 3.5)
Aim 2
The second step was to determine whether the case definitions of OXMIS and Read codes 
determined for congenital heart defects in step 1 produce similar prevalence rates within the 
GPRD to those derived from population-based sources in the UK.
The prevalence rates of congenital heart defects for the years 2001, 2002, and 2003 
determined from the GPRD computerized infant record data were compared to those obtained 
from the NCAS and the EUROCAT. The inclusion/exclusion criteria, definition of a defect, area of 
population coverage and years of data collection used in the population-based sources were 
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matched as closely as possible to the criteria used in the GPRD.  Prevalence rates were 
determined among live births only.  Additionally, prevalence rates were calculated in the GPRD 
for the year 2001 both in infants up to one year of age and in children up to six years of age. 
Prevalence of specific congenital heart defects was determined for each data source and by age 
from the GPRD.
Prevalence rates were calculated according to geographical region. The GPRD only covers 
portions of the UK; therefore, only data from the EUROCAT UK registries were included to 
calculate corresponding prevalence.  The GPRD covers different regions than EUROCAT and 
NCAS, therefore only the regions common to each data source were used for comparisons.  The 
GPRD includes regions of Eastern, North West, South East, and South West England as well as 
the Northern and Yorkshire Region, Trent, West Midlands, and London.  North Ireland and 
Scotland are also included in the GPRD regions.  For comparisons with EUROCAT, the GPRD 
regions of Eastern, North Ireland, South West and West Midlands regions were excluded.  
Scotland was also excluded because the EUROCAT Glasgow registry did not contribute data for 
2001-2003.  For comparisons with NCAS, the GPRD regions of North Ireland and Scotland were 
excluded.
Denominators used were also according to each geographical region.  The denominator used 
for comparisons with EUROCAT and NCAS was the number of live births within the GPRD within 
the geographical regions covered by each data system.  The denominator used to calculate 
prevalence for NCAS was all live births in England and Wales.  The denominator used to 
calculate prevalence for EUROCAT was all live births in the geographic regions covered by the 
EUROCAT registries.  The number of live births for each geographic region was obtained from 
the Office of National Statistics. 
Similarly to EUROCAT and NCAS, all prevalence rates and counts for specific types of heart 
defects from the GPRD were based on cases, not defects [65]. Thus an infant with a VSD and 
atrial septal defect (ASD) was counted once in all congenital heart defects, once in VSD and once 
in ASD.  The same principle was also applied when children up to age six were examined.  A 
case could only be counted once per specific heart defect even if it had multiple medical codes.  
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Minor heart defects excluded by EUROCAT and NCAS were excluded when calculating 
prevalence for GPRD. 
Aims 3 and 4
Using existing literature, medical record abstraction forms (questionnaires) were developed to 
assess whether the diagnosis recorded in the computerized medical record was concordant with 
the diagnosis recorded in the practitioner written or computerized notes for Aim 3.  Appendices C, 
D and E contain the medical record abstraction forms.  It determined whether the types of 
medical tests and findings documented in the medical record appeared to be consistent with 
those which would be expected to confirm the patient’s diagnosis.  The medical records 
abstraction form also aimed to assess the patient’s age at diagnosis as well as the reasons that 
the congenital heart defect was suspected for Aim 4.
Explanation of individual items on medical records abstraction form
Question 1: confirms the diagnosis of congenital heart defect.  The database shows that there is 
a congenital heart defect but this question will confirm the diagnosis from the practitioner’s record.  
Using the practitioner’s record as the gold standard we will determine from this question, the 
percentage of diagnoses that were correct in the computerized medical record.  Thus the positive 
predictive value of the computerized medical record will be determined. 
Question 2: assesses the patient’s age at diagnosis.  This question will demonstrate what the 
distribution of age of diagnosis is in the GPRD.  The ultimate aim is to provide data that the 
GPRD can assess birth defects as well as a pharmaceutical company sponsored pregnancy 
registry.  Typically the pharmaceutical company sponsored pregnancy registries do not get many 
reports of defects in children after birth.  Thus the aim of this question is to provide data on how 
many defects would be missed by only examining defects at birth.  This question will also provide 
data if there are differences in the age at which different types of congenital heart defects are 
diagnosed. 
Question 3: the reasons the defect was suspected.  This question aims to assess what type of 
information the GPRD can provide with regard to suspicion of a congenital heart defect. This 
question aims to quantify what percentage of defects were suspected based on symptoms and 
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signs, abnormal findings, family history and maternal risk factors.  A congenital heart defect  that 
is not associated with a family history of a congenital heart defect, an extracardiac anomaly or a 
suspected chromosomal abnormality has a possibility of being induced by another factor, (for 
example a medication).  Therefore this question aims to assess in what percentage, a risk factor 
was present.  For the percentage in which a risk factor was not present, it is possible to speculate 
that this group of defects has the potential to be medication related.  The age the defect was 
diagnosed can be compared with the reason for suspicion of diagnosis to see if there is an 
association between the two.  This question may help to clarify factors associated with delays in 
diagnosis. 
Question 4: who made the diagnosis.  Many neonatal units in the UK do not have pediatric 
cardiologists readily available and thus neonatalogists perform their role.  [66] Also within the 
GPRD, the general practitioner often fills the role of the pediatrician.  This question will determine 
to what extent pediatric cardiologists relative to other practitioners are involved in the diagnosis of 
congenital heart defects (specifically VSD, TOF, and COA) within the UK GPRD population.  This 
question also aims to assess whether the person who diagnosed the congenital heart defect is 
associated with whether the computerized diagnosis was confirmed by the medical records 
abstraction form. 
Question 5: to document the findings of the echocardiogram and other diagnostic tests.  This 
question will determine if the types of medical tests appear to be consistent with those which 
would be expected to be needed to confirm the diagnosis.  It will also determine if the findings 
from the echocardiogram appear to be consistent with those which would be expected to be seen 
with the diagnosis stated in the computerized medical record. Tests used to confirm the diagnosis 
of a VSD, TOF, and COA are usually echocardiogram and/or catheterization.  Usually patients 
undergo physical exam with auscultation, electrocardiogram, possibly a chest x-ray, possible 
blood tests, and blood pressure measurements and then referred for echocardiogram for a 
confirmatory diagnosis.  [41, 52] Catheterization is usually reserved for cases that are more 
severe and complex.  [52]
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Question 6 (VSD medical records abstraction form only): type of VSD. Using the OXMIS and 
Read codes, the type of VSD that was observed cannot be determined.  The aim of this question 
is to determine whether the type of VSD can be identified.  If the type can be identified it may be 
important for future research of drug exposure and VSD because if a drug is causing a VSD, it is 
likely that it will be the same kind for the same exposure. 
Question 7: whether the patient was referred to cardiology center.  This question attempts to 
determine where the diagnosis was made and if there are referral notes within the computerized 
record. 
Question 8: additional heart defects.  Often congenital heart defects are not isolated defects but 
are usually associated with other congenital heart defects.  This question aims to assess what 
other defects are seen with the defects in question and whether the additional defects received 
an OXMIS and Read code within the patient record.  Heart defects are often associated with 
other organ system defects as well, and these defects will be able to be ascertained from the 
computerized medical record information. 
A sample of records with codes for ventricular septal defect, coarctation of the aorta and 
Tetralogy of Fallot will be separated from the other records.  The MHRA was asked to send the 
medical records abstraction forms to the practitioners corresponding to the sample of records.   
Using the medical records abstraction form completed by the practitioner as the gold standard, 
the third step determined the positive predictive value of the computerized medical record 
corresponding to the group of congenital heart defects listed in Appendix B.  Using information 
from the medical record abstraction forms, the fourth step determined whether the GPRD can 
provide additional information about timing and presentation of specific congenital heart defects. 
Aim 5
This aim assessed whether free text comments fields obtained from the mother and infant
provide additional information to the computerized infant record data.  According to the GPRD 
recording guidelines, the condition of each newborn must be recorded in the child’s own record, 
as normal birth, prematurity or any birth defect [12].  Practitioners are also instructed to place 
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birth defects in mother’s comment section as well as in the infants’ record.  It is unknown whether 
the mother’s comments section is needed in addition to the infants’ record to obtain complete 
birth defect information.  More detailed information may be contained within the mother’s free text 
comments section as the practitioners are not limited by a coding system when entering data into 
the free text field.  To date, studies have not been performed to address what is contained within 
the mother’s free text comments section.  This study aimed to assess if there is additional 
detailed information within the mother’s free text comments field that is not contained within the 
child’s record.  If there is detailed information contained within the free text comments field, it may 
also reduce the need for medical record review.  
The sample of infant records corresponding to VSD, TOF and COA used to identify 
practitioners for the medical records abstraction forms was used to complete the fifth step.  This 
cohort of patients was also linked to their mother’s using the mother-infant link.  The mother-infant 
link algorithm has been developed by the MHRA.  Mothers and infants are linked by practice-
specific family numbers, date of birth of infant and delivery/birth records of the mother and 
registration date of pregnancy.  [67]
Within the GPRD, each medical encounter is listed as event which has a free text comments 
section associated with it.  Free text comments sections were obtained for the event codes that 
distinguished the 200 cases of VSD, TOF and COA as well as their respective mothers as 
described below.  
The free text comments sections for the 141 mothers were obtained in two ways to increase 
the probability that a mother’s comments section containing information about the child would be 
obtained.  First, the comments section were obtained by searching all of the mothers’ free text 
comments sections for the time period of a year prior and 2 years after the delivery date.  All free 
text comments containing keywords including congen, heart,  Fallot, tetra ,cardiac, defect, 
anomal, septal were extracted. 
Separate from the first extraction, the mother and baby clinical event codes were reduced to 
include only 1) mothers that had event year that was equal to the birth year of the baby, 2) infants 
that had an event less than 6 months from their date of birth, 3) infants where the time until 
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registration was less than the time from birth until event and 4) event codes from the mother's 
record that were specific to conditions that related to birth or postnatal events.  The free text 
comments sections corresponding to the event codes found from the exclusion above were 
extracted. 
A small subset of these event codes contained event dates that were recorded prior to an 
infant’s date of birth.  Records with events that were more than 140 days prior to birth date were 
excluded because very few (if any) prenatal diagnoses would be detected before the pregnancy 
reached 20 weeks.  The free text comments sections corresponding to the event codes prior to 
an infant’s date of birth were also extracted. 
Study population
The computerized information from the GPRD will be extracted and reviewed. For aim 2, the 
study population will include a cohort of patients aged zero to six years of age with a code 
corresponding to a congenital heart defect (Appendix B) between the years of 2001, 2002 and 
2003 from the full-feature GPRD.  The study population will be limited to children who have been 
followed since birth or time of registration (if there is a delay after birth up to 6 months) by the 
same general practitioner or practice.  Registration of an infant with a general practitioner may 
take up to 6 months.[67] Between birth and 6 months, the information about the infant should be 
recorded within the mother's record.  When the infant receives their own record, at registration, 
the information is transferred from the mother's record.  [11] Children who have a delay in 
registration after birth will be included to capture the cases that do not register with their general 
practitioner because they are still in the care of the hospital.  This would probably only include 
very severe cases.  Children must be permanently registered with their general practitioner to be 
included.  Permanent registration includes patients who have left the practice, those who have 
applied for registration and those who have died but not visitor patients.  [68] Children who have 
left the practice who have a valid transfer date will be included because records of patients 
transferred out remain on the database and are available for study.  [11] Children who have 
transferred into practices will not be included due to the possibility that the date of diagnosis is 
before the transfer date, thus we would not be able to access their records. 
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For steps three through five, the study population included a cohort of 75 cases of TOF, 36 
cases of COA and 373 cases of VSD identified between the years of 1992 to 2003.  Using GPRD 
medical record codes, Inclusion criteria of 1) date of birth of 1992 or later, 2) acceptable patient 
and clinical details, 3) currently registered in practice and 4) active practice status was applied to 
the sample of VSD, TOF and COA records.  Further inclusion criteria of 1) an event between 
1998 and 2003, and 2) a populated field for role of the person entering the information were 
applied to only the VSD sample.  The 200 medical record abstraction forms sent to practitioners 
included 23 cases of COA and 72 cases of TOF and a randomized sample of 105 cases of VSD.  
This cohort of patients was also linked to their mothers using the mother-infant link.  A sample 
of 141 mother’s records of the 200 VSD, TOF and COA patients was also included. 
Observational period
The observational period will consist of birth until the child’s sixth birthday.  The median age of 
diagnosis of congenital heart defects has been shown to be 6 months (range of 2 weeks to 11 
years of age).  [41] Ventricular septal defects were detected at a median age of 4 months and 
coarctation of the aorta at a median age of 8 months.  Tetralogy of Fallot has been shown to be 
typically diagnosed at birth or before discharge.  [41] These defects should normally be captured 
within the first year of life but a six year time window will be used to ensure that most defects are 
captured.  The MACDP uses a six year time period to capture birth defects, thus we are able to 
compare the data to this data source.  [35]
Data analysis
The first step was to create operational case definitions of congenital heart defects and thus it 
does not require any analysis.  The purpose of the following analyses is to determine whether the 
case definitions of OXMIS and Read codes determined for congenital heart defects in step 1 
produce similar prevalence rates to population-based sources and provide accurate 
representation of practitioner records.  
Prevalence rates were determined in the years 2001, 2002 and 2003 for all three data sources.  
Chi-square tests, rate ratios and 95% confidence intervals were calculated comparing 1) the 
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prevalence of congenital heart defects between the GPRD and the NCAS 2) the prevalence of 
congenital heart defects between the GPRD and EUROCAT and 3) the prevalence of congenital 
heart defects between infants up to age one in the GPRD and infants up to age six within the 
GPRD, 4) the prevalence of ventricular septal defect between infants up to age one in the GPRD 
and infants up to age six within the GPRD in the year 2001 and 5) the prevalence of specific 
defects in 2001 between the GPRD and NCAS and EUROCAT respectively. Specific defects 
were only compared if the number produced by the GPRD was greater than ten.  All analyses 
were conducted using SAS 8 (SAS Institute, Cary, NC).  NCAS and EUROCAT do not have 
stratified sampling schemes and therefore do not have weighted data therefore we can calculate 
95% confidence intervals for differences in prevalence (rate ratios) between GPRD and the 
population based sources.
Using the medical record abstraction form completed by the practitioner as the gold standard, 
the positive predictive value of the computerized medical record was determined as the 
proportion of diagnoses in the computerized records that had a concordant diagnosis from the 
medical record abstraction form. 
Frequencies and percentages among the specific defects were calculated for the ages at which 
the congenital heart defects were diagnosed, the reasons the defect was suspected, who made 
the diagnosis, the findings of the electrocardiograms, and any additional heart defects reported.  
The frequencies and percentages were used to demonstrate whether there is any variation 
among the type of congenital heart defects recorded.  The electronic medical records were hand-
searched where the medical record abstraction form data indicated non-concordance with the 
computerized medical record diagnosis. 
The percent agreement between infant diagnoses captured within the mother’s free text 
comments section, and the infants’ record was determined.  The proportion of congenital heart 
defects captured in both the mother’s and infants free text comments section was determined.
Study size
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The study consisted of data from 1992 through 2003.  Data from 1998 to 2003 was used 
because this is the time period that is captured by the Full-Feature GPRD (FFGPRD) and is 
included in the mother-infant link.  Historical data contained in the files of the FFGPRD was used 
for data before 1998.  There are approximately 20,000 births per year covered by the GPRD.  [14]
It was estimated that there will be about 100 congenital heart defects seen each year.  Ventricular 
septal defects comprise about 30%, Tetralogy of Fallot comprise about 10% and coarctation of 
the aorta comprise about 6% of the total number of congenital heart defects.  Throughout the 6-
year study period it was estimated that a total of 600 congenital heart defects including 
approximately 180 cases of ventricular septal defects, 60 cases of Tetralogy of Fallot and 36 
cases of coarctation of the aorta were likely to be obtained.  
A positive predictive value (PPV) of 0.7 was taken to be the least acceptable value that will 
indicate an adequate predictive value of the computerized records.  As stated in Section 2.4, 
published literature indicates that there is good agreement between the computerized medical 
record and the practitioner's medical record for a number of diagnoses.  Positive predictive value 
of the computerized records have ranged from 87%-100% for a variety of conditions. [18, 19, 21, 
22] Based upon previous literature, a PPV of greater than 70% is expected but the lower value of 
70% was used to determine that there was adequate sample size in the event that the 
computerized medical records produce a lower PPV since congenital heart defects have never 
been examined within the GPRD.  The standard error of the PPV is maximal for PPV equal to 
50% and decreases with increasing PPV for PPV greater than 50% [16]. Therefore the standard 
errors computed below assuming a PPV of 70% should be even lower if higher PPVs are found. 
A total of approximately 276 cases (cases of VSD, TOF and COA) was expected to be 
obtained, however a sample of 200 was used due to financial restrictions.  A sample of 
approximately 100 ventricular septal defects and all cases of Tetralogy of Fallot (n 60) and 
coarctation of the aorta (n 36) was expected.  For the time period of 1992 to 2003, a total of 373 
cases of VSD, 75 cases of TOF and 36 cases of COA were actually obtained. 
This series of calculations shown in table 3.6 demonstrates that if the positive predictive value
is at least 0.7 , then standard errors no larger than those in the table should be obtained with the 
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sample sizes shown.  Thus, adequate precision was able to be obtained with the number of 
cases seen in a 6 year time period.
Of note, we excluded patients who have a transfer into the practice before the date of 
diagnosis.  In a document published by the Office of Population and Census on information for 
researchers using the GPRD, it states that there is an annual turnover of 5-15% of practice 
populations as patients move and transfer to new practices.  [11] Previous literature has also 
shown that the percentage of records that are unavailable due to transfer out of practice range 
from 3% to 10%.  [15, 20, 22] If the transfer rate equals 5% or more, we would have to decrease 
the total number of births that are available to us for use in the sample size calculation.  
If the transfer rate was 5%, the population of births available for study would be 19000.  Using 
a prevalence of 5 in 1000 and a population of 19000, we would still expect 95 defects in one year.  
Thus it is estimated that we would obtain 570 cases of congenital heart defects including 171 
cases of VSD, 57 cases of TOF, and 34 cases of COA.  If the transfer rate was 10%, the 
population of births available for study would be 18000.  Using a prevalence of 5 in 1000 and a 
population of 18000, we would still expect 90 defects in one year.  Thus it is estimated that we 
would obtain 540 cases of congenital heart defects including 162 cases of VSD, 54 cases of TOF, 
and 32 cases of COA. 
Human Subjects
Since this is a secondary data analysis, protected patient information and confidentiality were 
the ethical issues raised in the design of the study.  The patient records in the GPRD are 
anonymous in order to maintain patient confidentiality.  Each patient has a unique patient 
identifier, which is assigned by the computer when a patient registers with their doctor.  All 
identifiers such as name and address have been removed.  Only year of birth is kept, except for 
children under five for whom month of birth is also recorded, after five years the month is erased.  
A code for the practice at which the patient is registered is contained within the unique identifier 
so that a practice can be contacted for specific inquires about individual patient records, however 
it is not possible for anyone other than the practice to identify any individual patient.  The free text 
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information included unique free text identifiers which were given to the MHRA, the agency that 
maintains the GPRD, and then the free text was anonymized removing patient names, dates of 
birth, practice names, practitioner names and names of hospitals or clinics. 
Data is provided geographically in aggregates so that practices cannot be identified.  The 
practices cannot be contacted by the investigator.  When the medical record abstraction forms 
were sent, the investigator sent a letter to the MHRA, and the agency forwarded the medical
records abstraction forms to the respective practices.  
A data use agreement was signed undertaking agreement to the conditions for safeguarding 
confidentiality.  Data were reviewed by the agency before being transmitted to the investigator to 
ensure complete patient and practitioner confidentiality and anonymity. 
Approval was granted by the Scientific and Ethnic Advisory Group for the GPRD to ensure that 
patient confidentiality is protected and to ensure the scientific and ethical soundness of the 
research project.  Approval was also granted by the UNC Institutional Review Board to ensure 
patient confidentiality and ethical standards. 
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Table 3.1:  GPRD Tetralogy of Fallot Medical Codes
GPRD
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
235367
ATRESIA OF PULMONARY ARTERY 
WITH SEPTAL DEFECT 745.2
220579 TETRALOGY OF FALLOT 745.2
253550 TETRALOGY OF FALLOT 745.2
217133 TETRALOGY OF FALLOT NOS 745.2
208176
TETRALOGY OF FALLOT,
UNSPECIFIED 745.2
299424
VENTRICULAR SEPTAL DEFECT IN 
FALLOTS TETRALOGY 745.2
235367
ATRESIA OF PULMONARY ARTERY 
WITH SEPTAL DEFECT 745.2
281047
DEXTRATRANSPOSITION OF AORTA 
IN FALLOTS TETRALOGY 745.2
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Table 3.2: GPRD Ventricular Septal Defect Medical Codes
GPRD 
MEDICAL
CODE DESCRIPTION
ICD-9 
CODE
247790 ABSENCE SEPTUM VENTRICULAR 745.40
290169 GERBODES DEFECT 745.40
272008
INTERVENTRICULAR SEPTAL 
DEFECT 745.40
217134
OTHER SPECIFIED VENTRICULAR 
SEPTAL DEFECT 745.4
262734 ROGERS DISEASE 745.40
284503 ROGERS DISEASE 745.40
247791 SYNDROME EISENMENGERS 745.40
208177 VENTRICULAR SEPTAL DEFECT 745.4
208178
VENTRICULAR SEPTAL DEFECT 
NOS 745.4
290168
VENTRICULAR SEPTAL DEFECT, 
UNSPECIFIED 745.4
304981
VSD (VENTRICULAR SEPTAL 
DEFECT) 745.4
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Table 3.3:  GPRD Coarctation of the Aorta Medical Codes
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
307120 COARCTATION AORTA 747.1
217144 COARCTATION OF AORTA 747.1
235364
COARCTATION OF AORTA
NOS 747.1
244365
POSTDUCTAL 
COARCTATION OF AORTA 747.1
272027
PREDUCTAL 
COARCTATION OF AORTA 747.1
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Table 3.4: Specific Heart Defect Categories from EUROCAT/NCAS to which GPRD medical 
codes were assigned
Category of Heart Defect ICD-9 Codes included 
Congenital Heart Defects 745.0-745.9
746.0-746.9
747.0-747.4
Anomalies of cardiac chambers and 
connections 
7450.0, 745.1, 745.3, 745.7
     Common Arterial Truncus 745.00
     Transposition of Great Vessels       745.10
     Single Ventricle 745.3
Malformations of Cardiac Septa 745.01,745.2, 745.4, 745.5, 745.6, 745.8, 
745.9
     Ventricular Septal Defect 745.4
     Atrial Septal Defect 745.5
     Atrioventricular Septal Defect 745.6
     Tetralogy of Fallot 745.2
Malformations of Valves 746.0-746.7
     Tricuspid Atresia and Stenosis 746.1
     Ebstein’s anomaly 746.2
     Aortic Valve stenosis 746.3
     Hypoplastic Left heart 746.7
Malformations of Great arteries and veins 747.1, 747.2, 747.3, 747.42, 747.43
Excludes 747.0
     Coarctation of aorta 747.1
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Table 3.5 Exclusion List
GPRD 
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
240860 ATRIAL INVERSION OP FOR TRANSPOSITION OF GREA 745.1
286699 ATRIAL INVERSION OPS FOR TRANSPOSITION OF GRE 745.1
286699
ATRIAL INVERSION OPS FOR TRANSPOSITION OF GREAT 
VESSELS 745.10
250041
SENNING CORRECTION FOR TRANSPOSITION OF GREAT 
VESSELS 745.1
204690 OTHER CORRECTION OF TRANSPOSITION OF GREAT VE 745.12
204690
OTHER CORRECTION OF TRANSPOSITION OF GREAT 
VESSELS 745.12
204691
OTHER CORRECTION OF TRANSPOSITION OF GREAT 
VESSELS NOS 745.12
222688
OTHER CORRECTION OF TRANSPOSITION OF GREAT 
VESSELS OS 745.12
295811
CORRECT FALLOT TETRALOGY-VALVED RIGHT VENTR 
OUTFLOW CONDUIT 745.2
240856 CORRECTION OF TETRALOGY OF FALLOT 745.2
204688 CORRECTION OF TETRALOGY OF FALLOT NOS 745.2
259253 OTHER SPECIFIED CORRECTION OF TETRALOGY OF FALLOT 745.2
266658 TETRALOGY OF FALLOT TOTAL CORRECTION 745.2
202923 CORRECTION FALLOTS TETRALOGY COMPLETE 745.2
213707 REVISION OF CORRECTION OF TETRALOGY OF FALLOT 745.2
240857
CORRECT FALLOT TETRALOGY-RIGHT VENTRIC OUTFLOW 
CONDUIT NEC 745.2
240858
CORRECT FALLOT TETRALOGY-RIGHT VENTRICULAR 
OUTFLOW PATCH 745.2
257426 VSD CLOSURE (VENTRICULAR SEPTAL DEFECT) 745.4
238988 VSD REPAIR (VENTRICULAR SEPTAL DEFECT) 745.4
284918 PATENT FORAMEN OVALE CLOSURE 745.5
286702 CLOSURE OF PERSISTENT OSTIUM PRIMUM 745.61
250062 REPAIR OF SUBAORTIC STENOSIS 746.81
259290 CLOSURE OF PATENT DUCTUS ARTERIOSUS NEC 747
294032 CLOSURE PATENT DUCTUS ARTERIOSUS 747
277615 DIVISION OF PATENT DUCTUS ARTERIOSUS 747.00
286741 LIGATION OF PATENT DUCTUS ARTERIOSUS 747
295850 OPEN CORRECTION OF PATENT DUCTUS ARTERIOSUS 747
286740 OPEN CORRECTION OF PATENT DUCTUS ARTERIOSUS ( 747
250079 OPEN CORRECTION OF PATENT DUCTUS ARTERIOSUS N 747
240902
OTHER SPECIFIED OPEN CORRECTION OF PATENT DUCTUS 
ARTERIOSUS 747
257429 PATENT DUCTUS ARTERIOSUS REPAIR 747
240903 PERCUT TRANSLUM PROSTH OCCLUS PATENT DUCTUS A 747
286742 REVISION OF CORRECTION OF PATENT DUCTUS ARTERIOSUS 747
266662 EXCISION COARCTATION WITH GRAFT 747.1
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 Table 3.5  Exclusion List (continued)
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
268528
HAMILTON REPAIR COARCTATION OF AORTA USING 
SUBCLAVIAN FLAP 747.1
277562
CORRECTION OF TOTAL ANOMALOUS PULMONARY 
VENOUS CONNECTION 747.41
268475
CORRECTION OF TOTAL ANOMALOUS PULMONARY 
VENOUS CONNECTION OS 747.41
222690
CORRECTION TOTAL ANOMALOUS PULMONARY VENOUS 
CONNECTION NOS 747.41
253563 BOTALLIS PATENT DUCTUS 747
226275 PATENT DUCTUS ARTERIOSUS 747
304985 PERSISTENT DUCTUS ARTERIOSUS 747
247800 PERSISTENT DUCTUS BOTALLI 747
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Table 3.6: Sample size, 95% Confidence Intervals and Standard Error
Number of cases
N(Defect)
Positive Predictive 
Value
95% Confidence 
Interval
Standard Error
200 (Total) 0.7 (0.636, 0.764) 0.0324
100 (VSD) 0.7 (0.610, 0.790) 0.0458
60 (TOF) 0.7 (0.584, 0.816) 0.0591
36 (COA) 0.7 (0.550, 0.850) 0.0763
[14, 68]
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Abstract
Objective: To examine whether the rates of all, and specific types of, congenital heart defects 
obtained from the General Research Practice Database (GPRD) are similar to those obtained 
from UK national systems. 
Methods: The prevalence rates of heart defects for the years 2001, 2002 and 2003 were 
determined from the GPRD and compared to both the National Congenital Anomaly System 
(NCAS) and the European Concerted Action of Congenital Anomalies and Twins (EUROCAT). 
Chi-square tests, rate ratios and 95% confidence intervals were calculated comparing the 
prevalence of: 1)heart defects overall, and 2) specific types of heart defects from the GPRD with
those from national sources, as well as 3) heart defects in infants up to age one with children up 
to age six within the GPRD.  
Results: The prevalence of heart defects from the GPRD was more than twice as high as in the 
NCAS and slightly higher than in the EUROCAT. All differences reached statistical significance. 
The prevalence of specific heart defects varied across the GPRD, NCAS and EUROCAT.  The 
differences in prevalence varied by age group, type of heart defect and usual time of diagnosis. 
Conclusion:  The GPRD may provide a more complete estimate of prevalence of the most 
commonly occurring heart defects than current UK national systems.   The database offers
significant advantages for estimating the prevalence of heart defects in the UK because it does 
not rely on voluntary reporting and allows for defects diagnosed after one year of age to be 
included. 
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Introduction
The formation of the heart is a complex process with many opportunities for errors to occur.  
Congenital heart defects are the most common and most fatal type of birth defect. Some factors 
which may increase the likelihood of the presence of a heart defect include maternal infections, 
heredity, and the presence of other birth defects [1, 2]. A number of medications have been 
implicated in causing heart defects when used by pregnant women. A causal relationship cannot 
be confirmed or ruled out for many of the medications. [3, 4]  In order to properly assess the 
association between maternal medication use and heart defects, an accurate and complete 
source of background prevalence rate is essential. 
The published prevalence of congenital heart defects among live births ranges from 1.74 to 9 
in 1000, and varies by source and type of data collection [5-14] (Table 4.1).  The prevalence 
estimates depend on the methods of case ascertainment, the inclusion/exclusion criteria, the
degree to which prenatal diagnoses are included and the duration of follow-up, definitions of a 
heart defect, and diagnostic categorisations [5-7, 9, 15]. 
The current sources of heart defect prevalence within the UK include the National Congenital 
Anomaly System (NCAS) and the European Concerted Action of Congenital Anomalies and 
Twins (EUROCAT).  These sources rely on voluntary reporting from birth defects registries 
across England and Wales. National estimates from the NCAS have been shown to be 
underestimated because ascertainment to the national register is low due to voluntary reporting 
and is non-uniform due to incomplete population coverage [16].  In 1999, the system covered all
births in Wales and 23% of births in England [17].  Additionally, defects detected after birth tend 
not to be reported [17].  
The UK General Practice Research Database (GPRD) may provide both a more uniform and 
more complete estimate of heart defect prevalence than the national systems.  As the UK 
National Health System (NHS) provides universal coverage, it is unlikely that a segment of the 
population is systematically excluded from the GPRD [18]. As a medical records based database, 
it does not rely on voluntary reporting of birth defects. In recent years, informed consent has also 
become a threat to the operation of registries relying on clinician notification [19]. Using the 
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GPRD may overcome this limitation because the data do not rely on patient consent for reporting 
while remaining in anonymised format to maintain strict patient confidentiality.  
An additional advantage of the GPRD is that there is no age limit to defect ascertainment. 
Congenital heart defects have been shown to be diagnosed at varying ages. The median age of 
diagnosis of heart defects is 6 months (range of 2 weeks to 11 years of age). [11]  The 
EUROCAT system only records anomalies up to one year of age [20].  
To date, the prevalence of congenital heart defects has neither been examined within GPRD 
nor compared to population-based sources. The objective of this study is to examine whether the 
rates of all heart defects, as well as specific types of heart defects, obtained from the GPRD are 
similar to those from UK population-based sources. 
Methods
The prevalence rates of congenital heart defects for 2001, 2002 and 2003 were determined 
from the GPRD computerised infant record data and compared to those obtained from the NCAS 
and the EUROCAT. The inclusion/exclusion criteria, definition of a defect, area of population 
coverage and years of data collection used in the population based sources were matched as 
closely as possible to the criteria used in the GPRD. Prevalence rates were determined among 
live births only.  Prevalence of specific congenital heart defects was determined for each data 
source and by age from the GPRD.
Data Sources
The GPRD contains information on three million patients in the UK (a geographical and 
demographically representative sample of approximately 4.6% of the UK population) and covers 
approximately 30,000 births per year [18].  There are approximately 350 general practices 
contributing to the GPRD, all members of the National Health Service (NHS) in England [21]. 
The EUROCAT began in 1979 and is a European network of population-based registries for 
the epidemiologic surveillance of congenital anomalies [17]. It records congenital anomalies for 
live births, fetal deaths and induced abortions. 
The National Congenital Anomaly System (NCAS) is a surveillance system which began in 
1949 and is run by the Office of National Statistics. It records congenital anomalies for both live 
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and stillbirths in England and Wales. The NCAS uses the defect exclusion list developed by 
EUROCAT in 1990. Spontaneous and induced abortions are not included in the system. [5]. 
Case definitions and classification
The coding system of the GPRD (OXMIS and Read coding) is based on text, therefore a 
standardised group of codes corresponding to congenital heart defects within the GPRD did not 
previously exist.  The current study created case definitions in the GPRD for all congenital heart 
defects and specific defect categories used by EUROCAT and NCAS.  EUROCAT and NCAS 
define a congenital heart defect as an anomaly of the heart, of great vessels and endocardial 
fibroelastosis corresponding to ICD-9 codes; 745.0-745.9 746.0-746.9, 747.0-747.4  [20]
EUROCAT and NCAS both exclude minor heart defects of 1) functional or unspecified cardiac 
murmur, 2) absence or hypoplasia of umbilical artery, or single umbilical artery and 3) patent 
ductus arteriosus in infants less than 37 weeks or less than 2500 grams. The GPRD medical 
code descriptions were reviewed by a paediatric cardiologist (JL) and assigned to the categories 
of ICD-9 codes corresponding to the EUROCAT and NCAS categories. 
Prevalence rates were calculated according to geographical region. The GPRD covers different 
regions than EUROCAT and NCAS, therefore only the regions common to each data source were 
used for comparisons.  The denominator used for comparisons with EUROCAT and NCAS was 
the number of live births within the GPRD within the regions covered by each data system.  The 
denominator used to calculate prevalence for NCAS was all live births in England and Wales. The 
denominator used to calculate prevalence for EUROCAT was all live births in the regions covered
by the EUROCAT registries (obtained from the Office of National Statistics). 
Similarly to EUROCAT and NCAS, all prevalence rates and counts for specific types of heart 
defects from the GPRD were based on cases, not defects [22]. Thus an infant with a ventricular 
septal defect (VSD) and atrial septal defect (ASD) was counted once in all congenital heart 
defects, once in VSD and once in ASD.  
Analysis
Prevalence rates and 95% confidence intervals were determined for 2001, 2002 and 2003 for 
all three data sources. Chi-square tests, rate ratios and 95% confidence intervals were calculated 
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comparing the prevalence of 1) heart defects between the GPRD and the NCAS 2) heart defects 
between the GPRD and EUROCAT and 3) heart defects between infants up to age one and 
infants up to age six within the GPRD, 4) ventricular septal defect between infants up to age one 
and infants up to age six within the GPRD in 2001 and 5) specific defects in 2001 between the 
GPRD and NCAS and EUROCAT respectively. Specific defects were only compared if the 
number produced by the GPRD was greater than ten because the small sample sizes would 
produce invalid chi-square estimates [23].  All analyses were conducted using SAS 8 (SAS 
Institute, Cary, NC). 
Results
Using the GPRD, 169 cases of congenital heart defects among live births were identified in 
2001, 158 cases in 2002 and 138 cases in 2003. Thus for the years of 2001, 2002 and 2003 the 
prevalence of all heart defects in the GPRD was 54 per 10,000, 53 per 10,000 and 45 per 10,000 
respectively (difference in prevalence rates among years not statistically significant).  The overall 
prevalence in the GPRD was more than twice as high in the GPRD than in the NCAS (Table 4.2) 
and slightly higher in the GPRD than in EUROCAT (Table 4.2).  All differences were statistically 
significant. 
The rates of specific heart defects also varied across GPRD, NCAS and EUROCAT in 2001 
(Table 4.3). The GPRD produced a prevalence rate of malformations of cardiac septa almost four 
times higher than NCAS (RR=3.7, 95% CI (3.1- 4.5)) and nearly twice as high as EUROCAT 
(RR= 1.8, 95% CI (1.5-2.2)).  The rate of VSD within the GPRD was six times higher than in 
NCAS (RR= 5.9, 95% CI (4.8-7.2)) and over two times higher than EUROCAT (RR= 2.4, 95% CI 
(2.0-3.0)).  The rate of TOF in GPRD was more than four times higher than in NCAS (RR=4.3, 
95% CI (2.4-7.8)) and more than twice as high as EUROCAT (RR= 2.4, 95% CI (1.3-4.4)) (Table 
4.3). The GPRD did not include any cases of very rare defects such as single ventricle, tricuspid 
atresia, and Ebstein’s anomaly within the time frame of 2001- 2003.
The GPRD prevalence calculated for 2001 for infants up to age one compared to the 
prevalence calculated for children up to age six varies by type of congenital heart defect.  The 
overall prevalence of congenital heart defects is significantly lower for infants up to age one 
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compared to children up to age six (Table 4.3) (RR = 0.64, 95% CI (0.52-0.77).  VSD prevalence 
is also significantly lower in infants up to age one as compared to children up to age six. (Tables 
4.3 and 4.4) (RR=0.61 95% CI (0.48-0.77).  
Discussion
The GPRD has the potential to produce a more complete estimate of prevalence of the more 
commonly occurring congenital heart defects compared to currently available UK national 
systems. Its advantages include case ascertainment methods that do not rely on voluntary 
reporting and a theoretically unlimited duration of follow-up time.
The comparisons among the GPRD, the NCAS and EUROCAT demonstrate that the GPRD 
produces significantly higher prevalence rates of all heart defects than either of the national 
systems. Published rates of heart defects vary greatly (1.7-9 in 1000) [5, 6, 9, 10, 12-14, 17, 24]
This study attempted to standardise the methods used to calculate prevalence to evaluate how 
similar the various rates obtained from data sources were to one another. However the results 
show that the difference in data collection methods resulted in considerable variation in 
prevalence rates among the three sources. The EUROCAT and NCAS are both voluntary 
systems which rely on reporting by practitioners or hospitals, and consequently not all cases are 
reported [7]. Since the GPRD is a medical records database, cases are systematically obtained 
from all medical records.  Therefore, as expected, the GPRD prevalence of all heart defects was 
higher than both the NCAS and EUROCAT. 
Another difference between the voluntary sources and the medical record database is the 
duration of follow-up. The EUROCAT system only records anomalies up to one year of age [20].  
Using the GPRD, the prevalence rate was calculated for children up to age six for more complete 
case ascertainment. Thus as expected a higher prevalence rate was obtained for children up to 
six years of age compared to those up to age one because the age of diagnosis ranges from 2 
weeks to 11 years of age (mean 6 months) [11]. Defects that are usually more serious and 
diagnosed at birth or in the first year of life such as transposition of the great vessels and 
Tetralogy of Fallot tended to have similar prevalence rates when the rate was calculated for 
children up to age six compared to infants up to age one [11]. Defects that can be diagnosed later 
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in infancy and into early childhood such as VSD, malformations of cardiac septa, malformations 
of valves and coarctation of aorta tended to have a higher prevalence when the rate was 
calculated for children up to age six  [11]. These findings were consistent with a Danish study 
assessing prevalence of congenital heart defects in children up to five years of age that showed 
VSD was among the most frequent diagnoses in children diagnosed after age one [13].
The Metropolitan Atlanta Birth Congenital Defects Program (MACDP) currently includes birth 
defects diagnosed until age six [24]. In 1995, the MACDP reported a rate of 4.9 per 1000 live 
births for congenital heart defects in infants up to age one, and a rate of 9.1 per 1000 live births 
for children up to age six [24]. These rates are similar to those that were demonstrated in the 
GPRD; 5.4 per 1000 in infants up to age one and 8.6 per 1000 in children up to age six. Thus, the 
GPRD may provide a more complete source of information than the UK national systems for 
defects that are diagnosed into early childhood.   
The current results suggest that the GPRD is a good source of information for determining the 
prevalence of commonly occurring congenital heart defects but may not allow for the 
determination of the prevalence of rare heart defects during a short time period. The GPRD did 
not detect any cases of very rare defects such as single ventricle, tricuspid atresia, and Ebstein’s 
anomaly within the three year time frame of the study. In the NCAS, which has a larger population 
base (approximately 600,000 births per year), the rate for single ventricle was 0.1 per 10000, for 
tricuspid atresia was 0.1 per 10000 and for Ebstein’s anomaly was 0.2 per 10000. Given the 
number of births covered by the GPRD each year (approximately 30,000) one would not expect 
to detect a case of a defect that occurs less than 0.5 per 10000. Of note, cases of these rare 
defects were captured when a ten year time period was examined (data not shown). 
The rates of specific heart defects also varied across GPRD, NCAS and EUROCAT as well as 
by type of heart defect (Table 4.4). It is possible that these rates varied because the sample size 
from the GPRD was insufficient to show differences in the more rare defects compared to the 
population based systems. It is also possible that the higher rates obtained from the GPRD may 
be due to better ascertainment methods. This may be important as the GPRD rate of TOF, a very 
serious defect, was four times higher than the NCAS and twice as high as in the EUROCAT. TOF 
57
has been implicated in association with medication use during pregnancy [4, 25] and thus future 
studies examining medication use in pregnancy may find the GPRD a useful data source. 
Another possibility is that this finding could be due to a difference in distribution of specific defects 
across geographical areas; as different areas were used for comparisons among GPRD, NCAS 
and EUROCAT for specific heart defects. 
A potential limitation of the GPRD is that the prevalence is based only on a single code in the 
computerised medical record and thus could misrepresent true prevalence. The EUROCAT and 
NCAS both have quality assurance checks to verify cases. Duplication checks, range error 
checks and at least one malformation or syndrome code are verified. While the medical records 
within the GPRD are also verified for plausible event dates and acceptable patient details, the 
code that is entered into the computerised system is not routinely validated by another clinician. 
Currently a validation study of some of the most commonly occurring heart defects is underway 
to assess the possible impact on prevalence rates. Preliminary results indicate a 93% positive 
predictive value of the computerised medical record information, suggesting that it is unlikely that 
the prevalence rates calculated in the current study misrepresent the true prevalence in the 
GPRD.  
Another potential limitation of the GPRD is that it does not include cases diagnosed prenatally
or in stillbirths. While this may be limitation for calculating prevalence in defects where a large 
proportion are diagnosed prenatally, the percentage of congenital heart defects diagnosed 
prenatally tends to be low.  Estimates from EUROCAT in 2001 suggest that 84% of congenital 
heart defects were assessed at or after birth [17]. In a study in Italy of 1311 cases of heart defect 
undergoing routine ultrasound, only 99 cases (7.5%) had been identified prenatally. [10] Another 
study in Denmark demonstrated prenatal terminations accounted for only 1.5% of the cases of 
heart defects during a 13 year period [13].
GPRD is unable to determine the prevalence among stillbirths because an infant does not 
receive a medical record if death occurs before delivery.  However this is unlikely to appreciably 
change the prevalence of heart defects.  In 2003 in NCAS, stillbirths accounted for only 0.5% of 
the total number of births per year. Stillbirths accounted for only 4% of the total number of 
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congenital heart defects in EUROCAT in 2003 [17].  Similarly, published studies have 
demonstrated that inclusion of stillbirths does not change the prevalence appreciably. A study 
assessing the temporal variability in birth prevalence of heart defects included only live births 
because the proportion of stillbirths was very small [27].  Other studies assessing the prevalence 
of heart defects in Italy and Denmark demonstrated stillbirths only accounted for 0.8% and 2.5% 
of the cases of heart defects respectively in over 10 years of data collection. [10, 13]
In summary, the GPRD appears to provide a more complete estimate of the prevalence of the 
most commonly occurring heart defects than current UK national systems. GPRD does not rely 
on voluntary reporting and allows for defects diagnosed after one year of age to be included. It is 
important to have a complete source of background prevalence estimates for heart defects so 
that associations with medications or other factors can be assessed. The current results suggest 
that the GPRD is a valuable source of information regarding prevalence estimates for heart 
defects in the UK population. 
This study is based in part on data from the Full Feature General Practice Research Database 
obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. 
However, the interpretation and conclusions contained in this report are those of the authors 
alone.
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The Utility of the GPRD to examine selected congenital heart defects- a validation study
Wurst K, Ephross S, Loehr J, Clark D, Guess H*
Abstract
Objective: The purpose of this research was 1) to validate that ventricular septal defect (VSD), 
Tetralogy of Fallot (TOF) and coarctation of the aorta (COA) can be studied in the U.K. General 
Practice Research Database (GPRD) and 2) to understand which available components 
(computerized medical records, questionnaires, and maternal/infant free text information) provide 
maximal information about these heart defects. 
Methods: The positive predictive value (PPV)s of the computerized medical record for VSD, 
TOF, and COA were determined. Free text comments sections were obtained for the 200 cases 
of VSD, TOF, and COA, and for their respective mothers.  Concordance between infant’s free text 
information and questionnaires was calculated.  The proportion of congenital heart defects 
captured in the mother’s free text was determined.  
Results: A 93% response rate was achieved (n=186/200 questionnaires sent).  Overall, a PPV of 
93% was achieved (VSD= 90.5%, TOF= 90%, COA= 100%).  Approximately half of the records 
contained infant free text information. The infant’s free text contained information on the type and 
size of VSD, echocardiogram findings and surgery or cardiac catheterization.  Concordance 
between the infant’s free text and questionnaire information occurred in most cases (92-100 %).  
The proportion of information in the mother’s free text was low (4-19%).  
Conclusion: The GPRD computerized medical records are sufficient to assess VSD, TOF, and 
COA.  This study confirms that maternal free text information provides a low yield of limited 
information pertaining to the infants’ congenital heart defect, while the infant free text may provide 
additional information usually obtainable from practitioner questionnaires.  The information 
provided by infant free text may limit the need for practitioner questionnaire validation.  
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Introduction
Congenital heart defects are the most common and most fatal type of birth defect.  Some 
factors which may increase the likelihood of the presence of a congenital heart defect include 
maternal infections, heredity, environmental factors and the presence of other birth defects [1, 2]. 
A number of medications have been implicated in causing congenital heart defects when used by 
pregnant women during the first trimester [2-4].  A causal relationship cannot be confirmed or 
ruled out for many of the medications.  [3, 4]
Currently much of the information on the occurrence of birth defects associated with 
medication use is provided from voluntary pregnancy registries and case control studies.  These 
registries were established for the purpose of monitoring prenatal drug exposures for evidence of 
teratogenicity.  They provide an early warning system for potential teratogenic effects associated 
with the use of specific medications during pregnancy and provide data to supplement animal 
toxicology studies [5]. Voluntary pregnancy registries are good for detecting a signal of major 
teratogenicity but there are some known limitations of using a voluntary pregnancy registry to 
determine the risk of birth defects such as small sample size, reporting bias due to the voluntary 
nature the registries, poor or incomplete exposure ascertainment, losses to follow-up, lack of an 
internal control group, and lack of confounding information.  There are also limitations in using 
case control studies such as biased or incomplete medication exposure ascertainment [6] and 
limited follow-up time.   
The UK General Practice Research Database (GPRD), an automated medical record 
database, may provide another source of data to evaluate medication and birth defects 
associations.  The GPRD was established in June 1987, at which time participating general 
practitioners received practice computers and a text-based practice management system in 
return for undertaking data quality training and submitting anonymized patient data for research 
purposes [7, 8]. Currently, the GPRD contains information on three million patients in the UK, 
accounting for more than 35 million person years of data [7, 8].  There are approximately 1,500 
contributing general practitioners within the GPRD, all members of the National Health Service 
(NHS) in England who act as the main access to all forms of health care provision within the NHS 
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[9]. The geographical, sex, age and smoking status distributions have been shown to be 
representative of the UK population [7] . The GPRD covers approximately 30,000 births per year 
[7]. 
The GPRD includes data on medication use, diagnoses, procedures and some information on 
patient characteristics such as height, weight, smoking status, alcohol use and social status as 
well as prescription information regarding the date of prescription, indication, dosage form, timing, 
dose, concomitant medications, prescriber, and treatment frequency.  As a medical records 
based database, the GPRD does not rely on voluntary reporting of birth defects.  In recent years, 
informed consent has become a threat to the operation of registries relying on clinician 
notification [10]. Using the GPRD may overcome this limitation because the data do not rely on 
patient consent for reporting while remaining in anonymized format to maintain strict patient 
confidentiality.  An additional advantage in using the GPRD is that there is theoretically unlimited 
follow-up time for data ascertainment.
To date, there has been limited research that has examined medication use in pregnancy using 
the GPRD.  Studies have included exposure to antiepileptics, fluconazole and acid-suppressing 
medications and their association with birth defects overall [11-13], with limited validation of birth 
outcomes.  Additional validation work focusing on specific defects is needed to assess the utility 
of data to study medication use in pregnancy within the GPRD and its association with the 
occurrence of specific defects. 
The purpose of this research is to validate that three of the most common types of congenital 
heart defects can be studied in the GPRD.  Specifically, ventricular septal defect (VSD), Tetralogy 
of Fallot (TOF) and coarctation of the aorta (COA) will be examined.  The information obtained 
from this study is essential to future research studying congenital heart defects within the GPRD.  
There are several ways to access the information contained within the GPRD. 
Detailed data can be obtained as 1) a dataset of computerized medical records including all 
clinical and prescription events, 2) computerized medical records plus follow up information 
including anonymized copies of death certificates, post mortems, hospital discharge summaries 
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or questionnaires to general practitioners or 3) computerized medical records plus a notes section 
which contains free text comments or 4) a combination of all three types of information.  
Within the GPRD, each medical encounter is listed as an event which has a free text
comments section associated with it.  A unique reference number identifies the existence of free 
text comments associated with each event record.  This free text can be retrieved from the 
Medicines and Healthcare products Regulatory Agency (MHRA) by providing the free text 
reference number.  Historically the free text comments section was a part of the GPRD 
computerized medical record.  In order to retain patient confidentiality, the free text comments 
were removed in 2000 and are only available in an anonymized form from the MHRA.  
There are few studies pertaining to the information contained in the free text comments section 
in the GPRD.  The free text field is not easily queried using standard computer programs and is 
not generally used in GPRD studies to identify exposures and outcomes [14]. However, it has not 
been examined whether the free text section contains detailed information pertaining to the 
timing, presentation, and details of diagnosis.  Obtaining the free text information may be more 
efficient than obtaining practitioner questionnaires.  Questionnaire validation is an additional 
service provided by the GPRD Division to assist researchers who require more detailed 
information than what is contained within the medical records.[8] It requires a researcher to 
contact and effect the validation work through the GPRD Division to ensure that full confidentiality 
of the practices and patients is maintained.[8]  The GPRD division contacts the practitioner 
corresponding to the patient medical record and anonymizes any response given by the 
practitioner. 
The main objective of this study was to understand what available components, (computerized 
medical records, questionnaires and infant and maternal free text information) of the GPRD data 
provide information about congenital heart defects.  Further, the PPV of the computerized 
recorded diagnosis of specific congenital heart defects was determined using a medical records 
abstraction questionnaire as the gold standard.  This study also determined whether the GPRD 
can provide additional information about timing, presentation, and details of diagnosis of specific 
congenital heart defects.  Finally we evaluated whether the free text comments section from the 
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infant’s and mother’s records provides supplemental information to the defect data obtained from 
the infant’s computerized record.  
Methods
Questionnaires to assess Positive Predictive Value
Using existing literature on congenital heart defect diagnosis in UK, typical age at congenital 
heart diagnosis, medical test findings and common types of VSD, as well as input from a pediatric 
cardiologist (JL) about reasons a congenital heart defect is suspected and electrocardiogram 
findings, three medical records abstraction questionnaires (“questionnaires”) were developed to 
assess whether the diagnosis recorded in the computerized medical record was concordant with 
that recorded in the practitioner written or computerized notes.  It was calculated that a total of 
200 questionnaires would ensure the sample size was large enough to demonstrate a positive 
predictive value (PPV) of at least 0.7 [15, 16].  A random sample of VSDs, the most common non-
cyanotic congenital heart defect, TOF, the most common cyanotic congenital heart defect, and 
COA, one of the most common and serious congenital heart defects [17] were used to determine 
PPV (Table 4.5).  
Using GPRD medical record codes, cases of VSD, TOF and COA were identified between the 
years of 1992 to 2003 (Case definition previously described- KW) (Table 4.5).  Inclusion criteria of 
1) date of birth of 1992 or later, 2) acceptable patient and clinical details, 3) currently registered in 
practice and 4) active GPRD practice status was applied to the sample of records.  Further 
inclusion criteria of 1) an event between 1998 and 2003, and 2) a non-missing field for role of the 
person entering the information were applied to only the VSD sample.  The 200 questionnaires 
sent to practitioners included 23 cases of COA and 72 cases of TOF and a randomized sample of 
105 cases of VSD.  
Using the questionnaire completed by the practitioner as the gold standard, the PPV of the 
computerized medical record was determined as the proportion of diagnoses in the computerized 
records that had a concordant diagnosis in the questionnaire.  
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Infant Free Text Comments Information
Free text comments sections were obtained for the event codes for the 200 cases of VSD, TOF 
and COA as well as their respective mothers as described below.  
A small subset of the total number (n=129) of congenital heart defect infant event codes 
contained event dates that were prior to the infant’s date of birth.  These free text comments 
sections were also obtained (n=43). 
Concordance between the infant diagnostic information in the infant’s free text information and 
diagnostic information obtained from both the questionnaires and computerized medical records 
was calculated. 
Mother Free Text Comments Information
A sample of 141 mothers of the 200 VSD, TOF, and COA patients was obtained using the 
Medicines and Healthcare Products Regulatory Agency (MHRA) constructed GPRD mother infant 
link which is a linkage of medical records of women to the medical records of their offspring [18].  
Mothers and infants are linked by practice specific family identification numbers, date of birth of 
infant and delivery/birth records of the mother and GPRD registration date of pregnancy.  [19]
The comments section were obtained by searching all of the 141 mothers’ free text comments 
sections for the time period of one year prior and two years following the infant’s delivery date.  
All free text comments containing keywords including “congen, heart, Fallot, tetra, cardiac, defect, 
anomal, septal” were extracted.  The mothers’ free text comments sections corresponding to the 
event codes prior to an infant’s date of birth were also extracted. Records with events that were 
more than 140 days prior to birth date were excluded.  
The percent agreement between infant diagnoses captured within the mother’s free text 
comments section  and the proportion of defects captured in the mother’s  free text comments 
section were determined.
Practitioner questionnaires to assess diagnosis details, timing, and presentation of specific 
defects
For each specific defect, age at diagnosis, reason(s) for suspecting the defect, who made the 
diagnosis, findings of the echocardiograms, and any additional co-occurring heart defects were 
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evaluated.  The computerized medical records were hand-searched where the questionnaire data 
indicated non-concordance with the computerized medical record diagnosis.
Results
Questionnaire information
 A 93% response rate was achieved for the practitioner questionnaire (n=186/200 sent).  The 
individual response rates for VSD, TOF, and COA were 91%, 97%, and 91% respectively.  
Overall the questionnaires contained very complete information: missing values accounted for 
less than 3% of the data for all questions with the exception of the date of diagnosis where 14.5% 
were missing. 
Concordance of questionnaire with medical record
Overall the PPV was 93%.  The PPV for VSD was 90.5%.  Six cases of medical record 
diagnosis of VSD had questionnaires returned indicating that the child did not have a VSD.  The 
questionnaires indicated that: the VSD had closed (n=1), repair of a VSD but subsequent 
diagnosis of an atrial septal defect (n=1), final diagnosis had been changed from VSD to 
pulmonary valve stenosis (n= 1), and/or VSD was miscoded (n=1).  Two questionnaires merely 
stated the child did not have a VSD,   The corresponding medical records showed: a medical 
code for VSD and subsequent codes for pulmonary stenosis (n=1), a code for VSD listed only 
once within the medical record (n=3), and other recordings on the same date for unrelated 
conditions (n=1).  In one case the medical record was unavailable.  
The PPV for TOF was 90%; there were seven cases of non-concordance between the 
computerized medical record data and questionnaire data.  In each case, the GPRD medical 
code for VSD in Fallot’s tetralogy was used to suggest the patient had TOF.  In six of these 
cases, the medical record contained subsequent codes for VSD.  One medical record had a code 
for VSD in Fallot’s tetralogy and had subsequent codes for pulmonary artery stenosis. 
The PPV for COA was 100%, with all questionnaires confirming the computerized medical 
record diagnosis. 
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Infant Free Text Comments Information
Forty-four percent of the total of the congenital heart defect records in the sample contained 
infant’s free text information pertaining to the defect of interest.  (Table 4.5)  The free text 
information contained supplemental information to the event code listed in the medical record.  
Most of the VSD free text records indicated either the type of VSD (13%) or the size of the VSD 
(small or moderate) (20%).  Echocardiogram findings (8%) or physician recommendation of 
antibiotic prophylaxis (9%) were also contained in many of the free text records.  (Table 4.6)  
Most of the TOF free text records (23%) included details about surgery or cardiac catheterization.  
(Table 4.6)  Most COA records (24%) indicated details about past or future surgery.  (Table 4.6)
Approximately 50% of the congenital heart defect infant records that had events before the 
date of birth records (63 out of 129) were invalid as they had unacceptable patient and event 
details.  Upon inspection, it was determined that the rest of the records did not contain 
information about diagnoses that occurred prior to birth and were coding errors. The medical 
records and free text comments sections obtained for those patients that had event codes prior to 
an infant's date of birth were not representative of a prenatal diagnosis.
Concordance of infant’s free text information and both questionnaires and computerized medical 
records 
In all but two infant computerized medical records, those that had free text comments sections 
associated with their record also had questionnaires returned (Table 4.5).  Concordance between 
the free text information and questionnaire information occurred in most cases.  The type of VSD 
specified in the questionnaire had a 92% concordance with the type specified in the infant’s free 
text comments section.  In the one case of non-concordance, the questionnaire indicated that the 
type of VSD could not be determined and the free text comments indicated that there were 
multiple VSDs.  There was 100% concordance between the information about a cardiac surgery 
contained in the free text and the information from the questionnaires for all defects.  In three 
cases (one TOF, one COA, one VSD), the free text comments sections listed additional 
diagnoses of heart defects while the questionnaire indicated no additional defects.  In one case of 
TOF, there were more echocardiogram findings listed in the free text comments than on the 
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questionnaire.  In two cases where the free text comments section indicated that a VSD 
spontaneously closed, the questionnaire data indicated no tests were performed and one 
indicated echocardiogram normal. 
Mother Free Text Comments Information
Twenty-nine percent of the total patient records (n=200) had a mother’s free text comments 
section containing information relevant to the infant’s heart defect.  Among the 141 mothers who 
could be linked to an infant, 40% of the mother’s records contained information with regard to the 
child’s defect. 
For VSD, most of the mother’s free text (29%) contained information relating to a prenatal 
ultrasound or cardiac scan in which a heart defect was suspected (Table 4.7).  Many of the 
records (18%) indicated details about the mothers’ emotional state with regard to the child’s 
congenital heart defect (Table 4.7). 
For TOF most of the mother’s free text (30%) contained information about the mothers’ 
emotional state with regard to the child’s congenital heart defect (Table 4.7).  Many of the records 
(21%) indicated that the mother had a child with TOF (either currently or in a past pregnancy). 
Of the COA records selected, only one mother’s free text record indicated that the infant 
explicitly had COA (Table 4.7).  Overall, 28% of all of the mother’s records contained information 
about the mothers’ emotional state with regard to the child’s congenital heart defect.  An 
additional sixteen percent contained information relating to a prenatal ultrasound or cardiac scans 
in which a heart defect was suspected. 
The extraction of mothers’ free text comments sections corresponding to the event codes prior 
to an infant’s date of birth returned no positive results. 
Diagnoses from the infant’s medical record and the free text information from mother’s records 
and the proportion of congenital heart defects captured in the mother’s free text comments 
sections
The proportion of diagnoses (where the actual defect name was mentioned) contained within 
the mother’s free text comments section was 5% for VSD, 19% for TOF, and 4% for COA: the 
total across all defects was 10%.  There was 100% agreement between the mothers’ free text 
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comments and the infants’ medical record and information from the questionnaire with regard to 
congenital heart defect diagnosis.  
Questionnaire information to assess details of diagnosis, timing, and presentation of specific 
defects 
The majority of cases of both VSD (34%) and TOF (27%) were diagnosed between one and 
three months of age while the majority of COA (50%) was diagnosed between birth and seven 
days (Table 4.8).  For all defects, over 50% of cases were diagnosed by 6 months of age (Table 
4.8). 
The majority of practitioners (62% and 28%) indicated that the reason for the suspicion of VSD 
and COA was a heart murmur, while patient symptoms were most often the reason for suspicion 
of TOF (26%)  (Table 4.9).  Many practitioners also indicated patient symptoms as the reason for 
suspicion for VSD and COA.  The percentage of defects that were suspected due to family 
history, a maternal risk factor, or another anomaly was 6% for VSD, 12% for TOF and 8% for 
COA.  Pediatric cardiologists made the final diagnosis in the majority (69%) of all cases of heart 
defect, while pediatricians made the final diagnosis in less than a quarter (21%).
The majority of VSDs were reported as muscular (43%), followed by membranous (29%) and 
type not specified (18%)  (Table 4.10).  In this sample, 8% of infants with VSD, 10% with TOF,
and 57% of COA patients had additional heart defects reported.  The defect most commonly seen 
with VSD in this sample was atrial septal defect (n=3).  The majority of defects seen with COA in 
this sample was VSD (n=9) followed by patent ductus arteriosus (n=2), and pulmonary stenosis 
(n=2).  The defect most commonly seen with TOF was pulmonary stenosis (n=2).   
Echocardiogram was performed in 85% of all cases of congenital heart defect, while no 
diagnostic tests were performed in only 10%.  While 35% of TOF patients underwent cardiac 
catheterization, it was seldom reported for either COA (10%) or VSD (1%).  Echocardiogram 
findings were consistent with the defect in question for VSD (58%) and TOF (63%).  For COA, 
practitioners commonly indicated (29%) that the echocardiogram demonstrated an abnormal 
aortic arch.  Cardiac surgery was performed for 20% of VSD patients, 97% of TOF patients, and 
86% of COA patients and the majority (75%) were referred to a cardiology center (VSD 64%, 
71
87% TOF and 90% COA).  Of the questionnaires that indicated the patient was referred, 48% 
contained requested anonymized notes from the referral.  Two questionnaires had missing 
information with regard to referrals. 
Discussion 
Questionnaire information
The results from this study indicate the computerized medical record information within the 
GPRD is sufficient to study the occurrence of the three specific congenital heart defects.  The 
PPV of the computerized medical record information of 93% suggests that questionnaire 
validation may not be necessary for future research examining VSD, TOF, and COA.  The results 
are consistent with published literature which indicates good agreement between the 
computerized medical record and the practitioner’s medical record for a number of diagnoses 
within the GPRD [20-23].
Concordance of questionnaire with medical record
There was no consistent reason why non-concordance for VSD occurred.  A medical record 
containing two codes for different congenital heart defects may suggest a change in diagnosis.  In 
this situation, it is recommended that record should be examined closely, free text comments 
reviewed and possibly  a questionnaire validation be performed   In cases where there are 
unrelated conditions coded on the same date, further investigation on the validity of these cases 
may also be warranted. 
This study also suggests that the code for VSD in Fallot’s tetralogy may not represent a true 
case of TOF.  This code was used to indicate TOF in eight patients within the sample and six of 
the questionnaires confirmed that the patient did not have TOF.  This GPRD medical code may 
actually be used in practice to indicate a VSD and not a VSD in Fallot’s tetralogy.  It is 
recommended that medical records using this code should be examined to assess whether there 
are medical codes for other congenital heart conditions following the code for VSD in Fallot’s 
tetralogy.  Free text comments review and questionnaire validation may be necessary in these 
cases to ascertain the final diagnosis.  
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Infant Free Text Comments Information
There have been few studies pertaining to the information contained in the free text comments 
section in the GPRD. Thus, it was unknown how many event records would contain free text 
comments. Because the study was exploratory, only the first event code from each patient record 
was used to extract free text information.
In approximately half of the records (50-57%), there was no free text available. This finding 
may be due to the sampling of event codes where only one event code was sampled from each 
patient record. Only one free text field was available per event code. 
A query of patient records was performed retrospectively to assess how many more event 
record codes could potentially contain free text information. Among patient records containing a 
VSD code, 35% of the records contained more than one code for VSD. Among those patient 
records with more than one code for VSD, the average number of event codes for VSD was 2.6. 
Among patient records containing a TOF code, 40% of the records contained more than one code 
for TOF. Among those patient records with more than one code for TOF, the average number of 
event codes for TOF was four. Among patient records containing a COA code, 40% of the 
records contained more than one code for COA. Among those patient records with more than one 
code for COA, the average number of event codes for COA was 2.8. Thus it is plausible that 
more infant free text information may be contained within event codes pertaining to VSD, TOF 
and COA that were not sampled for the current study. Therefore it is recommended for future 
research where detailed diagnostic information is needed, that all infant free text for all event 
dates for all codes that correspond to a specific defect be used to obtain as much information as 
possible.   
While the majority of the cases in the sample studied did not have a free text field available, the 
information contained within the available free text is promising. The infant free text comments 
sections provide information with regard to type of VSD, additional heart defects, surgery details, 
and echocardiographic findings. This information is usually only obtainable from practitioner
questionnaires.  
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Although only half (51%) of the patient records contained free text pertaining to the congenital 
heart defect of interest, this would indicate that questionnaire validation may only be necessary in 
half of the cases. Questionnaire validation is currently the standard practice to validate case 
records.  While any questionnaire validation is not a small undertaking, if the free text can provide 
the information to validate case records the number of questionnaires needed for validation may 
be reduced.  Obtaining the infant free text information is more efficient, less resource intensive 
and more rapid than obtaining practitioner questionnaire information. Thus, future research 
examining VSD, TOF, and COA, questionnaires may only be necessary in cases where free text 
information does not provide the information in question or where very detailed diagnostic 
information is required.
The high concordance rates between the free text information and practitioner questionnaire 
indicate that the information about type of VSD and cardiac surgery obtained from the free text 
comments may be reliable. However, the information from the free text was coded by only one 
non-blinded researcher. Thus the results may be biased toward a higher concordance rate as the 
researcher examined the information contained within the questionnaire prior to examining the 
free text information and had prior knowledge of the putative diagnosis. 
The GPRD computerized medical records indicated the fact of a diagnostic test but findings 
were not readily available.  In this sample, 30% (n=26) of the free text notes sections contained 
information about diagnostic tests or surgery.  Thus, if diagnostic test findings are of importance 
in a future study, free text may be of use and certainly questionnaires would be able to provide 
better information on diagnostic test information.  
Using the computerized medical record codes, the type of VSD could not be determined.  Type 
of VSD was contained within 26% of the free text comments sections.  These results suggest that 
the type of VSD may be able to be obtained from the free text comments section and/or from 
practitioner questionnaires.  The findings regarding type of VSD are consistent with published 
literature as muscular VSDs are the most common type reported [24].  This is important for future 
research of drug exposure and VSD because if a medication is associated with a VSD, it is likely 
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that it will be with a specific type of VSD [24]. Thus, the GPRD may be a valuable source to study 
type of VSD and drug exposure.
In this sample, the majority of cases of VSD and TOF did not have additional heart defects, 
while the majority of cases of COA did which is expected based on published literature.  A 
mulitcenter study examining the prevalence of congenital heart defects in France, Sweden and 
California reported the percentage of additional defects associated with VSD ranged from 2-6%, 
with TOF 2-9%, and with COA 16-28%.[25] The percentage of additional defects seen in this 
study is somewhat higher than those demonstrated by Pradat et al (2003) which may be due to a 
difference in populations studied.  It was difficult to ascertain from the medical records whether a 
record with a code for two defects actually had two separate defects or if a diagnosis was made 
and subsequently changed.  The free text notes and questionnaires can be of use in this 
situation.  Nine percent of the free text comments sections contained information about additional 
defects.  Multiple defects occurred in less than 15% of VSD and TOF while multiple defects 
occurred in over half of the cases of COA.  Thus free text notes and questionnaires may be 
particularly helpful for future COA research.  
Mothers’ Free Text Comments Information
According to the GPRD recording guidelines, practitioners are instructed to place birth defects 
in mother’s comment section as well as in the infants’ record [10].  The results showed that 
among the number of mothers that could be linked to an infant, only 40% of the mother’s records 
contained any information with regard to the child’s defect suggesting possible incomplete 
recording of infant’s defects in the mother’s record.  It is possible that only defects that are 
diagnosed within the first week of life are placed in the mother’s record as 32% of the sample had 
an age at diagnosis within the first week of life.  However the majority of the mother’s free text 
information contained information with regard to the mother’s condition and incidental information 
about the child.  
The sample of mother’s comments sections obtained from this study did not provide any 
additional information beyond the medical record and the information contained within the infant’s 
free text information with exception to the references of prenatal ultrasounds.  No other relevant 
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information was obtained from the mothers free text comments sections and the proportion of 
diagnoses contained within the mother’s free text comments section was low (5% for VSD, 19% 
for TOF, and 4% for COA).  Thus it is recommended that for future research, unless prenatal 
ultrasound information is pertinent to the study, the infant free text information should be obtained 
rather than mother’s free text information because it provides additional detailed diagnostic 
information and is more readily available because linkage between medical records is not 
necessary. 
Questionnaire information to assess details of diagnosis, timing, and presentation of specific 
defects 
The patient’s age at final diagnosis is difficult to ascertain from computerized medical records 
only.  Using the medical record, it is possible to examine at what dates the patient had an event 
pertaining to a congenital heart defect but it is not possible to assess when the defect diagnosis 
was confirmed as final.  The questionnaire may be of use if the date of final diagnosis is 
necessary to study, however the results suggest that even questionnaire data on date of final 
diagnosis may be incomplete. 
The results suggest that the GPRD can provide information on congenital heart defects 
diagnosed at varying ages.  In a US study, the frequency of major birth defects identified either 
prior to birth or during the first day of life comprised 70% of the total number of defects reported to 
the registry [26].  In the present study, only 20% of the sample was diagnosed prenatally to one 
day of life.  Thus, in theory, if diagnosis time were limited to before or at birth, 80% of the defects 
would be missed.  In this sample, 75% of the cases of VSD, 53% of the cases of TOF and 45% of 
the cases of COA were diagnosed after birth (after 2 days of life).  Because the GPRD contains 
information from the infants’ general practitioner, the GPRD may be a better source of information 
to examine defects that are diagnosed after birth than voluntary pregnancy registries that only 
have the ability to detect cases at or soon after birth.
Pregnancy registries and case control studies also usually limit their data collection to 
congenital heart defects diagnosed within the first year of life [6, 26]. In the GPRD sample, 10% 
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of VSD, 3% of TOF and 25% of COA was diagnosed after the age of 12 months.  Thus the ability 
to capture defects diagnosed after age one is an additional advantage of the GPRD. 
Within the GPRD medical records, referrals can be seen but information as to what type of 
specialist to whom the child was referred is not readily available.  Within the medical records the 
NHS Specialty referral and referral type (inpatient or outpatient) is available however they do not 
include either neonatalogists or pediatric cardiologists.  Thus if this information is pertinent to 
study, a questionnaire to the general practitioner would be warranted.   
Using the questionnaires, it was determined that the majority of congenital heart defects within 
this sample were referred to a cardiology center.  The high referral rates suggest that the 
diagnoses contained within the medical records are accurate.  Although, it was clear from the 
questionnaires that the patient was referred, referral notes were not readily available from either 
questionnaires (48%) or free text notes sections (7%).  Thus the GPRD may not be able to 
provide adequate information if referral patterns are to be studied.  
Information regarding the reason the diagnosis was suspected can only be obtained from 
questionnaires.  While there were references to prenatal cardiac scans contained within the 
mother’s free text notes, the yield of relevant information was low (7%).  If information about 
diagnostic suspicion is relevant to a study, questionnaires would be of use. 
Another potential limitation may be that discharge letters and other clinical information cannot 
be obtained for patients who changed practices or died.  Other published validation studies have 
shown the number of patients who change practices is relatively small (3% -10% depending on 
the condition) [20, 23, 27].  The number of deaths where information could not be obtained is also 
relatively small.  Published mortality statistics indicate that the mortality rate for infants up to age 
one is 1.97 per 100,000 for VSD, 2.48 per 100,000 for TOF and 1.86 per 100,000 for COA [17]. 
Thus in the 11 years of study it is estimated that information would be unavailable for an 
additional 7 cases of VSD, 8 cases of TOF and 6 cases of COA due to mortality. 
Recommendations for future research
In the specific situations where 1) a medical record contains two codes for different congenital 
heart defects, 2) cases where there are unrelated conditions coded on the same date and 3) 
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medical records with a code for “VSD in Fallot’s tetralogy”, it is recommended that the electronic 
record should be examined closely, free text comments reviewed and possibly a questionnaire 
validation be performed to determine the final diagnosis.    
It is recommended for future research where detailed diagnostic information is needed, that all 
infant free text for all event dates for all codes that correspond to a specific defect be used to 
obtain as much information as possible.  The additional information obtained from the infant free 
text may limit the need for questionnaires.  The infant free text can provide information on 
diagnostic test findings, type of VSD and referrals.  It is recommended that for future research, 
the investigators obtain infant free text prior to obtaining questionnaire information because the 
free text is more readily available and less resource intensive.  Any additional information that is 
not contained within the free text may be obtained by practitioner questionnaire.  If prenatal 
diagnoses and ultrasound findings are of interest, and infant free text and questionnaires do not 
provide information, the mother’s free text comments sections may provide a limited amount of 
additional information.  
Conclusion
In summary, the GPRD medical records are sufficient to assess the three specific congenital 
heart defects VSD, TOF, and COA.  This study confirms that maternal free text information 
provides a low yield of limited information pertaining to the infants’ congenital heart defect, but 
that the infant free text information may provide some additional detailed diagnostic information 
usually obtained from practitioner questionnaires.  Obtaining the infant free text information is 
more efficient and less resource intensive than obtaining practitioner questionnaire information.  
Thus, future research examining VSD, TOF, and COA, questionnaires may only be necessary in 
cases where free text information does not provide the information in question or where very 
detailed diagnostic information is required.  A theoretically unlimited duration of follow-up time in 
which a case can be detected and the availability of infant free text information make the GPRD a 
unique source for future studies of congenital heart defects.   
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Table 4.1:  Prevalence of all congenital heart defects, selected published literature 1999-
2004
Author, 
Year
Population  and 
Year
Data Source Prevalence of all 
congenital heart 
defects among live 
births
ONS, 2000 England and 
Wales, 2000
Congenital Anomaly Notification system 1.74 in 10002
Pradat 
2003
Sweden, 1981-
1992 
National population based system for the 
registration of congenital malformations 
2.50 in 1000 4
Pradat 
2003
France, 1983-
1992
Regional, population-based malformation 
monitoring registry 
2.89 in 1000 4
Pradat 
2003
California, US, 
1985-1992
Regional population based registry of 
congenital anomalies 
3.16 in 1000 4
Calzolari, 
2003
Italy, 1980-1994 Congenital Anomaly registry 4.65 in 1000  
Wren 2000 UK, 1985-1997 Diagnostic Database 5.6 in 1000 
Baron 2001 Arizona 
Medicaid, US, 
1990-1994
University of Arizona Pediatric Cardiology 
Unit Registry 
6 in 1000
Samanek 
1999
Bohemia, 1980-
1990
All children born in Bohemia 6.16 in 1000 
Garne, 
2004
Denmark, 1986-
1993
Population based EUROCAT registry 7.9 in 10001
Bosi 2003 Italy, 1992-1993 Centers of pediatric cardiology  8.3 in 1000 
Honein 
1999
Metropolitan 
Atlanta, US, 
1991-1995
Population based congenital defects 
program 
9 in 10003
1- Includes children diagnosed up to five years of age
2- Includes heart and circulatory defects
3- Includes stillbirths greater than 20 weeks of gestation
4- Includes stillbirths greater than 28 weeks of gestation
[7-10, 12-14, 27, 28]
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Table 4.2:  Prevalence* of Congenital Heart Defects: GPRD, NCAS and EUROCAT 2001, 
2002, and 2003, infants up to one year of age
GPRD** NCAS
N Rate 95% CI N Rate 95% CI Chi-Sq RR 95% CI
All 
congenital 
heart 
defects, 
2001
155 55.6 47.0-
64.0
1183 20.0 19.0-
21.0
158.34 2.79 2.37-
3.30
All 
congenital 
heart 
defects, 
2002
142 52.8 44.0-
61.0
1133 19.0 18.0-
20.0
144.44 2.78 2.34-
3.31
All 
congenital 
heart 
defects, 
2003
125 44.6 37.0-
52.0
1261 20.0 19.0-
21.0
74.51 2.20 1.83-
2.64
GPRD*** EUROCAT
All 
congenital 
heart 
defects, 
2001
99 51.4 41.0-
62.0
970 35.0 33.0-
37.0
14.09 1.48 1.21-
1.83
All 
congenital 
heart 
defects, 
2002
99 54.4 44.0-
65.0
956 42.0 39.0-
45.0
6.12 1.29 1.05-
1.59
All 
congenital 
heart 
defects, 
2003
89 47.8 38.0-
58.0
979 34.0 31.0-
36.0
10.36 1.42 1.15-
1.77
*Birth prevalence per 10,000 live births
**Number of live births GPRD corresponding to the geographical regions of NCAS: 2001, n= 
27860: 2002 n= 26882:  2003 n= 28005.
***Number of live births GPRD corresponding to the geographical regions of EUROCAT: 2001, 
n= 19249: 2002 n=18201:  2003 n= 18630
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Table 4.3:  Prevalence of specific types of heart defects from infants up to age one and 
children up to age 6 in the GPRD, infants up to age one in NCAS and EUROCAT, 2001
GPRD
Age 0-1 
NCAS EUROCAT GPRD
Age 0-6 
N Rate*
95% CI
N Rate*
95% CI
N Rate*
95% CI
N Rate*
95% CI
Congenital heart 
defects
169 54.4
46.0-63.0
1183 19.9
19.0-21.0
970 35.0
33.0-37.0
266 85.7
75.0-96.0
Anomalies of cardiac 
chambers and 
connections
9 2.9
1.0-4.8
116 2.0
1.6-2.3
94 3.4
2.7-4.0
9 2.9
1.0-4.8
Common arterial      
Truncus
2 0.6
0.2-1.5
13 0.2
0.1-0.3
9 0.3
0.1-0.5
2 0.6
0.2-1.5
Transposition of 
great vessels
7 2.3
0.6-3.9
64 1.1
0.8-1.3
53 1.9
1.4-2.4
7 2.3
0.6-3.9
Single ventricle 0 N/A 7 0.1
0.0-0.2
2 <0.1
0.0-0.2
0 N/A
Malformations of 
cardiac septa
139 44.8
37.3-52.2
716 12.0
11.2-12.9
685 25.0
22.7-26.4
216 69.6
60.3-78.8
Ventricular septal 
defect
113 36.4
29.7-43.1
369 6.2
5.6-6.8
423 15.0
13.7-16.6
186 59.9
51.3-68.5
Atrial septal defect 19 6.1
3.4-8.9
198 3.3
2.9-3.8
240 8.6
7.5-9.7
21 6.8
3.9-9.7
Atrioventricular 
septal defect
3 1.0
0.0-2.0
110 1.9
1.5-2.2
59 2.1
1.6-2.7
5 1.6
0.2-3.0
Tetralogy of Fallot 13 4.2
1.9-6.5
58 1.0
0.7-1.2
49 1.8
1.3-2.2
13 4.2
1.9-6.5
Malformations of 
valves
10 3.2
1.2-5.2
193 3.2
2.8-3.7
172 6.2
5.2-7.1
20 6.4
3.6-9.3
Tricuspid atresia and 
stenosis
0 N/A 4 0.1
0-0.13
5 0.2
0.2-0.3
0 N/A
Ebstein's anomaly 0 N/A 14 0.2
0.1-0.3
6 0.2
0.05-0.4
0 N/A
Aortic valve stenosis 1 0.3
0.0-0.9
22 0.4
0.2-0.5
22 0.8
0.5-1.1
2 0.6
0.0-1.5
Hypoplastic left 
heart
2 0.6
0.0-1.5
41 0.7
0.5-0.9
28 1.0
0.6-1.4
2 0.6
0.0-1.5
Malformations of 
great arteries and 
veins
12 3.9
1.7-6.1
279 4.7
4.1-5.2
250 9.0
7.8-10.0
16 5.2
2.6-7.7
Coarctation of aorta 3 1.0
0.0-2.0
69 1.2
0.9-1.4
75 2.7
2.1-3.3
7 2.3
0.6-3.9
*Birth prevalence per 10,000 live births
**Number of live births GPRD: 2001, n=  31050: 2002 n= 29805:  2003 n=30821.
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Table 4.4:  GPRD Prevalence of Congenital Heart Defects 2001, 2002 and 2003 and 
Prevalence of Ventricular Septal Defect in 2001:  Infants up to age one compared to 
children up to age 6
GPRD** Age 0-1 GPRD** Age 0-6  
N Rate 95% CI N Rate 95% CI Chi-Sq RR 95% CI
All 
congenital 
heart 
defects, 
2001
169 54.0 46.0-
63.0
266 86.0 75.0-
96.0
21.78 0.64 0.52-
0.77
All 
congenital 
heart
defects, 
2002
158 53.0 45.0-
61.0
262 88.0 77.0-
99.0
25.9 0.60 0.50-
0.73
All 
congenital 
heart 
defects, 
2003
138 45.0 37.0-
52.0
235 76.0 67.0-
86.0
25.38 0.59 0.48-
0.72
Ventricular 
Septal 
Defects, 
2001
113 36.0 30.0-
43.0
186 60.0 51.0-
68.0
17.9 0.61 0.48-
0.77
*Birth prevalence per 10,000 live births
a- Rates not statistically different by year. 
2001 and 2002 comparison chi-sq= 0.057 RR= 1.03 95% CI (0.83-1.28)
2001 and 2003 comparison chi-sq= 2.91 RR= 1.22 95% CI (0.97-1.52)
2002 and 2003 comparison chi-sq=2.12 RR=1.18 95% CI (0.94, 1.49)
**Number of live births GPRD 2001, n= 31050: 2002 n=29805:  2003 n=30821 
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Table 4.5:  Methods of Record Sources
VSD 
N (%) 
TOF 
N (%) 
COA 
N (%)
Total
N (%)
Cases identified  1992-2003 373 75 36 484*
Questionnaires sent 105 72 23 200
Questionnaires received ** 95 (90%) 70 (97%) 21 (91%) 186 (93%)
Questionnaires indicative of a 
concordant diagnosis
86 (91%) 63 (90%) 21 (100%) 170 (91%)
Questionnaires indicative of a non-
concordant diagnosis
9 (9%) 7 (10%) 0 16 (9%)
Medical events that had associated 
free text identifiers
73 (77%) 55 (79%) 18 (86%) 146 (78%)
Records that actually contained 
infant free text information
47 (49%) 30 (43%) 10 (48%) 87 (47%)
Records that could be linked to a 
mother
71 (74%) 53 (76%) 17 (81%) 141 (76%)
Records in which information was 
contained within the mothers free 
text comments section 
17 (18%) 37 (53%) 3 (14%) 57 (31%)
*1900 total cases of any congenital heart defect were identified between1992-2003
** All percentages are based on the number of questionnaires received except for the percentage 
of questionnaires received which is a percentage of questionnaires sent 
VSD n=95, TOF n=70, COA n=21
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Table 4.6:  Summary of Information: Infants Free Text Comments Sections*
Defect Type Information Number 
(%)**
No free text available 48 (50%)
Type of VSD 12 (13%)
Size of the VSD (small or moderate) 19 (20%)
Echocardiogram findings 8 (8%)
Physician advised antibiotic prophylaxis 9 (9%)
Full referral letters 4 (4%)
Information about additional defects  3 (3%)
Closed 5 (5%)
Unlikely to cause problems, no treatment required 2 (2%)
Medications 1 (1%)
Systolic murmur heard 1 (1%)
Repaired 3 (3%)
Referral Information 3 (3%)
Probable 1 (1%)
In neonatal ICU 1 (1%)
VSD
Unchanged 1 (1%)
No free text available 40 (57%)
Details about surgery or cardiac catheterization 16 (23%)
Indicated echocardiogram findings 2 (3%)
Contained full referral letters 2 (3%)
Referral Details 5 (7%)
Additional defects (two non -cardiac) 4 (6%)
No Live Vaccines 1 (1%)
Recommended Vaccines 1 (1%)
Systolic Murmur 1 (1%)
TOF
Weight Gain Slow 1 (1%)
No free text available 11 (52%)
Patient was transferred 1 (5%)
Medication 1 (5%)
Surgery (past or future), 5 (24%)
COA
Additional defect 1 (5%)
* Some notes contained information in more than one summary category
** All percentages are based on the number of questionnaires received 
VSD n=95, TOF n=70, COA n=21
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 Table 4.7:  Summary of Information: Mothers Free Text Comments Sections
Defect Type Information Number 
(%)*
No free text available 81 (82%)
Breastfeeding, Baby has probable VSD but feeding 
well
1 (1%)
Relative had child with congenital heart problems 2 (2%)
Having cardiac scan for baby 1 (1%)
Mother under stress from baby’s congenital heart 
surgery/condition
3 (3%)
Cardiac scan showed fetus with congenital heart 
defect/no congenital heart defect
5 (5%)
Baby born with defect 1 (1%)
Fetal heart beat heard/not heard 2 (2%)
Has baby with VSD, subsequent pregnancies need 
to have cardiac scan
1 (1%)
VSD
Child has VSD 1 (1%)
No free text available 33 (47%)
Update on mother’s condition from Caesarean 
section, baby has TOF 
2 (10%)
Mother with Stress/Depression, child has 
TOF/Congenital heart defect condition and or 
surgery
11 (52%)
Pregnant- prior pregnancy born with TOF 4 (19%)
Fetal heart heard 2 (10%)
Anomaly scan 1 (5%)
Child has congenital heart disease 4 (19%)
Ultra sound scan appeared normal/abnormal (n=1) 4 (19%)
Cannot exclude an underlying genetic syndrome or 
cardiac defects at this stage
1 (5%)
Correspondence from doctor addressed to mother 
about baby’s heart defect 
2 (10%)
Baby has heart murmur, scheduled for ECHO 1 (5%)
child had/is going to have heart surgery 5 (24%)
TOF
POST NATAL 1ST VISIT;BABY-TOF 1 (5%)
No free text available 18 (86%)
Fetal heart disease 1 (5%)
Letter from consultant, baby had COA 1 (5%)
COA
Ultrasound showed single live fetus, fetal heart beat 
heard
1 (5%)
* All percentages are based on the number of questionnaires received 
VSD n=95, TOF n=70, COA n=21
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Table 4.8:  Age at Diagnosis Reported in Questionnaire
Age at 
Diagnosis
Ventricular 
Septal Defect
Tetralogy of 
Fallot
Coarctation of 
the Aorta
Total
Diagnosed 
prenatally
3 (3%) 4 (6%) 1 (5%) 8 (4%)
Birth- 1 day 12 (13%) 12 (17%) 5 (24%) 29 (16%) 
2 days-less 
than 1 month
21 (22%) 20 (28%) 6 (29%) 47 (25%)
1-6 months 33 (35%)  19 (27%) 3 (14%) 55 (30%)
7-12 months 11 (12%) 3 (4%) 0 14 (8%)
Over 1 year 9 (9%) 4 (6%) 5 (24%) 16 (9%)
No Information 
Given
0 3 (4%) 1 (5%) 4 (2%)
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Table 4.9:  Reason for Diagnostic Suspicion Reported in Questionnaire
Reason for 
suspicion of 
diagnosis
Ventricular 
Septal Defect
Percent among 
VSD
Tetralogy of 
Fallot
Coarctation of 
the Aorta
Total
Percentage 
across all 
defects
Abnormal prenatal 
ultrasound / 
evaluation 
6 (5%) 4 (6%) 2 (10%) 12 (6%)
Family history of a 
congenital heart 
defect
3 (3%) 1 (1%) 1 (5%) 5 (3%) 
Maternal risk factor  1 (1%) 2 (3%) 0 3 (2%) 
Non-cardiac or 
chromosomal 
anomaly
3 (3%) 7 (10%) 2 (10%) 12 (6%) 
Patient symptoms 16 (14%) 22 (31%) 9 (43%) 47 (25%)
Heart Murmur 70 (62%) 18 (26%) 10 (48%) 98 (53%)
Abnormal 
Electrocardiogram 
or X-ray
10 (11%) 16 (23%) 1 (5%) 27(15%)
Other signs of 
congenital heart 
disease
4 (4%) 15 (21%) 11 (52%) 25 (13%)
No information 
given
0 4 (6%) 1 (5%) 5 (3%)
*Practitioner was able to choose more than one reason for suspicion of diagnosis 
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Table 4.10:  Type of VSD Reported from Questionnaire
Type of VSD Number (Percent)* 
Membranous (or Perimembranous) VSD 5 (29%) 
Muscular or Apical 37 (43%) 
Multiple or combination types of VSD 4 (5%)
Other type of VSD 4 (5%) 
Type of VSD was not specified 15 (18%) 
No information given N=4
* Among type of VSD reported
CHAPTER V DISCUSSION
Discussion of Specific Aims
Aim 1: Create a case definition of a congenital heart defect within the GPRD
The information obtained from this study is important to future research of any exposure and 
the outcome of congenital heart defects.  It was extremely important to create a case definition of 
congenital heart defects within the GPRD.  A standardized group of OXMIS and Read codes 
corresponding to congenital heart defects within the GPRD did not exist.  The case definitions are 
categorized according to the EUROCAT system which is frequently used by other sources as a 
standard for classification [40] thus making it feasible for future researchers to compare the 
GPRD to other sources. Tables 12 through 25 will be made available to researchers to use for 
future research examining congenital heart defects within the GPRD. 
Aim 2: Examine whether the rates of congenital heart defects obtained from the GPRD are 
similar to those obtained from UK population-based sources
This study determined that the grouping of codes for congenital heart defects from Aim 1 can 
provide similar or higher prevalence estimates to population based estimates. The grouping of 
codes can be used reliably in the future to study congenital heart defects and specific congenital 
heart defect categories.  The results of this study indicate that the GPRD not only produces 
similar prevalence rates but actually produced higher prevalence rates than the UK population 
based sources.  The GPRD has the potential to produce a more complete estimate of prevalence 
of the more commonly occurring congenital heart defects compared to currently available UK 
national systems.  As a medical records database, the GPRD can produce a more complete 
estimate of the prevalence rates.  Its advantages include case ascertainment methods that do not 
rely on voluntary reporting and a theoretically unlimited duration of follow-up time in which a case 
can be detected. 
91
The comparisons among the GPRD, the NCAS, and EUROCAT demonstrate that the GPRD 
produces significantly higher prevalence rates of all congenital heart defects than either of the 
national systems.  Published rates of congenital heart defects vary greatly (1.7-9 in 1000) [25, 26, 
33, 34, 37-40, 69]  This study attempted to standardize the methods used to calculate prevalence 
to evaluate how similar the various rates obtained from data sources were to one another. 
However the results show that the difference in data collection methods resulted in considerable 
variation in prevalence rates between the three sources.  The EUROCAT and NCAS are both 
voluntary systems which rely on reporting by practitioners or hospitals, and consequently not all 
cases are reported [6]. Since the GPRD is a medical records database, cases are systematically 
obtained from all medical records.  Therefore, as expected, the GPRD prevalence of all 
congenital heart defects was higher than both the NCAS and EUROCAT. 
Another difference between the voluntary sources and the medical record database is the 
duration of follow-up.  The EUROCAT and NCAS system only record anomalies up to one year of 
age [64].  Using the GPRD, the prevalence rate was calculated for children up to age six for more 
complete case ascertainment.  Within the GPRD, a higher prevalence of all congenital heart 
defects was seen when the rate was calculated for children up to age six than in infants up to age 
one.  Because the age of diagnosis of congenital heart defects ranges from 2 weeks to 11 years 
of age (mean 6 months) [41] , it is expected that a higher prevalence rate would be obtained for 
children up to six years of age compared to those up to age one. Defects that are usually more 
serious and diagnosed at birth or in the first year of life such as transposition of the great vessels 
and Tetralogy of Fallot tended to have similar prevalence rates when the rate was calculated for 
children up to age six compared to infants up to age one [41]. Defects that can be diagnosed later 
in infancy and into early childhood such as VSD, malformations of cardiac septa, malformations 
of valves and coarctation of aorta tended to have a higher prevalence when the rate was 
calculated for children up to age six  [41]. These findings were consistent with a Danish study 
assessing prevalence of congenital heart defects in children up to five years of age that showed 
VSD was among the most frequent diagnoses in children diagnosed after age one [39].
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The MACDP currently includes birth defects diagnosed until age six [69]. In 1995, the MACDP 
reported a rate of 4.9 per 1000 live births for congenital heart defects in infants up to age one, 
and a rate of 9.1 per 1000 live births for children up to age six [69]. These prevalence rates are 
similar to the prevalence rates that were demonstrated in the current study, in the GPRD; 5.4 per 
1000 in infants up to age one and 8.6 per 1000 in children up to age six.  Thus, the GPRD may 
provide a more complete source of information than the UK national systems for defects that are 
diagnosed into early childhood.   
The current results suggest that the GPRD is a good source of information for determining the 
prevalence of commonly occurring congenital heart defects but may not allow for the 
determination of the prevalence of rare heart defects during a short time period.  The GPRD did 
not detect any cases of very rare defects such as single ventricle, tricuspid atresia, and Ebstein’s 
anomaly within the three year time frame of the study.  In the NCAS, which has a larger 
population base (approximately 600,000 births per year), the rate for single ventricle was 0.1 per 
10000, for tricuspid atresia was 0.1 per 10000 and for Ebstein’s anomaly was 0.2 per 10000.  
Given the number of births covered by the GPRD each year (approximately 30,000) one would 
not expect to detect a case of a defect that occurs less than 0.5 per 10000.  Of note, cases of 
these rare defects were captured when a ten year time period was examined. 
The rates of specific heart defects also varied across GPRD, NCAS and EUROCAT as well as 
by type of congenital heart defect.  It is possible that these rates varied because the sample size 
from the GPRD was insufficient to show differences in the more rare defects compared to the 
population based systems.  The GPRD produced much higher rates than NCAS and EUROCAT 
for a number of defects including transposition, malformations of cardiac septa, ventricular septal 
defect, and Tetralogy of Fallot.  It is possible that the higher rates obtained from the GPRD may 
be due to better ascertainment methods.  This may be important as the GPRD rate of TOF, a 
very serious defect, was four times higher than the NCAS and twice as high as in the EUROCAT.  
TOF has been implicated in association with medication use during pregnancy [59, 61] and thus 
future studies examining medication use in pregnancy may find the GPRD a useful tool. Another 
possibility is that this finding could be due to a difference in distribution of specific defects across 
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geographical areas; as different areas were used for comparisons among GPRD, NCAS and 
EUROCAT for specific congenital heart defects. 
Another potential limitation of the GPRD is that it does not include cases diagnosed prenatally 
or in stillbirths.  It has been reported that national estimates from the NCAS  tend to be 
underestimates because no data exist on termination of pregnancy resulting from prenatal 
diagnosis of fetal anomaly [70]. While this may be a limitation for calculating prevalence in defects 
where a large proportion are diagnosed prenatally, the percentage of congenital heart defects 
diagnosed prenatally tends to be low.  Estimates from EUROCAT in 2001 suggested that 84% of 
congenital heart defects were assessed at or after birth [25].  In a study in Northern Italy of 1311 
cases of congenital heart defect who underwent routine ultrasound, only 99 cases (7.5%) had 
been  identified prenatally. [38] Another study in Denmark demonstrated prenatal terminations 
only accounted for 1.5% of the cases of congenital heart defects during a 13 year period [39]. For 
completeness, an exploratory study of a sample of plausible prenatal events recorded within the 
GPRD is underway to determine whether the GPRD can provide any information about congenital 
heart defects diagnosed prenatally.  
GPRD is unable to determine the prevalence among stillbirths because an infant does not 
receive a medical record if death occurs before delivery.  However this limitation is unlikely to 
appreciably change the prevalence of congenital heart defects.  In 2003 in NCAS, stillbirths 
accounted for only 0.5% of the total number of births per year.  Similarly in the EUROCAT in 2003 
stillbirths accounted for only 4% of the total number of congenital heart defects.  In EUROCAT,
the prevalence including stillbirths is 34.8 per 10000 and the prevalence only including live births 
is 33.5 per 10000 [25].  Similarly, published studies have demonstrated that inclusion of stillbirths 
does not change the prevalence appreciably.  A study assessing the temporal variability in birth 
prevalence of congenital heart defects only included live births because the proportion of 
stillbirths was very small [71].  Other studies assessing the prevalence of congenital heart defects 
in Italy and Denmark, demonstrated stillbirths only accounted for 0.8% and 2.5% of the cases of 
congenital heart defects respectively in over 10 years of data collection.  [38, 39]
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Aim 3: Determine  the positive predictive value of the computerized recorded diagnosis of 
specific congenital heart defects using a medical records abstraction form as the gold 
standard
The results from this study indicate the computerized medical record information within the 
GPRD is sufficient to study the occurrence of three specific congenital heart defects.  The PPV of 
the computerized medical record information of 93% suggests that medical record abstraction 
form validation may not be necessary for future research examining VSD, TOF and COA.  The 
results are consistent with published literature which indicates good agreement between the 
computerized medical record and the practitioner’s medical record for a number of diagnoses 
within the GPRD [15, 17, 19, 20].
A potential limitation of the GPRD is that the prevalence calculated in Aim 2 is based only on a 
single code in the computerized medical record and thus could misrepresent true prevalence.  
Other population-based sources have quality assurance checks to verify cases.  While the 
medical records within the GPRD are also verified for plausible event dates and acceptable 
patient details, the code that is entered into the computerized system is not routinely validated by 
a clinician.  The high positive predictive value of the computerized medical record information, 
suggests that it is unlikely that the prevalence rates calculated in Aim 2 misrepresent the true 
prevalence in live births in the GPRD. 
Aim 4: Determine whether the GPRD can provide additional information about timing and 
presentation of specific congenital heart defects
The results indicate that the various components within the GPRD can provide information 
regarding the patient’s age at final diagnosis, some information about referrals, and the reason 
the diagnosis was suspected, the type of VSD, additional heart defects, echocardiographic 
findings, and surgery details.  There was a limited amount of prenatal information available from 
the GPRD with regard to the specific congenital heart defects. 
The results suggest that the GPRD can provide information on congenital heart defects 
diagnosed at varying ages.  In a US study, the frequency of major birth defects identified either 
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prior to birth or during the first day of life comprised 70% of the total number of defects reported to 
the registry [6].  In the present study, only 20% of the sample was diagnosed prenatally to one 
day of life.  Thus, in theory, if diagnosis time were limited to before or at birth, 80% of the defects 
would be missed.  In this sample, 75% of the cases of VSD, 53% of the cases of TOF and 45% of 
the cases of COA were diagnosed after birth (after 2 days of life).  Because the GPRD contains 
information from the infants’ general practitioner, the GPRD may be a better source of information 
to examine defects that are diagnosed after birth than pregnancy registries that only have the 
ability to detect cases at or soon after birth 
Pregnancy registries and case control studies also usually limit their data collection to 
congenital heart defects diagnosed within the first year of life [6, 72]. In our sample, 10% of VSD, 
3% of TOF and 25% of COA was diagnosed after the age of 12 months.  Thus the ability to 
capture defects diagnosed after age one is an additional advantage of the GPRD. 
The patient’s age at final diagnosis is difficult to ascertain from computerized medical records 
only.  Using the medical record, it is possible to examine at what dates the patient had an event 
pertaining to a congenital heart defect but it is not possible to assess when the defect diagnosis 
was confirmed as final.  The medical record abstraction form may be of use if the date of final 
diagnosis is necessary to study, however the results suggest that even medical record 
abstraction form data on date of final diagnosis may be incomplete. 
Within the GPRD medical records, referrals can be seen but information as to what type of 
specialist to whom the child was referred is not readily available.  Within the medical records the 
NHS Specialty referral and referral type (inpatient or outpatient) is available however they do not 
include either neonatalogists or pediatric cardiologists.  Thus if this information is pertinent to 
study, a questionnaire to the general practitioner would be warranted.   
Using the medical record abstraction forms, it was determined that the majority of congenital 
heart defects within this sample were referred to a cardiology center.  The high referral rates 
suggest that the diagnoses contained within the medical records are accurate as they were made 
by a cardiology specialist.  Although, it was clear from the medical record abstraction forms that 
the patient was referred, referral notes were not readily available from either medical record 
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abstraction forms (48%) or free text notes sections (7%).  Thus the GPRD may not be able to 
provide adequate information if referral patterns are to be studied.  
Information regarding the reason the diagnosis was suspected can only be obtained from 
medical record abstraction form data.  While there were references made to prenatal cardiac 
scans contained within the sample of free text notes sections obtained from the mothers, the yield 
of relevant information was low (7% (n=10) of the total number of mothers that could be linked).  
If information about suspicion of diagnosis is relevant to a study, medical record abstraction forms 
would be of use. 
The GPRD computerized medical records indicated the fact of a diagnostic test but findings 
were not readily available.  In this sample, 30% (n=26) of the free text notes sections contained 
information about diagnostic tests or surgery.  Thus if diagnostic test findings are of importance in 
a future study, free text may be of use and certainly medical record abstraction forms would be 
able to provide information on diagnostic test information.  
Using the computerized medical record codes, the type of VSD could not be determined.  Type 
of VSD was contained within 26% of the free text comments sections.  If more free text comments 
sections were obtained for every event date that the patient had a code for the congenital heart 
defect in question, this number would likely rise.  These results suggest that the type of VSD may 
be able to be obtained from the free text comments section and/or from practitioner medical 
record abstraction forms.  The results demonstrate that using practitioner medical record 
abstraction forms, the type of VSD may be identified accurately.  The findings of type of VSD are 
consistent with published literature as muscular VSDs are most common type reported [73].  This 
is important for future research of drug exposure and VSD because if a medication is associated 
with a VSD, it is likely that it will be the same kind for the same exposure [73]. Thus the GPRD 
may be a valuable source to study type of VSD and exposure.
In this sample, the majority of cases of VSD and TOF did not have additional heart defects, 
while the majority of cases of COA did which is expected based on published literature.  A 
mulitcenter study examining the prevalence of congenital heart defects in France, Sweden and 
California reported the percentage of additional defects associated with VSD ranged from 2-6%, 
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with TOF 2-9%, and with COA 16-28%.[33] The percentage of additional defects seen in this 
study is somewhat higher than those demonstrated by Pradat et al (2003) which may be due to a 
difference in populations studied.  It was difficult to ascertain from the medical records whether a 
record with a code for two defects actually had two separate defects or if a diagnosis was made 
and subsequently changed.  The free text notes and medical record abstraction forms can be of 
use in this situation.  Nine percent (n=8) of the free text comments sections contained information 
about additional defects.  According to the defects used for our sample, multiple defects occurred 
in less than 15% of VSD and TOF while multiple defects occurred in over half of the cases of 
COA.  Thus free text notes and medical record abstraction forms may be particularly helpful for 
future COA research.  
Another potential limitation with regard to the ability of the GPRD to provide additional 
diagnostic information is that discharge letters and other clinical information cannot be obtained 
for patients who changed practices or died.  Other published validation studies have shown the 
number of patients who change practices is relatively small (3% -10% depending on the 
condition) [15, 20, 22].  The number of deaths where information could not be obtained is also 
relatively small.  Published mortality statistics indicate that the mortality rate for infants up to age 
one is 1.97 per 100,000 for VSD, 2.48 per 100,000 for TOF and 1.86 per 100,000 for COA [63]. 
Thus in the 11 years of study it is estimated that information would be unavailable for an 
additional 7 cases of VSD, 8 cases of TOF and 6 cases of COA due to mortality. 
Aim.5: Evaluate whether the free text comments section from the infant and mother’s
record provides supplemental information to the congenital heart defect data obtained 
from the infant’s computerized record.  
Infant Free Text Comments Information
The results from the exploratory analysis demonstrated that useful information was contained 
within the infant free text comments sections. The infant free text comments sections provide 
information with regard to type of VSD, additional heart defects, surgery details, and 
echocardiographic findings.  The results suggest that the infant free text comments sections may 
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be useful if additional detailed diagnostic information is needed.  The results indicate the infant 
free text information may provide some of the information usually obtained from practitioner 
questionnaires.  The high concordance rates between the free text information and practitioner 
questionnaire indicate that the information about type of VSD and cardiac surgery obtained from 
the free text comments is reliable.  
Free text information was not available for the majority of event codes used to identify VSD, 
TOF and COA (51%).  However, an important limitation to note, this study only used a sample of 
all the medical events a patient had to indicate a VSD, TOF or COA.  Thus more infant free text 
information may be contained within other medical events pertaining to VSD, TOF and COA.  
Among patient records containing a VSD code, 35% (N=573/1764) of the records contained more 
than one code for VSD. Among those patient records with more than one code for VSD, the 
average number of event codes for VSD was 2.6. Among patient records containing a TOF code, 
40% (N=109/269) of the records contained more than one code for TOF. Among those patient 
records with more than one code for TOF, the average number of event codes for TOF was four. 
Among patient records containing a COA code, 40% (N=34/83) of the records contained more 
than one code for COA. Among those patient records with more than one code for COA, the 
average number of event codes for COA was 2.8. It is recommended for future research where 
detailed diagnostic information is needed, that all infant free text for all event dates for all codes 
that correspond to a specific defect be used to obtain as much information as possible.   
Although only half (51%) of the patient records contained free text pertaining to the congenital 
heart defect of interest, this would indicate that questionnaire validation may only be necessary in 
half of the cases. Questionnaire validation is currently the standard practice to validate case 
records.  While any questionnaire validation is not a small undertaking, if the free text can provide 
the information to validate case records the number of questionnaires needed for validation may 
be reduced.  Obtaining the infant free text information is more efficient, less resource intensive 
and more rapid than obtaining practitioner questionnaire information. Thus, future research 
examining VSD, TOF, and COA, questionnaires may only be necessary in cases where free text 
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information does not provide the information in question or where very detailed diagnostic 
information is required.
Mother Free Text Comments Information
This study confirms that maternal free text information provides a low yield of limited 
information pertaining to the infants’ congenital heart defect.  According to the GPRD recording 
guidelines, practitioners are instructed to place birth defects in mothers comment section as well 
as in the infants’ record [10].  The results showed that among the number of mothers that could 
be linked to an infant, only 40% of the mother’s records contained any information with regard to 
the child’s defect thus suggesting possible incomplete recording of defects in the mother’s record 
with regard to the infant’s diagnosis.  It is possible that only defects that are diagnosed within the 
first week of life are placed in the mother’s record as 32% of our sample had an age at diagnosis 
within the first year of life.  However the majority of the mother’s free text information contained 
information with regard to the mother’s condition and incidental information about the child.  
The sample of mother’s comments sections obtained from this study did not provide any 
additional information beyond the medical record and the information contained within the infant’s 
free text information with exception to the references of prenatal ultrasounds.  No other relevant 
information was obtained from the mothers free text comments sections and the proportion of 
diagnoses contained within the mother’s free text comments section was low (5% for VSD, 19% 
for TOF, and 4% for COA).  Thus it is recommended that future research, unless prenatal 
ultrasound information is pertinent to the study, the infant free text information should be obtained 
rather than mother’s free text information because it provides additional detailed diagnostic 
information and is more readily available.  
An ideal database to study medication use in pregnancy and congenital heart defects 
The ultimate goal of this research is to provide the foundation for eventual study of the 
relationship between medication use in pregnancy and congenital heart defects within the GPRD.  
The current study evaluates whether the information provided by GPRD can be used for future 
research to assess a potential relationship between medication use in pregnancy and congenital 
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heart defects. The information provided from the current study demonstrates that the while the 
GPRD may not represent an “ideal” source, it is an improvement compared to other data sources 
in the study of congenital heart defects and medication in use in pregnancy.  
An ideal data source to study the relationship between medication use in pregnancy and 
congenital heart defects would include detailed prospectively recorded medication information 
and detailed accurate outcome information. It should contain accurate and detailed automated 
prospectively recorded medication information including information regarding full date for each 
prescription, indication, dosage form, timing, dose, concomitant medications, prescriber, and 
treatment frequency. This information should be recorded by the prescribing physician. Both 
inpatient and outpatient medications should be available for study. In addition to the automated 
prescription information, a linkage to prospective interview or diary data from women about their 
adherence to the medication regimen would be ideal. The interview or diary data would also 
contain information about over the counter medication use.  Interview or diary data would also 
help to determine the timing in pregnancy in which a medication was taken rather than when it 
was prescribed. 
The database should contain large numbers of exposed pregnant women.  It is difficult to study 
the relationship between medication use in pregnancy and congenital heart defects because they 
are very rare. Studies have shown that women do take medications while pregnant. A study 
whose aim was to provide information on the prevalence of the use of prescription drugs among 
pregnant women in the United States demonstrated that 64 percent of women were dispensed a 
medication other than a vitamin or mineral supplement within the 270 days prior to delivery. [74] 
However, the number of women taking the same medication during pregnancy is small.  To 
accrue a number of pregnant women prescribed the same medication may take a number of 
years. 
As stated previously, the prevalence of all congenital heart defects varies between one to nine 
in 1000. Assuming that the prevalence rate among unexposed women is one in 1000, in order to 
detect a relative risk of two, a sample size of approximately 23500 exposed pregnant women and 
23500 unexposed pregnant women would be needed. [75] The ideal database would also contain 
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a large number of unexposed pregnant women thus increasing the power of the study without 
increasing the number of exposed pregnant women needed. [75]  Thus if a sample size of 53600 
unexposed pregnant women was obtained then a sample size of approximately 13400 exposed 
pregnant women would be needed to detect a relative risk of two. The sample size requirements 
greatly increase when examining specific heart defects because the prevalence of these defects 
is very small. In order to detect a relative risk of two, for a defect that occurred in 1 in 10,000 live 
births a sample size of approximately 134,000 exposed pregnant women and 500,000 unexposed 
pregnant women would be necessary. [75] Thus an ideal database would have to have a very 
large population base and many years of data coverage in order to obtain sample sizes large 
enough to study the relationship between medication use and congenital heart defects.
    An ideal data source would also provide excellent outcome information.  It would also contain 
cases that are representative of all cases in that population. The data source would contain 
information about cases that are identified by a clinician and the diagnosis confirmed by another 
independent clinician. It would have stability in the population studied and contain complete follow 
up information. There should be an unlimited time frame in which a case of a congenital heart 
defect can be detected. 
    An ideal database to study congenital heart defects would not need to contain information 
about stillbirths and induced abortions because the number diagnosed among stillbirths and 
induced abortions is low. However inclusion of this data would make the findings of a study to 
determine the relationship between medication use and congenital heart defects more complete. 
The inclusion of this information would also be important when studying other birth defects where 
there is a large proportion of fetal deaths and/or induced abortions.  The database should also 
have the ability to link all exposed mothers to their children and include relevant confounding 
information such as family history, smoking and alcohol use. 
Comparisons of the GPRD to an ideal database
    The GPRD is an excellent source of prescription information. It contains accurate and detailed 
prospectively recorded medication information including information regarding full date for each 
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prescription, indication, dosage form, timing, dose, concomitant medications, prescriber, and 
treatment frequency.  Inpatient and outpatient medications are both included in GPRD. 
    Using the GPRD, medication adherence can be estimated by examining prescriptions that are 
filled consecutively. The GPRD is an optimal source of prescription information because every 
prescription that a practitioner writes is recorded; the prescription does not need to be filled at a 
pharmacy to be recorded within the GPRD system. However, as with all databases there is 
potential for misclassification.  If a woman is classified for study as exposed because she had a 
prescription record within her medical record but never actually consumed the medication then 
she would be misclassified. Thus, a database which contained a linkage to interview or diary data 
from women about their adherence to the medication regimen would be ideal. The interview or 
diary data would also contain information about over the counter medication use.  Interview or 
diary data would also help to determine the timing in pregnancy in which a medication was taken 
rather than when it was prescribed. This type of linkage is not currently available within GPRD 
however patients can be contacted retrospectively by questionnaire to verify medication use. 
    The GPRD is a good source of information because although exposure to medication in 
pregnancy may be rare, the GPRD covers approximately 30,000 births per year and there are 
many years of data (1992-present) that can be combined to produce a large sample size of 
exposed pregnant women. However, the GPRD may not provide a large enough sample size to 
study very rare specific defects.  Given the number of births each year the GPRD may only be 
able to detect large relative risks (greater than 2). The GPRD also has the ability to study more 
than one medication simultaneously. 
    This study demonstrated that the GPRD is a good source of congenital heart defect 
information. The PPV of 93% indicates that the medical codes for VSD, TOF, and COA within the 
medical record represent actual cases of these conditions.  While the PPV of the computerized 
medical record codes is good, the identification of cases from codes in medical records is not 
ideal. If a case was not identified correctly within the medical record, this case would be missed. 
Thus it is unknown how many cases of VSD, TOF and COA are coded as other diagnoses 
incorrectly. This is difficult to ascertain, as all diagnosis codes that could be mistaken for VSD, 
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TOF and COA would have to be sampled and verified by practitioner questionnaire.  Given the 
93% PPV for the VSD, TOF and COA diagnoses, it is expected that the PPV would be similar for 
other diagnoses thus the number of incorrectly coded diagnoses would be low.  A linkage 
between GPRD and a national birth defects monitoring program in the UK such as NCAS or 
EUROCAT could provide an estimate of cases that are not correctly coded within the medical 
records. However cases could still be missed as the UK national systems have voluntary 
reporting. 
    Many national monitoring programs rely on voluntary reporting of cases which could create 
reporting bias. The GPRD cases sampled are representative of all cases in the GPRD because 
cases are sampled from medical records and do not have to be reported. 
    An ideal data source would contain information about cases that are identified by a clinician 
and the diagnosis confirmed by another independent clinician. In the current study, 
questionnaires were used to validate the diagnosis. While the questionnaires provided good 
information about the diagnoses, it is unclear what sources the clinician used to verify the 
diagnosis. A separate review of the patient and/or medical record by another clinician would 
minimize misclassification of cases.  
    The GPRD contains very complete follow up information. A limitation of some prospective 
medication exposure registries is that they receive exposure information in many cases but no 
outcome information.  The GPRD provides a theoretically unlimited time for detection of a case 
which is ideal to capture heart defect cases which may be detected during infancy and childhood.  
Many Health Maintenance Organization (HMO) databases in the US have incomplete 
exposure/outcome information or limited follow-up time as many patients either have gaps in 
enrollment or transfer to another HMO.  While the GPRD patients can transfer practices, the 
GPRD does not have problems with gaps in enrollment because the UK NHS provides universal 
coverage.  The general practitioners within the GPRD who are all members of the NHS act as the 
main means of access to all forms of health care provision. Thus if a patient transfers to another 
GPRD practice, the record remains in the GPRD system. However, the GPRD system is not 
104
flawless because data from patients who transfer to non-GPRD practices can be lost from the 
system. 
    Another important aspect of an ideal database is the ability to link all exposed mothers to their 
children. The current study used the MHRA constructed mother- infant record linkage which 
linked 71% (141/200) of records in our study.  In order to obtain complete information about the 
relationship between a medication used in pregnancy and the occurrence of a congenital heart 
defect, a higher proportion of linked mother-infant pairs would be optimal. 
    An ideal source to study medication use in pregnancy would also include confounding 
information. The GPRD can provide information some confounding information.  The medical 
records can contain information about smoking, alcohol use, height, weight and social status [21]. 
While general practitioners are not required to enter this information, information on smoking 
status is available in 70% of the population [21].  However the quality of the information contained 
within the medical record may vary because the information has not been collected in a 
systematic manner as in a study where data is collected specifically about the confounding 
information.  Practitioner questionnaires and free text information may contain additional 
information about family history and other important social aspects not contained within the 
medical record. 
    In summary, an ideal database to study medication use in pregnancy and congenital heart 
defects a database would need to contain 1)accurate and detailed prospectively recorded 
prescription information and contain a linkage to interview or diary data from women about their 
adherence to the medication regimen, 2)large numbers of exposed pregnant women, 3) accurate 
outcome information identified and confirmed by clinicians with a linkage to a national source to 
determine missing cases , 4) an unlimited time for detection of a congenital heart defect case, 5) 
medical records that do not rely on continuous enrollment in a particular heath care system, 6) 
information about stillbirths and induced abortions, 7) a linkage of all exposed mothers to their 
children and finally 8) relevant confounding information. The GPRD includes many of aspects that 
constitute an ideal database thus it may provide an additional source of information to study the 
relationship between medication used in pregnancy and congenital heart defects.
CHAPTER VI CONCLUSION
Recommendations for future research
The results suggest that the GPRD is a good source to study congenital heart defects.  Future 
researchers can calculate prevalence rate estimates that are more complete than current UK 
national systems.  Prevalence rates should be calculated using children up to age six especially 
for defects can be diagnosed later in infancy and into early childhood such as VSD, 
malformations of cardiac septa, malformations of valves and coarctation of aorta.  The GPRD 
may not allow for the determination of the prevalence of rare heart defects during a short time 
period.  However if rare defects are of interest, it is recommended that ten years of data should 
be used or more to obtain cases.  
In the specific situations where 1) a medical record contains two codes for different congenital 
heat defects, 2) cases where there are unrelated conditions coded on the same date and 3) 
medical records with a code for “VSD in Fallot’s tetralogy”, it is recommended that electronic 
record should be examined closely, free text comments reviewed and possibly a questionnaire 
validation be performed to determine the final diagnosis.    
It is also recommended for future research where detailed diagnostic information is needed, 
that all infant free text for all event dates for all codes that correspond to a specific defect be used 
to obtain as much information as possible.  The additional information obtained from the infant 
free text may limit the need for questionnaires.  The infant free text can provide information on 
diagnostic test findings, type of VSD and referrals.  It is recommended that for future research, 
the infant free text is obtained prior to obtaining questionnaire information because the free text is 
more readily available and less resource intensive.  Any additional information that is not 
contained within the free text may be obtained by practitioner questionnaire.  If prenatal 
diagnoses and ultrasound findings are of interest, and infant free text and questionnaires do not
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provide information, the mother’s free text comments sections may provide a limited amount of 
additional information.  
Conclusions
In summary, the overall aim of this study was to provide validation that VSD, TOF and COA 
can be studied within the GPRD.  This study confirmed with a high positive predictive value that 
the computerized GPRD medical records are sufficient to assess the three specific congenital 
heart defects VSD, TOF and COA.  It also demonstrated that the GPRD has the potential to 
produce a more complete estimate of prevalence of the more commonly occurring congenital 
heart defects compared to currently available UK national systems.  The advantages of the 
GPRD as a medical records database including case ascertainment methods that do not rely on 
voluntary reporting, a theoretically unlimited duration of follow-up time in which a case can be 
detected and the availability of infant free text information make the GPRD a unique source for
future studies of congenital heart defects.   
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APPENDICES
APPENDIX A: Text strings used to determine OXMIS and Read congenital heart defect 
codes
ABSENT SEPTUM
COMMUNICATION BETWEEN AORTA AND PULMONARY ARTERY ABNORMAL
AORTIC SEPTAL DEFECT
COMMON AORTOPULMONARY TRUNK 
PERSISTANT TRUNCUS ARTERIOSUS
AORTICOPULMONARY WINDOW
TRANSPOSITION OF GREAT VESSELS
COMPLETE TRANSPOSITION OF GREAT VESSELS
CLASSICAL TRANSPOSITION OF GREAT VESSELS
DOUBLE OUTLET RIGHT VENTRICLE
DEXTRATRANSPOSITION OF AORTA
INCOMPLETE TRANSPOSITION OF GREAT VESSELS
ORIGIN OF BOTH GREAT VESSELS FROM RIGHT VENTRICLE
TAUSSIG-BING SYNDROME OR DEFECT
CORRECTED TRANSPOSITION OF GREAT VESSELS
TETRALOGY OF FALLOT
FALLOTS PENTALOGY
VENTRICULAR SEPTAL DEFECT WITH PULMONARY STENOSIS OR ATRESIA, 
DEXTRATRANSPOSITION OF AORTA, AND HYPERTROPHY OF RIGHT VENTRICLE
COMMON VENTRICLE
COR TRILOCULARE BIATRIATUM
SINGLE VENTRICLE
VENTRICULAR SEPTAL DEFECT
EISENMENGERS DEFECT 
EISENMENGERS COMPLEX
GERBO DEFECT
INTERVENTRICULAR SEPTAL DEFECT
LEFT VENTRICULAR-RIGHT ARTIAL COMMUNICATION
ROGERS DISEASE
OSTIUM SECUNDUM TYPE ATRIAL SEPTAL DEFECT 
OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 
ATRIUM SECUNDUM
FOSSA OVALIS 
LUTEMBACHERS SYNDROME 
PATENT FORAMEN OVALE 
PATENT OSTIUM SECUNDUM 
PERSISTENT  FORAMEN OVALE 
PERSISTENT OSTIUM SECUNDUM 
ENDOCARDIAL CUSHION DEFECT
OSTIUM PRIMUM DEFECT
PERSISTENT OSTIUM PRIMUM
ABSENCE OF ATRIAL SEPTUM
ATRIOVENTRICULAR CANAL TYPE VENTRICULAR SEPTAL DEFECT
COMMON ATRIOVENTRICULAR CANAL 
COMMON ATRIUM
OSTIUM ATRIOVENTRICULARE COMMUNE
PERSISTENT ATRIOVENTRICULAR CANAL
SINGLE ATRIUM
COR BILOCULARE
COR TRIOCULARE
PERSISTENT BULBUS CORDIS IN LEFT VENTRICLE
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APPENDIX A: Text strings used to determine OXMIS and Read congenital heart defect 
codes (Continued)
PREMATURE CLOSURE FORAMEN OVALE 
TRILOCULAR HEART
UNILOCULAR HEART
UNSPECIFIED DEFECT OF SEPTAL CLOSURE
ANOMALIES OF PULMONARY VALVE
PULMONARY VALVE ANOMALY
ATRESIA, CONGENITAL
STENOSIS, CONGENITAL
CONGENITAL INSUFFICIENCY OF PULMONARY VALVE
FALLOTS TRIAD
FALLOTS TRILOGY
SUPERNUMERARY PULMONIC CUSPS
TRICUSPID  ATRESIA AND STENOSIS, CONGENITAL
ABSENCE OF TRICUSPID VALVE
EBSTEINS ANOMALY
CONGENITAL STENOSIS OF AORTIC VALVE
CONGENITAL AORTIC STENOSIS
CONGENITAL INSUFFICIENCY OF AORTIC VALVE
BICUSPID AORTIC VALVE
CONGENITAL AORTIC INSUFFICIENCY
CONGENITAL MITRAL STENOSIS
FUSED COMMISSURE OF MITRAL VALVE
PARACHUTE DEFORMITY OF MITRAL VALVE
SUPERNUMERARY CUSPS OF MITRAL VALVE
CONGENITAL MITRAL INSUFFICIENCY
HYPOPLASTIC LEFT HEART SYNDROME
ATRESIA OF AORTIC VALVE
HYPOPLASIA OF AORTIC VALVE
SUBAORTIC STENOSIS
COR TRIATRIATUM
INFUNDIBULAR PULMONIC STENOSIS
SUBVALVULAR PULMONIC STENOSIS
OBSTRUCTIVE ANOMALIES OF HEART, NOT ELSEWHERE CLASSIFIED
UHLS DISEASE
CORONARY ARTERY ANOMALY
ANOMALOUS ORIGIN OF CORONARY ARTERY
ANOMALOUS COMMUNICATION OF CORONARY ARTERY
CORONARY ARTERY ABSENCE
CORONARY ARTERY ARISING FROM AORTA OR PULMONARY TRUNK
SINGLE CORONARY ARTERY
CONGENITAL HEART BLOCK
COMPLETE ATRIOVENTRICULAR BLOCK
INCOMPLETE ATRIOVENTRICULAR BLOCK
MALPOSITION OF HEART AND CARDIAC APEX
ABDOMINAL HEART
LEVOCARDIA
DEXTROCARDIA
MESOCARDIA
ECTOPIA CORDIS
ATRESIA OF CARDIAC VEIN
HYPOPLASIA OF CARDIAC VEIN
CONGENITAL CARDIOMEGALY
CONGENITAL LEFT VENTRICLE DIVERTICULUM
CONGENITAL PERICARDIAL DEFECT
109
APPENDIX A: Text strings used to determine OXMIS and Read congenital heart defect 
codes (Continued)
ACCESSORY CUSPS
ACCESSORY HEART VALVE
AGENESIS OF HEART
AGENESIS OF HEART VALVE
BIFID APEX OF HEART
DISPLACEMENT OF VENTRICULAR SEPTUM
DIVERTICULA OF HEART
EBSTEINS DEFORMITY OF MITRAL VALVE
EBSTEINS DEFORMITY OF MITRAL LEAFLETS
FUSION OF HEART VALVE CUSPS
HEMICARDIA
HYPOPLASIA OF HEART
UNSPECIFIED ANOMALY OF HEART
CONGENITAL WEAK HEART
PATENT DUCTUS ARTERIOSUS
PATENT DUCTUS BOTALLI
PERSISTENT DUCTUS ARTERIOSUS
CORARCTATION OF AORTA
CORARCTATION OF AORTA PREDUCTAL 
CORARCTATION OF AORTA POSTDUCTAL
HYPOPLASIA OF AORTIC ARCH
INTERRUPTION OF AORTIC ARCH
OTHER ANOMALIES OF AORTA
ANOMALY OF AORTA, UNSPECIFIED
ANOMALY OF AORTIC ARCH
ANOMALOUS ORIGIN, RIGHT SUBCLAVIAN ARTERY
DEXTRATRAPOSITION OF AORTA
DOUBLE AORTIC ARCH
KOMMERELLS DIVERTICULUM
OVERRIDING AORTA
PERSISTENT CONVOLUTIONS, AORTIC ARCH
PERSISTENT RIGHT AORTIC ARCH
AORTIC RING SYNDROME
ATRESIA OF AORTA 
STENOSIS OF AORTA
ABSENCE OF AORTA 
APLASIA OF AORTA 
HYPOPLASIA OF AORTA 
STRICTURE OF AORTA 
SUPRAVALVULAR AORTIC STENOSIS
ANEURYSM OF SINUS OF VALSALVA
CONGENITAL ANEURYSM OF AORTA 
CONGENITAL DILATION OF AORTA
RUPTURED SINUS OF VALSALVA
TORSION OF AORTA
ANOMALIES OF PULMONARY ARTERY 
AGENESIS OF PULMONARY ARTERY 
ATRESIA OF PULMONARY ARTERY 
COARCTATION OF PULMONARY ARTERY 
HYPOPLASIA OF PULMONARY ARTERY 
STENOSIS OF PULMONARY ARTERY 
PULMONARY ARTERIOVENOUS ANEURYSM
ANOMALY OF GREAT VEINS
ANOMALY NOT OTHERWISE SPECIFIED OF PULMONARY VEINS
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ANOMALY NOT OTHERWISE SPECIFIED OF VENA CAVA
TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION 
TOTAL ANOMALOUS PULMONARY VENOUS RETURN
SUBDIAPHRAGMATIC TOTAL ANOMALOUS PULMONARY VENOUS RETURN
SUPRADIAPHRAGMATIC TOTAL ANOMALOUS PULMONARY VENOUS RETURN
PARTIAL ANOMALOUS PULMONARY VENOUS CONNECTION
PARTIAL ANOMALOUS PULMONARY VENOUS RETURN
OTHER ANOMALIES OF GREAT VEINS
ABSENCE OF VENA CAVA INFERIOR 
ABSENCE OF VENA CAVA SUPERIOR
CONGENITAL STENOSIS OF VENA CAVA INFERIOR
CONGENITAL STENOSIS OF VENA CAVA SUPERIOR 
PERSISTENT LEFT POSTERIOR CARDINAL VEIN
PERSISTENT LEFT SUPERIOR VENA CAVA
SCIMITAR SYNDROME
TRANSPOSITION OF PULMONARY VEINS
TERMINATION ANOMALOUS PORTAL VEIN
COMMON TRUNCUS
AORTOPULMONARY WINDOW
TRANSPOSITION OF GREAT VESSELS
TRANSPOSITION WITH INLET VSD
TRANSPOSITION WITH PERIMEMBRANOUS VSD
L-TRANSPOSITION, VENTRI IN VERSION
VENTRICULAR INVERSION
DOUBLE OUTLET LEFT VENTRICLE
TETRALOGY OF FALLOT
FALLOTS TETRALOGY WITH ASD
FALLOTS TETRALOGY
COMMON VENTRICLE
DOUBLE INLET RIGHT VENTRICLE
DOUBLE INLET LEFT VENTRICLE
VENTRICULAR SEPTAL DEFECT
EISENMENGERS SYNDROME
GERBODE DEFECT
VSD
MEMBRANOUS VSD
PERIMEMBRANOUS VSD
MUSCULAR VSD
MID-MUSCULAR VSD
CYSTALLINE VSD
SUB-CYSTALLINE VSD
TYPE 1 VSD
TYPE 2 VSD
TYPE II VSD
TYPE I VSD
APICAL VSD
SEPTAL VSD
MALALIGNMENT VSD
VENTRICULAR SEPTAL DEFECT
MEMBRANOUS VENTRICULAR SEPTAL DEFECT
PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT
MUSCULAR VENTRICULAR SEPTAL DEFECT
MID-MUSCULAR VENTRICULAR SEPTAL DEFECT
CYSTALLINE VENTRICULAR SEPTAL DEFECT
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SUB-CYSTALLINE VENTRICULAR SEPTAL DEFECT
TYPE 1 VENTRICULAR SEPTAL DEFECT
TYPE 2 VENTRICULAR SEPTAL DEFECT
TYPE II VENTRICULAR SEPTAL DEFECT
TYPE I VENTRICULAR SEPTAL DEFECT
APICAL VENTRICULAR SEPTAL DEFECT
SEPTAL VENTRICULAR SEPTAL DEFECT
MALALIGNMENT VENTRICULAR SEPTAL DEFECT
PERIMEMBRANOUS VENTRICULAR SEPTAL DEFECT
MUSCULAR VENTRICULAR SEPTAL DEFECT
MID-MUSCULAR VENTRICULAR SEPTAL DEFECT
OSTIUM SECUNDUM TYPE ATRIAL SEPTAL DEFECT 
NONCLOSURE OF FORAMEN OVALE
OSTIUM SEPTUM SECUNDUM DEFECT
FOSSA OVALIS ATRIAL SEPTAL DEFECT
FENESTRATED ASD
FENESTRATED ATRIAL SEPTAL DEFECT
ASD
AURICULAR SEPTAL DEFECT
PARTIAL FORAMEN OVALE
ENDOCARDIAL CUSHION DEFECT
PRIMUM ASD
PRIMUM ATRIAL SEPTAL DEFECT
SINGLE COMMON ATRIUM
SINGLE COMMON ATRIUM, COR TRILOCULARE BIVENTRICULARE
COMMON ATRIOVENTRICULAR CANAL WITH VSD
COMMON ATRIOVENTRICULAR CANAL WITH VENTRICULAR SEPTAL DEFECT
COMPLETE ATRIOVENTRICULAR CANAL DEFECT WITH VENTRICULAR SEPTAL DEFECT
COMPLETE ATRIOVENTRICULAR CANAL DEFECT WITH VSD
COMPLETE ATRIOVENTRICULAR CANAL DEFECT
COMPLETE AV CANAL DEFECT
UNSPECIFIED DEFECT OF SEPTAL CLOSURE
HOLE IN HEART
ANOMALIES OF PULMONARY VALVE
ATRESIS, HYPOPLASIA OF PULMONARY VALVE
ABSENT PULMONARY VALVE
CONGENITAL ATRESIA OF PULMONARY VALVE
CONGENITAL STENOSIS OF PULMONARY VALVE
ATRESIA OF PULMONARY VALVE
STENOSIS OF PULMONARY VALVE
SMALL PULMONARY VALVE
CONGENITAL PULMONARY VALVE REGURGITATION
THICKENED PULMONARY VALVE
DYSPLASTIC PULMONARY VALVE
ENLARGED PULMONARY VALVE
DILATED PULMONARY VALVE
BICUSPID PULMONARY VALVE
DYSMORPHIC PULMONARY VALVE
REDUNDANT PULMONARY VALVE
ANOMALY OF PULMONARY VALVE
TRICUSPID  ATRESIA AND STENOSIS, CONGENITAL
TRICUSPID  ATRESIA
TRICUSPID  STENOSIS
ABNORMAL TRICUSPID VALVE
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BICUSPID TRICUSPID VALVE
BICUSPID RIGHT ATRIOVENTRICULAR VALVE
BICUSPID RIGHT AV VALVE
CLEFT TRICUSPID VALVE
DYSPLASTIC RIGHT ATRIOVENTRICULAR VALVE
DYSPLASTIC RIGHT AV VALVE
DYSPLASTIC TRICUSPID VALVE
ENLARGED RIGHT ATRIOVENTRICULAR VALVE
ENLARGED RIGHT AV VALVE
ENLARGED TRICUSPID VALVE
REDUNDANT TRICUSPID VALVE
RIGHT ATRIOVENTRICULAR VALVE ATRESIA
RIGHT ATRIOVENTRICULAR VALVE STENOSIS
RIGHT ATRIOVENTRICULAR VALVE HYPOPLASIA
RIGHT AV VALVE ATRESIA
RIGHT AV VALVE STENOSIS
RIGHT AV VALVE HYPOPLASIA
RIGHT ATRIOVENTRICULAR VALVE ANEURYSM
RIGHT AV VALVE ANEURYSM
SMALL RIGHT ATRIOVENTRICULAR VALVE
SMALL RIGHT AV VALVE
THICKENED RIGHT ATRIOVENTRICULAR VALVE
THICKENED RIGHT AV VALVE
TRICUSPID VALVE ANEURYSM
THICKENED TRICUSPID VALVE
TRICUSPID VALVE PROLAPSE
CONGENITAL TRICUSPID VALVE INSUFFICIENCY
CONGENITAL TRICUSPID VALVE REGURGITATION
CONGENITAL RIGHT ATRIOVENTRICULAR VALVE INSUFFICIENCY
CONGENITAL RIGHT ATRIOVENTRICULAR VALVE REGURGITATION
CONGENITAL RIGHT AV VALVE INSUFFICIENCY
CONGENITAL RIGHT AV VALVE REGURGITATION
TRICUSPID VALVE INCOMPETENCE
CONGENITAL STENOSIS OF AORTIC VALVE
SUBVALVULAR AORTIC STENOSIS
SMALL AORTIC VALVE
CONGENITAL INSUFFICIENCY OF AORTIC VALVE
CONGENITAL AORTIC VALVE INSUFFICIENCY
CONGENITAL AORTIC VALVE REGURGITATION
CONGENITAL BICUSPID AORTIC VALVE
AORTIC VALVE INCOMPETENCE
AORTIC VALVE ATRESIA
AORTIC ANNULUS DEFECT
HYPOPLASTIC AORTIC VALVE
 DYSPLASTIC AORTIC VALVE
THICKENED AORTIC VALVE
DYSMORPHIC AORTIC VALVE
QUADRICUSPID AORTIC VALVE
ABNORMAL AORTIC VALVE
ANOMALY OF AORTIC VALVE
CONGENITAL MITRAL STENOSIS
CONGENITAL LEFT ATRIOVENTRICULAR STENOSIS
CONGENITAL LEFT AV STENOSIS
THICKENED MITRAL VALVE
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THICKENED LEFT ATRIOVENTRICULAR VALVE
THICKENED LEFT AV VALVE
ABSENCE OF MITRAL VALVE
ATRESIA OF MITRAL VALVE
HYPOPLASIA OF MITRAL VALVE
ABNORMAL MITRAL VALVE
ABSENCE OF LEFT ATRIOVENTRICULAR VALVE
ABSENCE OF LEFT AV VALVE
ATRESIA OF LEFT ATRIOVENTRICULAR VALVE
ATRESIA OF LEFT AV VALVE
HYPOPLASIA OF LEFT ATRIOVENTRICULAR VALVE
HYPOPLASIA OF LEFT AV VALVE
CLEFT LEFT ATRIOVENTRICULAR VALVE
CLEFT LEFT AV VALVE
CLEFT MITRAL VALVE
DOUBLE ORIFICE MITRAL VALVE
DYSPLASTIC LEFT ATRIOVENTRICULAR VALVE
DYSPLASTIC LEFT AV VALVE
DYSPLASTIC MITRAL VALVE
LEFT ATRIOVENTRICULAR VALVE PROLAPSE
LEFT AV VALVE PROLAPSE
MITRAL VALVE ANOMALY
MITRAL VALVE PROLAPSE
PARACHUTE LEFT ATRIOVENTRICULAR VALVE
PARACHUTE LEFT AV VALVE
PARACHUTE MITRAL VALVE
CONGENITAL MITRAL INSUFFICIENCY
CONGENITAL LEFT ATRIOVENTRICULAR VALVE INSUFFICIENCY
CONGENITAL LEFT AV VALVE INSUFFICIENCY
CONGENITAL LEFT ATRIOVENTRICULAR VALVE REGURGITATION
CONGENITAL LEFT AV VALVE REGURGITATION
CONGENITAL MITRAL REGURGITATION
TRILOGY OF FALLOT
ANOMALIES OF PERICARDIUM
ANOMALIES OF MYOCARDIUM
ANOMALY OF PERICARDIUM
ANOMALY OF MYOCARDIUM
CONGENITAL CARDIOMEGALY
CONGENITAL HYPERTROPHIC CARDIOMYOPATHY
HEART RHABDOMYOMA
VENTRICULAR SEPTAL THICKENING
VENTRICULAR SEPTAL HYPERTOPHY
SHONES COMPLEX
TUMOR OF THE HEART
HYPOPLASTIC HEART
LONG Q-T SYNDROME
LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
HYPOPLASTIC LEFT VENTRICLE
HYPOPLASTIC RIGHT HEART
HYPOPLASTIC RIGHT VENTRICLE
HYPOPLASTIC VENTRICLE
ANOMALY OF CORONARY ARTERY
ANOMALIES OF CORONARY ARTERY
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ANOMALY OF HEART
HEART ANOMALY
CARDIAC ANOMALY
HEART ANOMALIES
CARDIAC ANOMALIES
 HYPOPLASTIC ATRIUM
DEFECT OF THE ATRIA
TRUNCAL VALVE
TRUNCAL VALVE INSUFFICIENCY
TRUNCAL VALVE REGURGITATION
TRUNCAL VALVE STENOSIS
NARROW TRUNCAL VALVE
SINGLE ATRIOVENTRICULAR VALVE
SINGLE AV VALVE
SINGLE ATRIOVENTRICULAR VALVE INSUFFICIENCY
SINGLE ATRIOVENTRICULAR VALVE REGURGITATION
SINGLE AV VALVE INSUFFICIENCY
SINGLE AV VALVE REGURGITATION
ANOMALOUS BANDS OF HEART
ACYANOTIC CONGENITAL HEART DISEASE
CYANOTIC CONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE
CONGENITAL HEART DEFECT
PULMONIC ATRESIA
PULMONIC STENOSIS
PULMONIC HYPOPLASIA
PDA
PREDUCTAL CORARCTATION OF AORTA
PROXIMAL CORARCTATION OF AORTA
POSTDUCTAL CORARCTATION OF AORTA
DISTAL CORARCTATION OF AORTA
JUXTADUCTAL CORARCTATION OF AORTA
PSEUDOTRUNCUS ATERIOSUS
AORTIC HYPOPLASIA
TUBULAR HYPOPLASIA OF AORTA
SMALL AORTA
NARROWING OF AORTA
INTERRUPTED AORTIC ARCH
SUPRAAORTIC STENOSIS
SUPRAVALVULAR STENOSIS
DOUBLE AORTIC ARCH
DEXTROPOSITION AORTA
MALALIGNED AORTA
ENLARGED AORTA
COLLATERAL VESSEL INVOLVING AORTA
PSEUDOCOARCTATION OF AORTA
ANOMALY OF AORTA
ANOMALY OF PULMONARY ARTERY
ABSENCE OF PULMONARY ARTERY
PULMONARY ARTERY ATRESIA
 PULMONARY ARTERY AGENESIS
PULMONARY ARTERY ATRESIA
PULMONARY ARTERY COARCTATION
PULMONARY ARTERY HYPOPLASIA
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PULMONARY ARTERY STENOSIS
SUPRAVALVULAR PULMONARY STENOSIS
PULMONARY ARTERY NARROWING
PERIPHERAL PULMONARY STENOSIS
PERIPHERAL PULMONIC STENOSIS
PULMONARY ARTERY BRANCH STENOSIS
PERIPHERAL PULMONIC STENOSIS MURMUR
ANEURYSM OF PULMONARY ARTERY
DILATATION OF PULMONARY ARTERY
ENLARGED PULMONARY ARTERY
PULMONARY ARTERIOVENOUS MALFORMATION
SMALL PULMONARY ARTERY
OVERRIDING PULMONARY ARTERY
COLLATERAL VESSEL INVOLVING PULMONARY ARTERY
ANOMALY OF GREAT VEIN
STENOSIS OF VENA CAVA
STENOSIS OF INFERIOR VENA CAVA
STENOSIS OF SUPERIOR VENA CAVA
SMALL  VENA CAVA
SMALL  INFERIOR VENA CAVA
SMALL  SUPERIOR VENA CAVA
PERSISTENT LEFT SUPERIOR VENA CAVA
BILATERAL SUPERIOR VENA CAVA
ANOMALOUS PORTAL VEIN TERMINATION
PARTIAL ANOMALOUS PULMONARY VENOUS RETURN
PORTAL VEIN-HEPATIC ARTERY FISTULA
ENLARGED VENA CAVA
ENLARGED INFERIOR VENA CAVA
ENLARGED SUPERIOR VENA CAVA
PULMONARY VEIN ATRESIA
PULMONARY VEIN STENOSIS
DILATED VENA CAVA
DILATED INFERIOR VENA CAVA
DILATED SUPERIOR VENA CAVA
ABSENT VENA CAVA
ABSENT INFERIOR VENA CAVA
ABSENT SUPERIOR VENA CAVA
INTERRUPTED INFERIOR VENA CAVA
BILATERAL INFERIOR VENA CAVA
ANOMALOUS PULMONARY VENOUS RETURN
COMMON TRUNCUS
AORTOPULMONARY WINDOW
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GPRD 
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
211552 ABSENCE SEPTUM BETWEEN AORTA & PULMONARY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND PULMONARY 
ARTERY 745.00
272004 AORTIC SEPTAL DEFECT 745
208173 AORTIC SEPTAL DEFECT 745.00
244350 AORTICOPULMONARY SEPTAL DEFECT 745.00
217130 COMMON TRUNCUS 745.00
238588 DEFECT AORTIC SEPTAL 745.00
220577 DEFECT AORTOPULMONARY 745.00
238587 DEFECT SEPTAL AORTOPULMONARY 745.00
226265 HEART BULB OR SEPTAL CLOSURE DEFECTS NOS 745.00
290174 OTHER HEART BULB AND SEPTAL CLOSURE DEFECT 745.00
281046 PERSISTENT TRUNCUS ARTERIOSUS 745.00
290167 PERSISTENT TRUNCUS ARTERIOSUS 745.00
343160 PERSISTENT TRUNCUS ARTERIOSUS 745.00
208174 TRUNCUS ARTERIOSUS 745.00
340815 TRUNCUS ARTERIOSUS 745.00
284501 TRUNCUS ARTERIOSUS (PERSISTENT) 745.00
262728
BULBUS CORDIS AND CARDIAC SEPTAL CLOSURE
ANOMALIES 745
299420
CONGENITAL HEART DISEASE, SEPTAL AND BULBAR 
ANOMALIES 745
272005 AORTOPULMONARY WINDOW 745
275392 AORTOPULMONARY WINDOW 745
272006 OTHER SPECIFIED TRANSPOSITION OF GREAT VESSELS 745.1
304980 TRANSPOSITION GREAT ARTERIES 745.10
220578 TRANSPOSITION GREAT VESSELS 745.10
299422 TRANSPOSITION OF GREAT VESSELS 745.1
257053 DOUBLE OUTLET RIGHT VENTRICLE 745.11
299423 DOUBLE OUTLET RIGHT VENTRICLE 745.11
262732 DOUBLE OUTLET RIGHT VENTRICLE NOS 745.11
208175 DOUBLE OUTLET RIGHT VENTRICLE, UNSPECIFIED 745.11
202526 TAUSSIG- BING MALFORMATION 745.11
262731 TAUSSIG-BING SYNDROME 745.11
235367 ATRESIA OF PULMONARY ARTERY WITH SEPTAL DEFEC 745.2
220579 TETRALOGY OF FALLOT 745.2
253550 TETRALOGY OF FALLOT 745.2
217133 TETRALOGY OF FALLOT NOS 745.2
208176 TETRALOGY OF FALLOT, UNSPECIFIED 745.2
299424 VENTRICULAR SEPTAL DEFECT IN FALLOTS TETRALOG 745.2
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GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
262733 COMMON VENTRICLE 745.3
235361 COR TRILOCULARE 745.30
211553 COR TRILOCULARE BIATRIATUM 745.3
202527 COR TRILOCULARE BIVENTRICULARE 745.30
272010 COR TRILOCULARE BIVENTRICULARE 745.30
247790 ABSENCE SEPTUM VENTRICULAR 745.40
290169 GERBODES DEFECT 745.40
272008 INTERVENTRICULAR SEPTAL DEFECT 745.40
217134 OTHER SPECIFIED VENTRICULAR SEPTAL DEFECT 745.4
262734 ROGERS DISEASE 745.40
284503 ROGERS DISEASE 745.40
247791 SYNDROME EISENMENGERS 745.40
208177 VENTRICULAR SEPTAL DEFECT 745.4
208178 VENTRICULAR SEPTAL DEFECT NOS 745.4
290168 VENTRICULAR SEPTAL DEFECT, UNSPECIFIED 745.4
304981 VSD (VENTRICULAR SEPTAL DEFECT) 745.4
253552 ATRIAL SEPTAL DEFECT NOS 745.50
304982 DEFECT ATRIAL SEPTAL 745.50
244353 LUTEMBACHERS SYNDROME 745.50
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
284504 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.50
226262 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT NOS 745.5
235354
OTHER SPECIFIED OSTIUM SECUNDUM ATRIAL SEPTAL 
DEFECT 745.5
262735 PATENT FORAMEN OVALE 745.5
290171 PATENT OSTIUM SECUNDUM 745.5
257038 SYNDROME LUTEMBACHERS 745.50
284505 ENDOCARDIAL CUSHION DEFECT COMPLETE TYPE 745.60
229655 ENDOCARDIAL CUSHION DEFECT PARTIAL TYPE 745.60
290172 ENDOCARDIAL CUSHION DEFECTS 745.60
272009 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281050 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281049 ENDOCARDIAL CUSHION DEFECTS, UNSPECIFIED 745.60
244351 LEFT VENTRICLE TO RIGHT ATRIAL COMMUNICATION 745.60
262736 OTHER SPECIFIED ENDOCARDIAL CUSHION DEFECTS 745.6
290173 OSTIUM PRIMUM DEFECT 745.61
226263 PERSISTENT OSTIUM PRIMUM 745.61
244352 PERSISTENT OSTIUM SECUNDUM 745.61
235355 OSTIUM PRIMUM TYPE INTERAURICULAR SEPTAL DEFECT 745.61
266255 ABSENCE SEPTUM ATRIAL 745.69
217135 COMMON ATRIOVENTRICULAR CANAL 745.69
208180 COMMON ATRIOVENTRICULAR-TYPE VENTRICULAR SEPT 745.69
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CODE
253554 COMMON ATRIUM 745.69
257037 COMMON ATRIUM 745.69
244354 OTHER SPECIFIED ATRIAL SEPTAL DEFECT 745.69
220581 SINGLE ATRIUM 745.69
266256 OSTIUM ATRIOVENTRICULARE COMMUNE 745.69
235356 COR BILOCULARE 745.7
272204
[X]OTHER CONGENITAL MALFORMATIONS OF CARDIAC 
SEPTA 745.90
290166 CARDIAC SEPTAL DEFECTS 745.90
253546 HEART SEPTAL DEFECTS 745.90
290170 AURICULAR SEPTAL DEFECT NOS 745.9
208179 INTERAURICULAR SEPTAL DEFECT 745.9
244355 OTHER CONGENITAL HEART ANOMALIES 746
290176 OTHER PULMONARY VALVE ANOMALY NOS 746
272011 PULMONARY VALVE ANOMALY, UNSPECIFIED 746
272012 RIGHT HYPOPLASTIC HEART SYNDROME 746
238589 ATRESIA PULMONARY VALVE CONGENITAL 746.01
217137 CONGENITAL ATRESIA OF PULMONARY VALVE NOS 746.01
290175 CONGENITAL ATRESIA OF THE PULMONARY VALVE 746.01
247797 HYPOPLASIA VENTRICULAR RIGHT 746.01
247796 SYNDROME HYPOPLASTIC RIGHT HEART 746.01
262738 CONGENITAL FUSION OF PULMONARY VALVE SEGMENT 746.02
217139 CONGENITAL FUSION OF PULMONIC CUSPS 746.02
217136 HYPOPLASIA OF PULMONARY VALVE 746.02
257052 STENOSIS PULMONARY ARTERY 746.02
303789 STENOSIS PULMONARY VALVE 746.02
293626 STENOSIS PULMONARY VALVE CONGENITAL 746.02
229656 BICUSPID PULMONARY VALVE 746.02
272205
[X]OTHER CONGENITAL MALFORMATIONS OF PULMONARY 
VALVE 746.09
262740 CONGENITAL INSUFFICIENCY OF THE PULMONARY VALVE 746.09
266259 QUADRICUSPID PULMONARY VALVE 746.09
299642
[X]CONGENITAL MALFORMATION OF TRICUSPID VALVE, 
UNSPECIFIED 746.10
225198 [X]TRICUSPID VALVE DISORDERS/DISEASES CE 746.10
220583 ATRESIA TRICUSPID VALVE 746.10
243272 DISORDERS OF BOTH AORTIC AND TRICUSPID VALVES 746.10
265776 INCOMPETENCE TRICUSPID 746.10
274919 INSUFFICIENCY TRICUSPID 746.10
247792 INSUFFICIENCY TRICUSPID CONGENITAL 746.10
298347
NONRHEUMATIC TRICUSPID VALVE STENOSIS WITH 
INSUFFICIENCY 746.10
257043 STENOSIS TRICUSPID CONGENITAL 746.10
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306410 TRICUSPID (VALVE) DISEASE 746.10
306411 TRICUSPID (VALVE) STENOSIS 746.10
270877 TRICUSPID INCOMPETENCE, CAUSE UNSPECIFIED 746.10
243270 TRICUSPID INCOMPETENCE, NON-RHEUMATIC 746.10
261637 TRICUSPID INSUFFICIENCY, NON-RHEUMATIC 746.10
303750 TRICUSPID REGURGITATION 746.10
252400 TRICUSPID REGURGITATION, NON-RHEUMATIC 746.10
298312
TRICUSPID STENOSIS AND INCOMPETENCE, CAUSE 
UNSPECIFIED 746.10
270878
TRICUSPID STENOSIS AND INSUFFICIENCY, CAUSE 
UNSPECIFIED 746.10
289061 TRICUSPID STENOSIS, NON-RHEUMATIC 746.10
289031 TRICUSPID VALVE DISEASE NEC 746.10
225113 TRICUSPID VALVE DISORDERS NOS 746.10
243269 TRICUSPID VALVE DISORDERS, NON-RHEUMATIC 746.10
266257 EBSTEIN ABNORMALITY 746.20
304983 EBSTEIN ANOMALY TRICUSPID VALVE 746.20
281052 EBSTEINS ANOMALY 746.20
309754 AORTIC STENOSIS 746.30
270910 AORTIC STENOSIS ALONE, CAUSE UNSPECIFIED 746.30
257039 ATRESIA AORTIC VALVE CONGENITAL 746.30
303748 STENOSIS AORTIC 746.30
275395 STENOSIS AORTIC CONGENITAL 746.30
211554 QUADRICUSPID AORTIC VALVE 746.3
272013 BICUSPID AORTIC VALVE 746.4
307119 BICUSPID AORTIC VALVE 746.40
293624 ATRESIA MITRAL VALVE CONGENITAL 746.50
253557 CONGENITAL MITRAL STENOSIS 746.50
208183 CONGENITAL MITRAL STENOSIS NOS 746.50
226267 CONGENITAL MITRAL STENOSIS, UNSPECIFIED 746.50
279935 MITRAL INCOMPETENCE AND AORTIC STENOSIS 746.50
207044 MITRAL STENOSIS 746.5
298310 MITRAL STENOSIS AND AORTIC INSUFFICIENCY 746.50
270873 MITRAL STENOSIS WITH REGURGITATION 746.50
303744 STENOSIS MITRAL 746.50
229660 STENOSIS MITRAL CONGENITAL 746.50
262745 CONGENITAL MITRAL INSUFFICIENCY 746.60
229657 MALFORMATION MITRAL VALVE EBSTEIN-LIKE 746.60
299430 HYPOPLASTIC AORTIC ORIFICE OR VALVE 746.70
281053 HYPOPLASTIC LEFT HEART SYNDROME 746.7
272015 OTHER SPECIFIED HEART ANOMALIES 746.8
272019 OTHER SPECIFIED HEART ANOMALIES 746.8
247793 STENOSIS SUBVALVAR AORTIC CONGENITAL 746.81
235359 SUBAORTIC STENOSIS 746.81
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CODE
299426 COR TRIATRIATUM 746.82
211556 COR TRIATRIATUM 746.82
275397 UHLS ANOMALY 746.84
235360 UHLS DISEASE 746.84
281054 OBSTRUCTIVE HEART ANOMALY NEC 746.84
281055 OBSTRUCTIVE HEART ANOMALY NEC NOS 746.84
257045 ABNORMAL CORONARY ARTERY 746.85
281058 ANOMALOUS CORONARY ARTERY COMMUNICATION 746.85
290177 CONGENITAL ABSENCE OF CORONARY ARTERY 746.85
262746 CONGENITAL STRICTURE OF CORONARY ARTERY 746.85
281056 CORONARY ARTERY ANOMALY 746.85
290178 CORONARY ARTERY ANOMALY NOS 746.85
244358 SINGLE CORONARY ARTERY 746.85
204725 TRANSPOSITION OF CORONARY ARTERY NEC 746.85
279974 COMPLETE ATRIOVENTRICULAR BLOCK 746.86
208184 CONGENITAL HEART BLOCK 746.86
272016 CONGENITAL HEART BLOCK NOS 746.86
290179 CONGENITAL HEART BLOCK, UNSPECIFIED 746.86
226270 ABDOMINAL HEART 746.87
253560 DEXTROCARDIA 746.87
257047 DEXTROCARDIA 746.87
299429 ECTOPIA CORDIS 746.87
247795 ECTOPIA CORDIS 746.87
226269 LEVOCARDIA 746.87
299428 MESOCARDIA 746.87
202597 DEXTROCARDIA WITH COMPLETE TRANSPOSITION 746.87
293625 ACCESSORY CUSPS HEART VALVE CONGENITAL 746.89
262748 CONGENITAL CARDIOMEGALY 746.89
281059 FUSION OF HEART VALVE CUSPS NEC 746.89
290183 HEMICARDIA 746.89
290180 HYPOPLASIA OF HEART NOS 746.89
272022 CONGENITAL PERICARDIAL DEFECT 746.89
217360
[X]CONGENITAL MALFORMATION OF AORTIC AND MITRAL 
VALVES UNSP 746.9
272206
[X]OTHER CONGENITAL MALFORMATIONS OF AORTIC & 
MITRAL VALVES 746.9
284513 ABSENCE DUCTUS ARTERIOSUS 746.9
281061 ACYANOTIC CONGENITAL HEART DISEASE NOS 746.9
202596 ATRESIA CONGENITAL 746.9
244374 ATRESIA OF ARTERY NEC 746.9
272023 ATRESIA OF HEART VALVE NEC 746.9
279968
COMBINED DISORDERS OF MITRAL, AORTIC AND 
TRICUSPID VALVES 746.9
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APPENDIX B: GPRD medical codes and the corresponding assigned ICD-9 code used to 
define all congenital heart defects (Continued)
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
279968
COMBINED DISORDERS OF MITRAL, AORTIC AND
TRICUSPID VALVES 746.9
279968
COMBINED DISORDERS OF MITRAL, AORTIC AND
TRICUSPID VALVES 746.9
208186 CONGENITAL HEART ANOMALY NOS 746.9
281060 CONGENITAL HEART ANOMALY NOS 746.9
238594 CONGENITAL HEART LESION 746.9
272020 CONGENITAL INSUFFICIENCY OF HEART VALVE NEC 746.9
272014
CONGENITAL MALFORMATION OF AORTIC AND MITRAL 
VALVES UNSP 746.9
244378 CONGENITAL MALFORMATION OF GREAT ARTERIES, UN 746.9
244363 CYANOTIC CONGENITAL HEART DISEASE NOS 746.9
261639 DISORDERS OF BOTH MITRAL AND TRICUSPID VALVES 746.9
261639 DISORDERS OF BOTH MITRAL AND TRICUSPID VALVES 746.9
281051 DOUBLE OUTLET LEFT VENTRICLE 746.9
266260 HYPOPLASTIC RIGHT HEART SYNDROME 746.9
259294
OTHER CONNECTION FROM AORTA TO PULMONARY
ARTERY NOS 746.9
262749 OTHER SPECIFIED HEART ANOMALIES NOS 746.9
303851 STENOSIS ARTERY 746.9
226274 ANOMALOUS BANDS OF HEART 746.9
290184 ANOMALOUS BANDS OF HEART NOS 746.9
244362 UNSPECIFIED ANOMALY OF HEART VALVE 746.9
307120 COARCTATION AORTA 747.1
217144 COARCTATION OF AORTA 747.1
235364 COARCTATION OF AORTA NOS 747.1
244365 POSTDUCTAL COARCTATION OF AORTA 747.1
272027 PREDUCTAL COARCTATION OF AORTA 747.1
272028 INTERRUPTION OF AORTIC ARCH 747.11
253565 POSTDUCTAL INTERRUPTION OF AORTA 747.11
299432 PREDUCTAL INTERRUPTION OF AORTA 747.11
272030 ANOMALY OF AORTA, UNSPECIFIED 747.2
208181 CONGENITAL AORTIC VALVE INSUFFICIENCY 747.2
253556 CONGENITAL AORTIC VALVE INSUFFICIENCY NOS 747.2
262744
CONGENITAL AORTIC VALVE INSUFFICIENCY, 
UNSPECIFIED 747.2
229658 INSUFFICIENCY AORTIC CONGENITAL 747.20
299433 OTHER ANOMALIES OF AORTA 747.2
290188 OTHER ANOMALIES OF AORTA NOS 747.2
262752 OTHER ANOMALY OF AORTA NOS 747.2
275394 REGURGITATION AORTIC (VALVE) CONGENITAL 747.20
202116 REGURGITATION AORTIC (VALVE) NONRHEUMATI 747.20
274982 ENLARGED AORTA 747.2
272029 ANOMALIES OF THE AORTA EXCLUDING COARCTION 747.21
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APPENDIX B: GPRD medical codes and the corresponding assigned ICD-9 code used to 
define all congenital heart defects (Continued)
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
272032 AORTIC ARCH ANOMALIES NOS 747.21
290186 DEXTRAPOSITION OF AORTA 747.21
253548 DEXTRATRANSPOSITION OF AORTA 747.21
272031 DOUBLE AORTIC ARCH 747.21
290185 HYPOPLASIA OF AORTIC ARCH, UNSPECIFIED 747.21
244368 KOMMERELLS DIVERTICULUM 747.21
235365 OVERRIDING AORTA 747.21
262750 OVERRIDING AORTA 747.21
253568 PERSISTENT RIGHT AORTIC ARCH 747.21
217131 TRANSPOSITION OF AORTA 747.21
253569 VASCULAR RING, AORTA 747.21
257050 ABSENCE AORTA CONGENITAL 747.22
253570 APLASIA OF AORTA 747.22
299434 ATRESIA AND STENOSIS OF AORTA 747.22
262751 ATRESIA OF AORTA 747.22
235366 ATRESIA OR STENOSIS OF AORTA NOS 747.22
299435 CONGENITAL ABSENCE OF AORTA 747.22
253571 HYPOPLASIA OF AORTA 747.22
208187 POSTDUCTAL HYPOPLASIA OF AORTA 747.22
253564 PREDUCTAL HYPOPLASIA OF AORTA 747.22
299436 STRICTURE OF AORTA 747.22
244370 TUBULAR HYPOPLASIA OF AORTA 747.22
290189 ANEURYSM OF SINUS OF VALSALVA 747.29
284508 ANEURYSM SINUS VALSALVA 747.29
284509 ANEURYSM VALSALVAS 747.29
226276 CONGENITAL ANEURYSM OF AORTA 747.29
211561 ABNORMAL PULMONARY ARTERY 747.30
293632 ANOMALOUS ORIGIN PULMONARY ARTERY 747.30
244372 COARCTATION OF THE PULMONARY ARTERY 747.30
217147 CONGENITAL ABSENCE OF PULMONARY ARTERY 747.3
208190 CONGENITAL STRICTURE OF PULMONARY ARTERY 747.30
290191 DILATATION OF PULMONARY ARTERY 747.3
208189 HYPOPLASIA OF THE PULMONARY ARTERY 747.30
208189 HYPOPLASIA OF THE PULMONARY ARTERY 747.30
226277 OTHER SPECIFIED ANOMALY OF PULMONARY ARTERY 747.3
253573 PULMONARY ARTERY ANOMALIES 747.30
208188 PULMONARY ARTERY ATRESIA 747.3
253575 STENOSIS OF PULMONARY ARTERY 747.3
216019 ANEURYSM OF PULMONARY ARTERY 747.3
293629 ABNORMAL SINUS VENOSUS 747.40
266262 ABSENCE VEIN GREAT CONGENITAL 747.40
211560 ABSENCE VEIN PORTAL CONGENITAL 747.40
211560 ABSENCE VEIN PORTAL CONGENITAL 747.40
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APPENDIX B: GPRD medical codes and the corresponding assigned ICD-9 code used to 
define all congenital heart defects (Continued)
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
202536 ANOMALOUS VENAE CAVAE 747.40
208191 ANOMALY OF GREAT VEINS, UNSPECIFIED 747.40
275400 PORTAL CAVERNOMA 747.40
290181 HYPOPLASIA OF CARDIAC VEIN 747.4
272021 ATRESIA OF CARDIAC VEIN 747.4
238596 ANOMALOUS PULMONARY VEINS 747.41
208192
SUBDIAPHRAGMATIC TOTAL ANOMALOUS PULMONARY 
VENOUS RETURN 747.41
290193
SUPRADIAPHRAGMATIC TOTAL ANOMALOUS PULMONARY 
VENOUS RETURN 747.41
299438 TOTAL ANOMALOUS PULMONARY VENOUS RETURN - TAP 747.41
281062 TOTAL ANOMALOUS PULMONARY VENOUS RETURN NOS 747.41
253577 PARTIAL ANOMALOUS PULMONARY VENOUS RETURN 747.42
262756 ANOMALOUS PORTAL VEIN TERMINATION 747.49
217148 PERSISTENT LEFT POSTERIOR CARDINAL VEIN 747.49
262758 PERSISTENT LEFT POSTERIOR CARDINAL VEIN 747.49
290194 PERSISTENT LEFT SUPERIOR VENA CAVA 747.49
208193 SCIMITAR SYNDROME 747.49
235370 STENOSIS OF INFERIOR VENA CAVA 747.49
272033 STENOSIS OF SUPERIOR VENA CAVA 747.49
220590 SYNDROME SCIMITAR 747.49
272034 TRANSPOSITION OF PULMONARY VEINS 747.49
229661 ABSENCE VENA CAVA CONGENITAL 747.40
262755 ANOMALIES OF GREAT VEINS 747.40
202536 ANOMALOUS VENAE CAVAE 747.40
281047
DEXTRATRANSPOSITION OF AORTA IN FALLOTS 
TETRALOGY 745.2
235367 ATRESIA OF PULMONARY ARTERY WITH SEPTAL DEFECT 745.2
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APPENDIX C: Ventricular Septal Defect Medical Record Abstraction Form 
Dear General Practitioner,
A child in your practice has been identified as having computer-based records containing 
a diagnostic code suggesting the presence of one of three types of congenital heart defects: 
ventricular septal defect (VSD), Tetralogy of Fallot (TOF)  or coarctation of the aorta (COA).  We 
are conducting a study to determine whether the medical records of such children confirm the 
presence of these diagnoses. We will also determine whether the GPRD can provide additional 
information about timing and presentation of specific congenital heart defects.  The results will 
help future researchers to use the GPRD to correctly identify patients with congenital heart 
defects. 
Attached is a medical record abstraction form pertaining to the child whose record was 
sampled and found to contain such a code. The medical record abstraction form asks for detailed 
information about the patient that you may have within your written or computerized records.  If 
you do not have this patient's record, please indicate that on the medical record abstraction form 
and return.
Thank you.
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VENTRICULAR SEPTAL DEFECT MEDICAL RECORD ABSTRACTION FORM
Practice ID Patient ID Sex Year of Birth
1.) Has this patient ever been diagnosed with a ventricular septal defect?
Please tick one box below 
[  ] Yes, please confirm the date of diagnosis __ __ ____
[  ] No, if no please stop and return the medical record abstraction form
2) What was this patient’s age at diagnosis (date of final diagnosis)?  
Please tick one box below 
[  ] Diagnosed prenatally
[  ] Birth- 1 day 
[  ] 2 days-7 days
[  ] 8 days-14 days
[  ] 15 days or more but less than 1 month
[  ] 1-3 months
[  ] 4-6 months
[  ] 7-12 months
[  ] 13-23 months
[  ] 2-4 years
[  ] More than 4 years of age
3) What were the reasons the diagnosis of ventricular septal defect was 
suspected?
Please tick all boxes that apply below 
[  ] Abnormal prenatal ultrasound / evaluation 
[  ] Family history of a congenital heart defect
[  ] Maternal risk factor  Please specify_________________________________
[  ] Non-cardiac anomaly
[  ] Suspected chromosomal abnormality
[  ] Patient symptoms including but not limited to: trouble feeding, failure to gain 
weight, tachypnea, sweating
[  ] Heart Murmur
[  ] Abnormal Electrocardiogram
[  ] Abnormal X-ray 
[  ] Cardiac Insufficiency
[  ] Other signs of congenital heart disease
[  ] Other reason please specify ______________________________________
PLEASE COMPLETE PAGE 2
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4) Who made the final diagnosis? 
Please tick one box below 
[  ] Paediatric cardiologist
[  ] Other cardiologist
[  ] General practitioner 
[  ] Neonatalogist
[  ] Paediatrician
[  ] Other
5) Please indicate which diagnostic tests were performed in your practice or 
elsewhere to confirm the diagnosis of ventricular septal defect? 
Please tick all boxes that apply and provide all anonymized notes pertaining to any of the tests ticked below. 
[  ] No tests were performed If no tests were performed skip to question 6
[  ] Echocardiogram If an echocardiogram was performed please answer question 5A
[  ] Cardiac Catheterization If cardiac catheterization was performed please answer 
question 5B
[  ] Other procedure was performed to confirm diagnosis of ventricular septal defect
Please specify ___________________________________________________
5A) If an echocardiogram was performed please tick all of the findings that apply
Please tick all boxes that apply below
[  ] Echocardiogram normal 
[  ] Ventricular septal defect and no other abnormality
[  ] Left atrial enlargement
[  ] Right atrial enlargement
[  ] Left ventricular hypertrophy 
[  ] Biventricular hypertrophy 
[  ] Right ventricular hypertrophy 
[  ] Left ventricular enlargement
[  ]  Biventricular enlargement
[  ] Right ventricular enlargement 
[  ] Additional findings (please list)________________________________________
5B) If cardiac catheterization was performed, was the diagnosis consistent with 
the echocardiogram diagnosis? 
Please tick one box below 
[  ] Yes    
[  ] No  If no, please list additional findings _________________________________ 
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6) If the type of VSD could be identified, please indicate which type this patient 
had?
Please tick one box below 
[  ] Membranous (or Perimembranous)  VSD
[  ] Muscular (or Apical) VSD
[  ] Inlet VSD
[  ] Outlet VSD
[  ] Multiple or a combination of  types of VSD
[  ] Common Ventricle
[  ] Other type of VSD  please specify  _____________________________________
[  ] Type of VSD was not specified
7) Did this patient undergo cardiac surgery? 
Please tick one box below 
      [  ] Yes
[  ] No 
8) Was this patient referred to a cardiology centre? 
Please tick one box below 
[  ] Yes 
[  ]  No 
If yes, please provide all anonymized notes from the referral 
9) Has the patient ever been diagnosed with additional congenital heart defects? 
Please tick one box below 
[  ] Yes 
[  ] No
If yes, please list_______________________________________________________
10) Please provide the ID number of this patient’s mother for verification 
purposes. 
____________________________________
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APPENDIX D: Tetralogy of Fallot Medical Record Abstraction Form
Dear General Practitioner,
A child in your practice has been identified as having computer-based records containing 
a diagnostic code suggesting the presence of one of three types of congenital heart defects: 
ventricular septal defect (VSD), Tetralogy of Fallot (TOF)  or coarctation of the aorta (COA).  We 
are conducting a study to determine whether the medical records of such children confirm the 
presence of these diagnoses. We will also determine whether the GPRD can provide additional 
information about timing and presentation of specific congenital heart defects.  The results will 
help future researchers to use the GPRD to correctly identify patients with congenital heart 
defects. 
Attached is a medical record abstraction form pertaining to the child whose record was 
sampled and found to contain such a code. The medical record abstraction form asks for detailed 
information about the patient that you may have within your written or computerized records.  If 
you do not have this patient's record, please indicate that on the medical record abstraction form 
and return.
Thank you.
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TETRALOGY OF FALLOT MEDICAL RECORD ABSTRACTION FORM
Practice ID Patient ID Sex Year of Birth
1) Has this patient ever been diagnosed with Tetralogy of Fallot?
Please tick one box below 
[  ] Yes, please confirm the date of diagnosis __ __ ____
[  ] No, if no please stop and return the medical record abstraction form
2) What was this patient’s age at diagnosis (date of final diagnosis)?  
Please tick one box below 
[  ] Diagnosed prenatally
[  ] Birth- 1 day 
[  ] 2 days-7 days
[  ] 8 days-14 days
[  ] 15 days or more but less than 1 month
[  ] 1-3 months
[  ] 4-6 months
[  ] 7-12 months
[  ] 13-23 months
[  ] 2-4 years
[  ] More than 4 years of age
3) What were the reasons the diagnosis of Tetralogy of Fallot was suspected?
Please tick all boxes that apply below 
[  ] Abnormal prenatal ultrasound / evaluation 
[  ] Family history of a congenital heart defect
[  ] Maternal risk factor Please specify_________________________________
[  ] Non-cardiac anomaly
[  ] Suspected chromosomal abnormality
[  ] Abnormal Electrocardiogram
[  ] Abnormal X-ray 
[  ] Patient symptoms including but not limited to cyanosis or difficulty breathing
[  ] Hypercyanotic “Tet” Spells 
[  ] Other signs of congenital heart disease
[  ] Other reason please specify ________________________________________
4) Who made the final diagnosis? 
Please tick one box below 
[  ] Paediatric cardiologist 
[  ] Other cardiologist
[  ] General practitioner 
[  ] Neonatalogist
[  ] Paediatrician
[  ] Other
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5) Please indicate which diagnostic tests were performed in your practice or 
elsewhere to confirm the diagnosis of Tetralogy of Fallot ? 
Please tick all boxes that apply and provide all anonymized notes pertaining to any of the tests ticked below. 
[  ] No tests were performed If no tests were performed skip to question 6
[  ] Echocardiogram If an echocardiogram was performed please answer question 5A
[  ] Cardiac Catheterization  If cardiac catheterization was performed please answer 
question 5B
[  ] Other procedure was performed to confirm diagnosis of  Tetralogy of Fallot
Please specify ______________________
5A) If an echocardiogram was performed please tick all of the findings that apply
Please tick all boxes that apply below 
[  ] Echocardiogram normal
[  ] Echocardiogram demonstrated abnormalities consistent with Tetralogy of Fallot  and 
no other abnormality
[  ] Left atrial enlargement
[  ] Right atrial enlargement
[  ] Left ventricular hypertrophy 
[  ] Biventricular hypertrophy 
[  ] Right ventricular hypertrophy 
[  ] Left ventricular enlargement
[  ] Biventricular enlargement
[  ] Right ventricular enlargement 
[  ] Right Ventricular Outflow Obstruction 
[  ] Additional findings (please list) _____________________________________
5B) If cardiac catheterization was performed, was the diagnosis consistent with 
the echocardiogram diagnosis? 
Please tick one box below 
[  ] Yes    
[  ] No  If no, please list additional findings _______________________________ 
6) Did this patient undergo cardiac surgery? 
Please tick one box below 
[  ] Yes
[  ] No 
PLEASE COMPLETE PAGE 3
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7) Was this patient referred to a cardiology centre? 
Please tick one box below 
[  ] Yes 
[  ]  No 
If yes, please provide all anonymized notes from the referral 
8) Has the patient ever been diagnosed with additional congenital heart defects? 
Please tick one box below 
[  ] Yes 
[  ] No
If yes, please list_______________________________________________________
9) Please provide the ID number of this patient’s mother for verification purposes. 
____________________________________
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APPENDIX E: Coarctation of the Aorta Medical Record Abstraction Form
Dear General Practitioner,
A child in your practice has been identified as having computer-based records containing 
a diagnostic code suggesting the presence of one of three types of congenital heart defects: 
ventricular septal defect (VSD), Tetralogy of Fallot (TOF)  or coarctation of the aorta (COA).  We 
are conducting a study to determine whether the medical records of such children confirm the 
presence of these diagnoses. We will also determine whether the GPRD can provide additional 
information about timing and presentation of specific congenital heart defects.  The results will 
help future researchers to use the GPRD to correctly identify patients with congenital heart 
defects. 
Attached is a medical record abstraction form pertaining to the child whose record was 
sampled and found to contain such a code. The medical record abstraction form asks for detailed 
information about the patient that you may have within your written or computerized records.  If 
you do not have this patient's record, please indicate that on the medical record abstraction form 
and return.
Thank you.
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COARCTATION OF THE AORTA MEDICAL RECORD ABSTRACTION FORM
Practice ID Patient ID Sex Year of Birth
1) Has this patient ever been diagnosed with a coarctation of the aorta?
Please tick one box below 
[  ] Yes, please confirm the date of diagnosis __ __ ____
[  ] No, if no please stop and return the medical record abstraction form
2) What was this patient’s age at diagnosis (date of final diagnosis)?  
Please tick one box below 
[  ] Diagnosed prenatally
[  ] Birth- 1 day 
[  ] 2 days-7 days
[  ] 8 days-14 days
[  ] 15 days or more but less than 1 month
[  ] 1-3 months
[  ] 4-6 months
[  ] 7-12 months
[  ] 13-23 months
[  ] 2-4 years
[  ] More than 4 years of age
3) What were the reasons the diagnosis of coarctation of the aorta was 
suspected?     
Please tick all boxes that apply below 
[  ] Abnormal prenatal ultrasound / evaluation
[  ] Family history of a congenital heart defect
[  ] Maternal risk factor  Please specify____________________________
[  ] Non-cardiac anomaly
[  ] Suspected chromosomal abnormality
[  ] Abnormal Electrocardiogram
[  ] Abnormal X-ray 
[  ] Patient symptoms including but not limited to: failure to gain weight, tachypnea, 
sweating, or cyanosis
[  ] Heart murmur
[  ] Pulses and/or blood pressures consistent with coarctation of the aorta
[  ] Other signs of congenital heart disease
[  ] Other reason please specify ____________________________________
4) Who made the final diagnosis? 
Please tick one box below 
[  ] Paediatric cardiologist 
[  ] Other cardiologist
[  ] General practitioner 
[  ] Neonatalogist
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[  ] Paediatrician
[  ] Other
5) Please indicate which diagnostic tests were performed in your practice or 
elsewhere to confirm the diagnosis of coarctation of the aorta?
Please tick all boxes that apply and provide all anonymized notes pertaining to any of the tests ticked below. 
[  ] No tests were performed If no tests were performed skip to question 6
[  ] Echocardiogram If an echocardiogram was performed please answer question 5A
[  ] Cardiac Catheterization  If cardiac catheterization was performed please answer 
question 5B
[  ] Other procedure was performed to confirm diagnosis of ventricular septal defect
Please specify ______________________
5A) If an echocardiogram was performed please tick all of the findings that apply
Please tick all boxes that apply below 
[  ] Echocardiogram normal 
[  ] Abnormal aortic arch indicative of coarctation of the aorta 
[  ] Echocardiogram demonstrated coarctation of the aorta and no other abnormality
[  ] Left atrial enlargement
[  ] Right atrial enlargement
[  ] Left ventricular hypertrophy 
[  ] Biventricular hypertrophy 
[  ] Right ventricular hypertrophy 
[  ] Left ventricular enlargement
[  ] Biventricular enlargement
[  ] Right ventricular enlargement 
[  ] Left ventricular hypoplasia
[  ] Mitral valve abnormality 
[  ] Aortic valve including bicuspid aortic valve 
[  ] Additional findings (Please list)  ____________________________
5B) If cardiac catheterization was performed, was the diagnosis consistent with 
the echocardiogram diagnosis? 
Please tick one box below 
 [  ] Yes    
 [  ] No, If no, please list additional findings ____________________ 
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6) Did this patient undergo cardiac or cardio-thoracic surgery? 
Please tick one box below 
[  ] Yes
[  ] No 
7) Was this patient referred to a cardiology centre? 
Please tick one box below 
[  ] Yes 
[  ] No 
If yes, please provide all anonymized notes from the referral 
8) Has the patient ever been diagnosed with additional congenital heart defects? 
Please tick one box below 
[  ] Yes 
[  ] No
If yes, please list_______________________________________________________
9) Please provide the ID number of this patient’s mother for verification purposes. 
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APPENDIX F:  GPRD Defects of cardiac chambers and connections medical codes
GPRD
MEDICAL CODE
DESCRIPTION ICD-9 
CODE
211552
ABSENCE SEPTUM BETWEEN AORTA & 
PULMONARY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND 
PULMONARY ARTERY 745.00
272004 AORTIC SEPTAL DEFECT 745
208173 AORTIC SEPTAL DEFECT 745.00
244350 AORTICOPULMONARY SEPTAL DEFECT 745.00
217130 COMMON TRUNCUS 745.00
238588 DEFECT AORTIC SEPTAL 745.00
220577 DEFECT AORTOPULMONARY 745.00
238587 DEFECT SEPTAL AORTOPULMONARY 745.00
226265
HEART BULB OR SEPTAL CLOSURE DEFECTS 
NOS 745.00
290174
OTHER HEART BULB AND SEPTAL CLOSURE 
DEFECT 745.00
281046 PERSISTENT TRUNCUS ARTERIOSUS 745.00
290167 PERSISTENT TRUNCUS ARTERIOSUS 745.00
343160 PERSISTENT TRUNCUS ARTERIOSUS 745.00
208174 TRUNCUS ARTERIOSUS 745.00
340815 TRUNCUS ARTERIOSUS 745.00
284501 TRUNCUS ARTERIOSUS (PERSISTENT) 745.00
262728
BULBUS CORDIS AND CARDIAC SEPTAL 
CLOSURE ANOMALIES 745
299420
CONGENITAL HEART DISEASE, SEPTAL AND 
BULBAR ANOMALIES 745
272005 AORTOPULMONARY WINDOW 745
275392 AORTOPULMONARY WINDOW 745
272006
OTHER SPECIFIED TRANSPOSITION OF GREAT 
VESSELS 745.1
304980 TRANSPOSITION GREAT ARTERIES 745.10
220578 TRANSPOSITION GREAT VESSELS 745.10
299422 TRANSPOSITION OF GREAT VESSELS 745.1
257053 DOUBLE OUTLET RIGHT VENTRICLE 745.11
299423 DOUBLE OUTLET RIGHT VENTRICLE 745.11
262732 DOUBLE OUTLET RIGHT VENTRICLE NOS 745.11
208175
DOUBLE OUTLET RIGHT VENTRICLE, 
UNSPECIFIED 745.11
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APPENDIX F:  GPRD Defects of cardiac chambers and connections medical codes
(Continued)
GPRD
MEDICAL  CODE
DESCRIPTION ICD-9 
CODE
202526 TAUSSIG- BING MALFORMATION 745.11
262731 TAUSSIG-BING SYNDROME 745.11
262733 COMMON VENTRICLE 745.3
235361 COR TRILOCULARE 745.30
211553 COR TRILOCULARE BIATRIATUM 745.3
202527 COR TRILOCULARE BIVENTRICULARE 745.30
272010 COR TRILOCULARE BIVENTRICULARE 745.30
235356 COR BILOCULARE 745.7
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APPENDIX G: GPRD Transposition of great vessels medical codes
GPRD 
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
272006
OTHER SPECIFIED TRANSPOSITION 
OF GREAT VESSELS 745.1
304980 TRANSPOSITION GREAT ARTERIES 745.10
220578 TRANSPOSITION GREAT VESSELS 745.10
299422 TRANSPOSITION OF GREAT VESSELS 745.1
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APPENDIX H: GPRD Single Ventricle medical codes
GPRD 
CODE
DESCRIPTION ICD-9 
CODE
262733 COMMON VENTRICLE 745.3
235361 COR TRILOCULARE 745.30
211553
COR TRILOCULARE 
BIATRIATUM 745.3
202527
COR TRILOCULARE 
BIVENTRICULARE 745.30
272010
COR TRILOCULARE 
BIVENTRICULARE 745.30
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APPENDIX I: GPRD Hypoplastic Left Heart medical codes
GPRD
MEDICAL 
CODE
DESCRIPTION
ICD-9 
CODE
299430
HYPOPLASTIC AORTIC 
ORIFICE OR VALVE 746.70
281053
HYPOPLASTIC LEFT HEART 
SYNDROME 746.7
141
APPENDIX J: GPRD Malformations of Cardiac Septa medical codes
GPRD
MEDICAL CODE DESCRIPTION
ICD-9 
CODE
211552
ABSENCE SEPTUM BETWEEN AORTA & 
PULMONARY 745.00
211552
ABSENCE SEPTUM BETWEEN AORTA & 
PULMONARY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND 
PULMONARY ARTERY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND 
PULMONARY ARTERY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND 
PULMONARY ARTERY 745.00
272004 AORTIC SEPTAL DEFECT 745
208173 AORTIC SEPTAL DEFECT 745.00
244350 AORTICOPULMONARY SEPTAL DEFECT 745.00
217130 COMMON TRUNCUS 745.00
238588 DEFECT AORTIC SEPTAL 745.00
220577 DEFECT AORTOPULMONARY 745.00
238587 DEFECT SEPTAL AORTOPULMONARY 745.00
226265
HEART BULB OR SEPTAL CLOSURE DEFECTS 
NOS 745.00
290174
OTHER HEART BULB AND SEPTAL CLOSURE 
DEFECT 745.00
281046 PERSISTENT TRUNCUS ARTERIOSUS 745.00
290167 PERSISTENT TRUNCUS ARTERIOSUS 745.00
343160 PERSISTENT TRUNCUS ARTERIOSUS 745.00
208174 TRUNCUS ARTERIOSUS 745.00
340815 TRUNCUS ARTERIOSUS 745.00
284501 TRUNCUS ARTERIOSUS (PERSISTENT) 745.00
262728
BULBUS CORDIS AND CARDIAC SEPTAL 
CLOSURE ANOMALIES 745
299420
CONGENITAL HEART DISEASE, SEPTAL AND 
BULBAR ANOMALIES 745
272005 AORTOPULMONARY WINDOW 745
275392 AORTOPULMONARY WINDOW 745
235367
ATRESIA OF PULMONARY ARTERY WITH SEPTAL 
DEFEC 745.2
220579 TETRALOGY OF FALLOT 745.2
253550 TETRALOGY OF FALLOT 745.2
217133 TETRALOGY OF FALLOT NOS 745.2
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APPENDIX J: GPRD Malformations of Cardiac Septa medical codes (Continued)
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
208176 TETRALOGY OF FALLOT, UNSPECIFIED 745.2
299424
VENTRICULAR SEPTAL DEFECT IN FALLOTS 
TETRALOG 745.2
235367
ATRESIA OF PULMONARY ARTERY WITH SEPTAL 
DEFEC 745.2
281047
DEXTRATRANSPOSITION OF AORTA IN FALLOTS 
TETRALOGY 745.2
281047
DEXTRATRANSPOSITION OF AORTA IN FALLOTS 
TETRALOGY 745.2
247790 ABSENCE SEPTUM VENTRICULAR 745.40
290169 GERBODES DEFECT 745.40
272008 INTERVENTRICULAR SEPTAL DEFECT 745.40
217134
OTHER SPECIFIED VENTRICULAR SEPTAL 
DEFECT 745.4
262734 ROGERS DISEASE 745.40
284503 ROGERS DISEASE 745.40
247791 SYNDROME EISENMENGERS 745.40
208177 VENTRICULAR SEPTAL DEFECT 745.4
208178 VENTRICULAR SEPTAL DEFECT NOS 745.4
290168 VENTRICULAR SEPTAL DEFECT, UNSPECIFIED 745.4
304981 VSD (VENTRICULAR SEPTAL DEFECT) 745.4
253552 ATRIAL SEPTAL DEFECT NOS 745.50
304982 DEFECT ATRIAL SEPTAL 745.50
244353 LUTEMBACHERS SYNDROME 745.50
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
284504 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.50
284504 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
226262
OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 
NOS 745.5
226262
OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 
NOS 745.5
235354
OTHER SPECIFIED OSTIUM SECUNDUM ATRIAL 
SEPTAL DEFECT 745.5
235354
OTHER SPECIFIED OSTIUM SECUNDUM ATRIAL 
SEPTAL DEFECT 745.5
262735 PATENT FORAMEN OVALE 745.5
290171 PATENT OSTIUM SECUNDUM 745.5
257038 SYNDROME LUTEMBACHERS 745.50
284505
ENDOCARDIAL CUSHION DEFECT COMPLETE 
TYPE 745.60
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GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
229655 ENDOCARDIAL CUSHION DEFECT PARTIAL TYPE 745.60
290172 ENDOCARDIAL CUSHION DEFECTS 745.60
272009 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281050 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281049 ENDOCARDIAL CUSHION DEFECTS, UNSPECIFIED 745.60
244351
LEFT VENTRICLE TO RIGHT ATRIAL 
COMMUNICATION 745.60
262736
OTHER SPECIFIED ENDOCARDIAL CUSHION 
DEFECTS 745.6
290173 OSTIUM PRIMUM DEFECT 745.61
226263 PERSISTENT OSTIUM PRIMUM 745.61
244352 PERSISTENT OSTIUM SECUNDUM 745.61
235355
OSTIUM PRIMUM TYPE INTERAURICULAR SEPTAL
DEFECT 745.61
266255 ABSENCE SEPTUM ATRIAL 745.69
217135 COMMON ATRIOVENTRICULAR CANAL 745.69
208180
COMMON ATRIOVENTRICULAR-TYPE 
VENTRICULAR SEPT 745.69
253554 COMMON ATRIUM 745.69
257037 COMMON ATRIUM 745.69
244354 OTHER SPECIFIED ATRIAL SEPTAL DEFECT 745.69
220581 SINGLE ATRIUM 745.69
266256 OSTIUM ATRIOVENTRICULARE COMMUNE 745.69
272204
OTHER CONGENITAL MALFORMATIONS OF 
CARDIAC SEPTA 745.90
290166 CARDIAC SEPTAL DEFECTS 745.90
253546 HEART SEPTAL DEFECTS 745.90
290170 AURICULAR SEPTAL DEFECT NOS 745.9
208179 INTERAURICULAR SEPTAL DEFECT 745.9
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APPENDIX K: GPRD Atrial Septal Defect medical codes
GPRD 
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
253552 ATRIAL SEPTAL DEFECT NOS 745.50
304982 DEFECT ATRIAL SEPTAL 745.50
244353 LUTEMBACHERS SYNDROME 745.50
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
284504 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
281048 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.50
284504 OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 745.5
226262
OSTIUM SECUNDUM ATRIAL SEPTAL DEFECT 
NOS 745.5
235354
OTHER SPECIFIED OSTIUM SECUNDUM 
ATRIAL SEPTAL DEFECT 745.5
262735 PATENT FORAMEN OVALE 745.5
290171 PATENT OSTIUM SECUNDUM 745.5
257038 SYNDROME LUTEMBACHERS 745.50
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APPENDIX L: GPRD Atrioventricular Septal Defect medical codes
GPRD 
MEDICAL 
CODE DESCRIPTION
ICD-9 
CODE
284505
ENDOCARDIAL CUSHION DEFECT 
COMPLETE TYPE 745.60
229655
ENDOCARDIAL CUSHION DEFECT PARTIAL 
TYPE 745.60
290172 ENDOCARDIAL CUSHION DEFECTS 745.60
272009 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281050 ENDOCARDIAL CUSHION DEFECTS NOS 745.60
281049
ENDOCARDIAL CUSHION DEFECTS, 
UNSPECIFIED 745.60
244351
LEFT VENTRICLE TO RIGHT ATRIAL
COMMUNICATION 745.60
262736
OTHER SPECIFIED ENDOCARDIAL CUSHION 
DEFECTS 745.6
290173 OSTIUM PRIMUM DEFECT 745.61
226263 PERSISTENT OSTIUM PRIMUM 745.61
244352 PERSISTENT OSTIUM SECUNDUM 745.61
235355
OSTIUM PRIMUM TYPE INTERAURICULAR 
SEPTAL DEFECT 745.61
266255 ABSENCE SEPTUM ATRIAL 745.69
217135 COMMON ATRIOVENTRICULAR CANAL 745.69
208180
COMMON ATRIOVENTRICULAR-TYPE 
VENTRICULAR SEPT 745.69
253554 COMMON ATRIUM 745.69
257037 COMMON ATRIUM 745.69
244354 OTHER SPECIFIED ATRIAL SEPTAL DEFECT 745.69
220581 SINGLE ATRIUM 745.69
266256 OSTIUM ATRIOVENTRICULARE COMMUNE 745.69
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APPENDIX M: GPRD Malformations of Valves medical codes
GPRD
MEDICAL  CODE DESCRIPTION
ICD-9 
CODE
244355 OTHER CONGENITAL HEART ANOMALIES 746
290176 OTHER PULMONARY VALVE ANOMALY NOS 746
272011
PULMONARY VALVE ANOMALY, 
UNSPECIFIED 746
272012 RIGHT HYPOPLASTIC HEART SYNDROME 746
238589 ATRESIA PULMONARY VALVE CONGENITAL 746.01
217137
CONGENITAL ATRESIA OF PULMONARY 
VALVE NOS 746.01
290175
CONGENITAL ATRESIA OF THE 
PULMONARY VALVE 746.01
247797 HYPOPLASIA VENTRICULAR RIGHT 746.01
247796 SYNDROME HYPOPLASTIC RIGHT HEART 746.01
262738
CONGENITAL FUSION OF PULMONARY 
VALVE SEGMENT 746.02
217139
CONGENITAL FUSION OF PULMONIC 
CUSPS 746.02
217136 HYPOPLASIA OF PULMONARY VALVE 746.02
257052 STENOSIS PULMONARY ARTERY 746.02
303789 STENOSIS PULMONARY VALVE 746.02
293626
STENOSIS PULMONARY VALVE 
CONGENITAL 746.02
229656 BICUSPID PULMONARY VALVE 746.02
272205
[X]OTHER CONGENITAL MALFORMATIONS 
OF PULMONARY VALVE 746.09
262740
CONGENITAL INSUFFICIENCY OF THE 
PULMONARY VALVE 746.09
266259 QUADRICUSPID PULMONARY VALVE 746.09
299642
[X]CONGENITAL MALFORMATION OF 
TRICUSPID VALVE, UNSPECIFIED 746.10
225198
[X]TRICUSPID VALVE 
DISORDERS/DISEASES CE 746.10
220583 ATRESIA TRICUSPID VALVE 746.10
243272
DISORDERS OF BOTH AORTIC AND 
TRICUSPID VALVES 746.10
265776 INCOMPETENCE TRICUSPID 746.10
274919 INSUFFICIENCY TRICUSPID 746.10
247792 INSUFFICIENCY TRICUSPID CONGENITAL 746.10
298347
NONRHEUMATIC TRICUSPID VALVE 
STENOSIS WITH INSUFFICIENCY 746.10
257043 STENOSIS TRICUSPID CONGENITAL 746.10
306410 TRICUSPID (VALVE) DISEASE 746.10
306411 TRICUSPID (VALVE) STENOSIS 746.10
270877
TRICUSPID INCOMPETENCE, CAUSE 
UNSPECIFIED 746.10
243270
TRICUSPID INCOMPETENCE, NON-
RHEUMATIC 746.10
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GPRD
MEDICAL  CODE DESCRIPTION
ICD-9 
CODE
261637
TRICUSPID INSUFFICIENCY, NON-
RHEUMATIC 746.10
303750 TRICUSPID REGURGITATION 746.10
252400
TRICUSPID REGURGITATION, NON-
RHEUMATIC 746.10
298312
TRICUSPID STENOSIS AND 
INCOMPETENCE, CAUSE UNSPECIFIED 746.10
270878
TRICUSPID STENOSIS AND 
INSUFFICIENCY, CAUSE UNSPECIFIED 746.10
289061 TRICUSPID STENOSIS, NON-RHEUMATIC 746.10
289031 TRICUSPID VALVE DISEASE NEC 746.10
225113 TRICUSPID VALVE DISORDERS NOS 746.10
243269
TRICUSPID VALVE DISORDERS, NON-
RHEUMATIC 746.10
266257 EBSTEIN ABNORMALITY 746.20
304983 EBSTEIN ANOMALY TRICUSPID VALVE 746.20
281052 EBSTEINS ANOMALY 746.20
309754 AORTIC STENOSIS 746.30
270910
AORTIC STENOSIS ALONE, CAUSE 
UNSPECIFIED 746.30
257039 ATRESIA AORTIC VALVE CONGENITAL 746.30
303748 STENOSIS AORTIC 746.30
275395 STENOSIS AORTIC CONGENITAL 746.30
211554 QUADRICUSPID AORTIC VALVE 746.3
272013 BICUSPID AORTIC VALVE 746.4
307119 BICUSPID AORTIC VALVE 746.40
293624 ATRESIA MITRAL VALVE CONGENITAL 746.50
253557 CONGENITAL MITRAL STENOSIS 746.50
208183 CONGENITAL MITRAL STENOSIS NOS 746.50
226267
CONGENITAL MITRAL STENOSIS, 
UNSPECIFIED 746.50
279935
MITRAL INCOMPETENCE AND AORTIC 
STENOSIS 746.50
207044 MITRAL STENOSIS 746.5
298310
MITRAL STENOSIS AND AORTIC 
INSUFFICIENCY 746.50
270873 MITRAL STENOSIS WITH REGURGITATION 746.50
303744 STENOSIS MITRAL 746.50
229660 STENOSIS MITRAL CONGENITAL 746.50
262745 CONGENITAL MITRAL INSUFFICIENCY 746.60
229657
MALFORMATION MITRAL VALVE EBSTEIN-
LIKE 746.60
299430 HYPOPLASTIC AORTIC ORIFICE OR VALVE 746.70
281053 HYPOPLASTIC LEFT HEART SYNDROME 746.7
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APPENDIX N: Malformations of Great Arteries and Veins
GPRD MEDICAL
CODE DESCRIPTION
ICD-9 
CODE
307120 COARCTATION AORTA 747.1
217144 COARCTATION OF AORTA 747.1
235364 COARCTATION OF AORTA NOS 747.1
244365 POSTDUCTAL COARCTATION OF AORTA 747.1
272027 PREDUCTAL COARCTATION OF AORTA 747.1
272028 INTERRUPTION OF AORTIC ARCH 747.11
253565 POSTDUCTAL INTERRUPTION OF AORTA 747.11
299432 PREDUCTAL INTERRUPTION OF AORTA 747.11
272030 ANOMALY OF AORTA, UNSPECIFIED 747.2
208181 CONGENITAL AORTIC VALVE INSUFFICIENCY 747.2
253556
CONGENITAL AORTIC VALVE INSUFFICIENCY 
NOS 747.2
262744
CONGENITAL AORTIC VALVE INSUFFICIENCY, 
UNSPECIFIED 747.2
229658 INSUFFICIENCY AORTIC CONGENITAL 747.20
299433 OTHER ANOMALIES OF AORTA 747.2
290188 OTHER ANOMALIES OF AORTA NOS 747.2
262752 OTHER ANOMALY OF AORTA NOS 747.2
275394
REGURGITATION AORTIC (VALVE) 
CONGENITAL 747.20
202116
REGURGITATION AORTIC (VALVE) 
NONRHEUMATI 747.20
274982 ENLARGED AORTA 747.2
272029
ANOMALIES OF THE AORTA EXCLUDING 
COARCTION 747.21
272032 AORTIC ARCH ANOMALIES NOS 747.21
290186 DEXTRAPOSITION OF AORTA 747.21
253548 DEXTRATRANSPOSITION OF AORTA 747.21
272031 DOUBLE AORTIC ARCH 747.21
290185 HYPOPLASIA OF AORTIC ARCH, UNSPECIFIED 747.21
244368 KOMMERELLS DIVERTICULUM 747.21
235365 OVERRIDING AORTA 747.21
262750 OVERRIDING AORTA 747.21
253568 PERSISTENT RIGHT AORTIC ARCH 747.21
217131 TRANSPOSITION OF AORTA 747.21
253569 VASCULAR RING, AORTA 747.21
257050 ABSENCE AORTA CONGENITAL 747.22
253570 APLASIA OF AORTA 747.22
299434 ATRESIA AND STENOSIS OF AORTA 747.22
262751 ATRESIA OF AORTA 747.22
235366 ATRESIA OR STENOSIS OF AORTA NOS 747.22
299435 CONGENITAL ABSENCE OF AORTA 747.22
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GPRD
MEDICAL  CODE DESCRIPTION
ICD-9 
CODE
253571 HYPOPLASIA OF AORTA 747.22
208187 POSTDUCTAL HYPOPLASIA OF AORTA 747.22
253564 PREDUCTAL HYPOPLASIA OF AORTA 747.22
299436 STRICTURE OF AORTA 747.22
244370 TUBULAR HYPOPLASIA OF AORTA 747.22
290189 ANEURYSM OF SINUS OF VALSALVA 747.29
284508 ANEURYSM SINUS VALSALVA 747.29
284509 ANEURYSM VALSALVAS 747.29
226276 CONGENITAL ANEURYSM OF AORTA 747.29
211561 ABNORMAL PULMONARY ARTERY 747.30
293632 ANOMALOUS ORIGIN PULMONARY ARTERY 747.30
244372 COARCTATION OF THE PULMONARY ARTERY 747.30
217147
CONGENITAL ABSENCE OF PULMONARY 
ARTERY 747.3
208190
CONGENITAL STRICTURE OF PULMONARY 
ARTERY 747.30
290191 DILATATION OF PULMONARY ARTERY 747.3
208189 HYPOPLASIA OF THE PULMONARY ARTERY 747.30
208189 HYPOPLASIA OF THE PULMONARY ARTERY 747.30
226277
OTHER SPECIFIED ANOMALY OF PULMONARY 
ARTERY 747.3
253573 PULMONARY ARTERY ANOMALIES 747.30
208188 PULMONARY ARTERY ATRESIA 747.3
253575 STENOSIS OF PULMONARY ARTERY 747.3
216019 ANEURYSM OF PULMONARY ARTERY 747.3
253577
PARTIAL ANOMALOUS PULMONARY VENOUS 
RETURN 747.42
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APPENDIX O: GPRD Common Arterial Truncus medical codes
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
211552
ABSENCE SEPTUM BETWEEN AORTA & 
PULMONARY 745.00
299421
ABSENT SEPTUM BETWEEN AORTA AND 
PULMONARY ARTERY 745.00
272004 AORTIC SEPTAL DEFECT 745
208173 AORTIC SEPTAL DEFECT 745.00
244350 AORTICOPULMONARY SEPTAL DEFECT 745.00
217130 COMMON TRUNCUS 745.00
238588 DEFECT AORTIC SEPTAL 745.00
220577 DEFECT AORTOPULMONARY 745.00
238587 DEFECT SEPTAL AORTOPULMONARY 745.00
226265 HEART BULB OR SEPTAL CLOSURE DEFECTS NOS 745.00
290174
OTHER HEART BULB AND SEPTAL CLOSURE 
DEFECT 745.00
281046 PERSISTENT TRUNCUS ARTERIOSUS 745.00
290167 PERSISTENT TRUNCUS ARTERIOSUS 745.00
343160 PERSISTENT TRUNCUS ARTERIOSUS 745.00
208174 TRUNCUS ARTERIOSUS 745.00
340815 TRUNCUS ARTERIOSUS 745.00
284501 TRUNCUS ARTERIOSUS (PERSISTENT) 745.00
262728
BULBUS CORDIS AND CARDIAC SEPTAL CLOSURE
ANOMALIES 745
299420
CONGENITAL HEART DISEASE, SEPTAL AND 
BULBAR ANOMALIES 745
272005 AORTOPULMONARY WINDOW 745
275392 AORTOPULMONARY WINDOW 745
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APPENDIX P: GPRD Aortic Valve Atresia and Stenosis medical codes
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
309754 AORTIC STENOSIS 746.30
270910
AORTIC STENOSIS ALONE, CAUSE 
UNSPECIFIED 746.30
257039
ATRESIA AORTIC VALVE
CONGENITAL 746.30
303748 STENOSIS AORTIC 746.30
275395 STENOSIS AORTIC CONGENITAL 746.30
211554 QUADRICUSPID AORTIC VALVE 746.3
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APPENDIX Q: GPRD Ebsteins Anomaly medical codes
GPRD
MEDICAL  
CODE DESCRIPTION
ICD-9 
CODE
266257
EBSTEIN 
ABNORMALITY 746.20
304983
EBSTEIN ANOMALY 
TRICUSPID VALVE 746.20
281052 EBSTEINS ANOMALY 746.20
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APPENDIX R: GPRD Tricuspid Atresia and Stenosis medical codes
GPRD
MEDICAL  
CODE DESCRIPTION ICD-9 CODE
299642
CONGENITAL MALFORMATION OF 
TRICUSPID VALVE, UNSPECIFIED 746.10
225198
TRICUSPID VALVE 
DISORDERS/DISEASES CE 746.10
220583 ATRESIA TRICUSPID VALVE 746.10
243272
DISORDERS OF BOTH AORTIC 
AND TRICUSPID VALVES 746.10
265776 INCOMPETENCE TRICUSPID 746.10
274919 INSUFFICIENCY TRICUSPID 746.10
247792
INSUFFICIENCY TRICUSPID 
CONGENITAL 746.10
298347
NONRHEUMATIC TRICUSPID 
VALVE STENOSIS WITH 
INSUFFICIENCY 746.10
257043
STENOSIS TRICUSPID 
CONGENITAL 746.10
306410 TRICUSPID (VALVE) DISEASE 746.10
306411 TRICUSPID (VALVE) STENOSIS 746.10
270877
TRICUSPID INCOMPETENCE, 
CAUSE UNSPECIFIED 746.10
243270
TRICUSPID INCOMPETENCE, NON-
RHEUMATIC 746.10
261637
TRICUSPID INSUFFICIENCY, NON-
RHEUMATIC 746.10
303750 TRICUSPID REGURGITATION 746.10
252400
TRICUSPID REGURGITATION, 
NON-RHEUMATIC 746.10
298312
TRICUSPID STENOSIS AND 
INCOMPETENCE, CAUSE 
UNSPECIFIED 746.10
270878
TRICUSPID STENOSIS AND 
INSUFFICIENCY, CAUSE
UNSPECIFIED 746.10
289061
TRICUSPID STENOSIS, NON-
RHEUMATIC 746.10
289031 TRICUSPID VALVE DISEASE NEC 746.10
225113
TRICUSPID VALVE DISORDERS 
NOS 746.10
243269
TRICUSPID VALVE DISORDERS, 
NON-RHEUMATIC 746.10
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